id	sid	tid	token	lemma	pos
dpc-3032	1	1	dermatology	dermatology	NOUN
dpc-3032	1	2	:	:	PUNCT
dpc-3032	1	3	practical	practical	ADJ
dpc-3032	1	4	and	and	CCONJ
dpc-3032	1	5	conceptual	conceptual	ADJ
dpc-3032	1	6	original	original	ADJ
dpc-3032	1	7	article	article	NOUN
dpc-3032	1	8	|	|	ADV
dpc-3032	1	9	dermatol	dermatol	ADJ
dpc-3032	1	10	pract	pract	NOUN
dpc-3032	1	11	concept	concept	NOUN
dpc-3032	1	12	.	.	PUNCT
dpc-3032	2	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	2	2	1	1	NUM
dpc-3032	2	3	a	a	DET
dpc-3032	2	4	non	non	ADJ
dpc-3032	2	5	-	-	ADJ
dpc-3032	2	6	interventional	interventional	ADJ
dpc-3032	2	7	study	study	NOUN
dpc-3032	2	8	on	on	ADP
dpc-3032	2	9	vismodegib	vismodegib	NOUN
dpc-3032	2	10	for	for	ADP
dpc-3032	2	11	 	 	SPACE
dpc-3032	2	12	basal	basal	NOUN
dpc-3032	2	13	cell	cell	NOUN
dpc-3032	2	14	carcinoma	carcinoma	NOUN
dpc-3032	2	15	in	in	ADP
dpc-3032	2	16	swedish	swedish	ADJ
dpc-3032	2	17	patients	patient	NOUN
dpc-3032	2	18	niels	niels	PROPN
dpc-3032	2	19	bendsöe1	bendsöe1	PROPN
dpc-3032	2	20	,	,	PUNCT
dpc-3032	2	21	john	john	PROPN
dpc-3032	2	22	paoli2,3	paoli2,3	PROPN
dpc-3032	2	23	,	,	PUNCT
dpc-3032	2	24	karin	karin	PROPN
dpc-3032	2	25	söderkvist4	söderkvist4	PROPN
dpc-3032	2	26	,	,	PUNCT
dpc-3032	2	27	bertil	bertil	PROPN
dpc-3032	2	28	persson1	persson1	PROPN
dpc-3032	2	29	,	,	PUNCT
dpc-3032	2	30	christina	christina	PROPN
dpc-3032	2	31	halldin2,3	halldin2,3	PROPN
dpc-3032	2	32	,	,	PUNCT
dpc-3032	2	33	linda	linda	PROPN
dpc-3032	2	34	ihrlund5	ihrlund5	PROPN
dpc-3032	2	35	,	,	PUNCT
dpc-3032	2	36	maria	maria	PROPN
dpc-3032	2	37	wolodarski6,7	wolodarski6,7	PROPN
dpc-3032	2	38	1	1	NUM
dpc-3032	2	39	skåne	skåne	NOUN
dpc-3032	2	40	university	university	NOUN
dpc-3032	2	41	hospital	hospital	NOUN
dpc-3032	2	42	,	,	PUNCT
dpc-3032	2	43	department	department	NOUN
dpc-3032	2	44	of	of	ADP
dpc-3032	2	45	dermatology	dermatology	NOUN
dpc-3032	2	46	and	and	CCONJ
dpc-3032	2	47	venereology	venereology	NOUN
dpc-3032	2	48	,	,	PUNCT
dpc-3032	2	49	lund	lund	PROPN
dpc-3032	2	50	,	,	PUNCT
dpc-3032	2	51	sweden	sweden	PROPN
dpc-3032	2	52	2	2	NUM
dpc-3032	2	53	department	department	NOUN
dpc-3032	2	54	of	of	ADP
dpc-3032	2	55	dermatology	dermatology	NOUN
dpc-3032	2	56	and	and	CCONJ
dpc-3032	2	57	venereology	venereology	NOUN
dpc-3032	2	58	,	,	PUNCT
dpc-3032	2	59	institute	institute	NOUN
dpc-3032	2	60	of	of	ADP
dpc-3032	2	61	clinical	clinical	ADJ
dpc-3032	2	62	sciences	science	NOUN
dpc-3032	2	63	,	,	PUNCT
dpc-3032	2	64	sahlgrenska	sahlgrenska	PROPN
dpc-3032	2	65	academy	academy	PROPN
dpc-3032	2	66	,	,	PUNCT
dpc-3032	2	67	university	university	PROPN
dpc-3032	2	68	of	of	ADP
dpc-3032	2	69	gothenburg	gothenburg	PROPN
dpc-3032	2	70	,	,	PUNCT
dpc-3032	2	71	gothenburg	gothenburg	PROPN
dpc-3032	2	72	,	,	PUNCT
dpc-3032	2	73	sweden	sweden	PROPN
dpc-3032	2	74	3	3	NUM
dpc-3032	2	75	region	region	NOUN
dpc-3032	2	76	västra	västra	PROPN
dpc-3032	2	77	götaland	götaland	NOUN
dpc-3032	2	78	,	,	PUNCT
dpc-3032	2	79	sahlgrenska	sahlgrenska	PROPN
dpc-3032	2	80	university	university	NOUN
dpc-3032	2	81	hospital	hospital	NOUN
dpc-3032	2	82	,	,	PUNCT
dpc-3032	2	83	department	department	NOUN
dpc-3032	2	84	of	of	ADP
dpc-3032	2	85	dermatology	dermatology	NOUN
dpc-3032	2	86	and	and	CCONJ
dpc-3032	2	87	venereology	venereology	NOUN
dpc-3032	2	88	,	,	PUNCT
dpc-3032	2	89	gothenburg	gothenburg	PROPN
dpc-3032	2	90	,	,	PUNCT
dpc-3032	2	91	sweden	sweden	PROPN
dpc-3032	2	92	4	4	NUM
dpc-3032	2	93	department	department	NOUN
dpc-3032	2	94	of	of	ADP
dpc-3032	2	95	radiation	radiation	NOUN
dpc-3032	2	96	sciences	sciences	PROPN
dpc-3032	2	97	,	,	PUNCT
dpc-3032	2	98	umeå	umeå	PROPN
dpc-3032	2	99	university	university	NOUN
dpc-3032	2	100	,	,	PUNCT
dpc-3032	2	101	umeå	umeå	PROPN
dpc-3032	2	102	,	,	PUNCT
dpc-3032	2	103	sweden	sweden	PROPN
dpc-3032	2	104	5	5	NUM
dpc-3032	2	105	roche	roche	PROPN
dpc-3032	2	106	ab	ab	PROPN
dpc-3032	2	107	,	,	PUNCT
dpc-3032	2	108	sweden	sweden	PROPN
dpc-3032	2	109	6	6	NUM
dpc-3032	2	110	department	department	NOUN
dpc-3032	2	111	of	of	ADP
dpc-3032	2	112	oncology	oncology	NOUN
dpc-3032	2	113	and	and	CCONJ
dpc-3032	2	114	pathology	pathology	NOUN
dpc-3032	2	115	,	,	PUNCT
dpc-3032	2	116	karolinska	karolinska	PROPN
dpc-3032	2	117	institute	institute	PROPN
dpc-3032	2	118	,	,	PUNCT
dpc-3032	2	119	stockholm	stockholm	PROPN
dpc-3032	2	120	,	,	PUNCT
dpc-3032	2	121	sweden	sweden	PROPN
dpc-3032	2	122	7	7	NUM
dpc-3032	2	123	theme	theme	NOUN
dpc-3032	2	124	cancer	cancer	NOUN
dpc-3032	2	125	,	,	PUNCT
dpc-3032	2	126	patient	patient	ADJ
dpc-3032	2	127	area	area	NOUN
dpc-3032	2	128	head	head	NOUN
dpc-3032	2	129	and	and	CCONJ
dpc-3032	2	130	neck	neck	NOUN
dpc-3032	2	131	,	,	PUNCT
dpc-3032	2	132	lung	lung	NOUN
dpc-3032	2	133	,	,	PUNCT
dpc-3032	2	134	and	and	CCONJ
dpc-3032	2	135	skin	skin	NOUN
dpc-3032	2	136	,	,	PUNCT
dpc-3032	2	137	karolinska	karolinska	PROPN
dpc-3032	2	138	university	university	PROPN
dpc-3032	2	139	hospital	hospital	PROPN
dpc-3032	2	140	solna	solna	PROPN
dpc-3032	2	141	,	,	PUNCT
dpc-3032	2	142	stockholm	stockholm	PROPN
dpc-3032	2	143	,	,	PUNCT
dpc-3032	2	144	sweden	sweden	PROPN
dpc-3032	2	145	key	key	ADJ
dpc-3032	2	146	words	word	NOUN
dpc-3032	2	147	:	:	PUNCT
dpc-3032	2	148	non	non	ADJ
dpc-3032	2	149	-	-	ADJ
dpc-3032	2	150	interventional	interventional	ADJ
dpc-3032	2	151	,	,	PUNCT
dpc-3032	2	152	prospective	prospective	ADJ
dpc-3032	2	153	,	,	PUNCT
dpc-3032	2	154	cohort	cohort	NOUN
dpc-3032	2	155	-	-	PUNCT
dpc-3032	2	156	study	study	NOUN
dpc-3032	2	157	,	,	PUNCT
dpc-3032	2	158	effectiveness	effectiveness	NOUN
dpc-3032	2	159	,	,	PUNCT
dpc-3032	2	160	safety	safety	NOUN
dpc-3032	2	161	citation	citation	NOUN
dpc-3032	2	162	:	:	PUNCT
dpc-3032	2	163	bendsöe	bendsöe	PROPN
dpc-3032	2	164	n	n	CCONJ
dpc-3032	2	165	,	,	PUNCT
dpc-3032	2	166	paoli	paoli	PROPN
dpc-3032	2	167	j	j	PROPN
dpc-3032	2	168	,	,	PUNCT
dpc-3032	2	169	söderkvist	söderkvist	PROPN
dpc-3032	2	170	k	k	PROPN
dpc-3032	2	171	,	,	PUNCT
dpc-3032	2	172	persson	persson	PROPN
dpc-3032	2	173	b	b	PROPN
dpc-3032	2	174	,	,	PUNCT
dpc-3032	2	175	halldin	halldin	VERB
dpc-3032	2	176	c	c	NOUN
dpc-3032	2	177	,	,	PUNCT
dpc-3032	2	178	ihrlund	ihrlund	NOUN
dpc-3032	2	179	l	l	NOUN
dpc-3032	2	180	,	,	PUNCT
dpc-3032	2	181	wolodarski	wolodarski	VERB
dpc-3032	2	182	.	.	PUNCT
dpc-3032	3	1	a	a	DET
dpc-3032	3	2	non	non	ADJ
dpc-3032	3	3	-	-	ADJ
dpc-3032	3	4	interventional	interventional	ADJ
dpc-3032	3	5	study	study	NOUN
dpc-3032	3	6	on	on	ADP
dpc-3032	3	7	vismodegib	vismodegib	NOUN
dpc-3032	3	8	for	for	ADP
dpc-3032	3	9	basal	basal	ADJ
dpc-3032	3	10	cell	cell	NOUN
dpc-3032	3	11	carcinoma	carcinoma	NOUN
dpc-3032	3	12	in	in	ADP
dpc-3032	3	13	swedish	swedish	ADJ
dpc-3032	3	14	patients	patient	NOUN
dpc-3032	3	15	.	.	PUNCT
dpc-3032	4	1	dermatol	dermatol	NOUN
dpc-3032	4	2	pract	pract	PROPN
dpc-3032	4	3	concept	concept	NOUN
dpc-3032	4	4	.	.	PUNCT
dpc-3032	5	1	2023;13(2):e2023211	2023;13(2):e2023211	X
dpc-3032	5	2	.	.	PUNCT
dpc-3032	6	1	doi	doi	PROPN
dpc-3032	6	2	:	:	PUNCT
dpc-3032	6	3	https://doi.org/10.5826/dpc.1302a211	https://doi.org/10.5826/dpc.1302a211	NOUN
dpc-3032	6	4	accepted	accept	VERB
dpc-3032	6	5	:	:	PUNCT
dpc-3032	6	6	april	april	PROPN
dpc-3032	6	7	9	9	NUM
dpc-3032	6	8	,	,	PUNCT
dpc-3032	6	9	2023	2023	NUM
dpc-3032	6	10	;	;	PUNCT
dpc-3032	6	11	published	publish	VERB
dpc-3032	6	12	:	:	PUNCT
dpc-3032	7	1	april	april	PROPN
dpc-3032	7	2	2023	2023	NUM
dpc-3032	7	3	copyright	copyright	NOUN
dpc-3032	7	4	:	:	PUNCT
dpc-3032	7	5	©	©	PROPN
dpc-3032	7	6	2023	2023	NUM
dpc-3032	7	7	bendsöe	bendsöe	NOUN
dpc-3032	7	8	et	et	PROPN
dpc-3032	7	9	al	al	PROPN
dpc-3032	7	10	.	.	PUNCT
dpc-3032	8	1	this	this	PRON
dpc-3032	8	2	is	be	AUX
dpc-3032	8	3	an	an	DET
dpc-3032	8	4	open	open	ADJ
dpc-3032	8	5	-	-	PUNCT
dpc-3032	8	6	access	access	NOUN
dpc-3032	8	7	article	article	NOUN
dpc-3032	8	8	distributed	distribute	VERB
dpc-3032	8	9	under	under	ADP
dpc-3032	8	10	the	the	DET
dpc-3032	8	11	terms	term	NOUN
dpc-3032	8	12	of	of	ADP
dpc-3032	8	13	the	the	DET
dpc-3032	8	14	creative	creative	ADJ
dpc-3032	8	15	commons	common	NOUN
dpc-3032	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3032	8	17	license	license	NOUN
dpc-3032	8	18	(	(	PUNCT
dpc-3032	8	19	by	by	ADP
dpc-3032	8	20	-	-	PUNCT
dpc-3032	8	21	nc-4.0	nc-4.0	NOUN
dpc-3032	8	22	)	)	PUNCT
dpc-3032	8	23	,	,	PUNCT
dpc-3032	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3032	8	25	,	,	PUNCT
dpc-3032	8	26	which	which	PRON
dpc-3032	8	27	permits	permit	VERB
dpc-3032	8	28	unrestricted	unrestricted	ADJ
dpc-3032	8	29	noncommercial	noncommercial	ADJ
dpc-3032	8	30	use	use	NOUN
dpc-3032	8	31	,	,	PUNCT
dpc-3032	8	32	distribution	distribution	NOUN
dpc-3032	8	33	,	,	PUNCT
dpc-3032	8	34	and	and	CCONJ
dpc-3032	8	35	reproduction	reproduction	NOUN
dpc-3032	8	36	in	in	ADP
dpc-3032	8	37	any	any	DET
dpc-3032	8	38	medium	medium	NOUN
dpc-3032	8	39	,	,	PUNCT
dpc-3032	8	40	provided	provide	VERB
dpc-3032	8	41	the	the	DET
dpc-3032	8	42	original	original	ADJ
dpc-3032	8	43	authors	author	NOUN
dpc-3032	8	44	and	and	CCONJ
dpc-3032	8	45	source	source	NOUN
dpc-3032	8	46	are	be	AUX
dpc-3032	8	47	credited	credit	VERB
dpc-3032	8	48	.	.	PUNCT
dpc-3032	9	1	funding	funding	NOUN
dpc-3032	9	2	:	:	PUNCT
dpc-3032	9	3	roche	roche	PROPN
dpc-3032	9	4	ab	ab	PROPN
dpc-3032	9	5	sponsored	sponsor	VERB
dpc-3032	9	6	this	this	DET
dpc-3032	9	7	study	study	NOUN
dpc-3032	9	8	.	.	PUNCT
dpc-3032	10	1	we	we	PRON
dpc-3032	10	2	would	would	AUX
dpc-3032	10	3	like	like	VERB
dpc-3032	10	4	to	to	PART
dpc-3032	10	5	thank	thank	VERB
dpc-3032	10	6	all	all	DET
dpc-3032	10	7	research	research	NOUN
dpc-3032	10	8	nurses	nurse	NOUN
dpc-3032	10	9	who	who	PRON
dpc-3032	10	10	assisted	assist	VERB
dpc-3032	10	11	with	with	ADP
dpc-3032	10	12	patient	patient	ADJ
dpc-3032	10	13	inclusion	inclusion	NOUN
dpc-3032	10	14	and	and	CCONJ
dpc-3032	10	15	follow	follow	NOUN
dpc-3032	10	16	-	-	PUNCT
dpc-3032	10	17	up	up	NOUN
dpc-3032	10	18	.	.	PUNCT
dpc-3032	11	1	medical	medical	ADJ
dpc-3032	11	2	writing	writing	NOUN
dpc-3032	11	3	support	support	NOUN
dpc-3032	11	4	was	be	AUX
dpc-3032	11	5	provided	provide	VERB
dpc-3032	11	6	by	by	ADP
dpc-3032	11	7	eva	eva	PROPN
dpc-3032	11	8	karlsson	karlsson	PROPN
dpc-3032	11	9	(	(	PUNCT
dpc-3032	11	10	scientific	scientific	ADJ
dpc-3032	11	11	consulting	consulting	NOUN
dpc-3032	11	12	ab	ab	PROPN
dpc-3032	11	13	)	)	PUNCT
dpc-3032	11	14	in	in	ADP
dpc-3032	11	15	the	the	DET
dpc-3032	11	16	preparation	preparation	NOUN
dpc-3032	11	17	of	of	ADP
dpc-3032	11	18	this	this	DET
dpc-3032	11	19	paper	paper	NOUN
dpc-3032	11	20	.	.	PUNCT
dpc-3032	12	1	responsibility	responsibility	NOUN
dpc-3032	12	2	for	for	ADP
dpc-3032	12	3	opinions	opinion	NOUN
dpc-3032	12	4	,	,	PUNCT
dpc-3032	12	5	conclusions	conclusion	NOUN
dpc-3032	12	6	and	and	CCONJ
dpc-3032	12	7	interpretation	interpretation	NOUN
dpc-3032	12	8	of	of	ADP
dpc-3032	12	9	data	datum	NOUN
dpc-3032	12	10	lies	lie	VERB
dpc-3032	12	11	with	with	ADP
dpc-3032	12	12	the	the	DET
dpc-3032	12	13	authors	author	NOUN
dpc-3032	12	14	.	.	PUNCT
dpc-3032	13	1	competing	compete	VERB
dpc-3032	13	2	interests	interest	NOUN
dpc-3032	13	3	:	:	PUNCT
dpc-3032	13	4	linda	linda	PROPN
dpc-3032	13	5	ihrlund	ihrlund	NOUN
dpc-3032	13	6	is	be	AUX
dpc-3032	13	7	employed	employ	VERB
dpc-3032	13	8	at	at	ADP
dpc-3032	13	9	roche	roche	PROPN
dpc-3032	13	10	ab	ab	PROPN
dpc-3032	13	11	.	.	PUNCT
dpc-3032	14	1	the	the	DET
dpc-3032	14	2	other	other	ADJ
dpc-3032	14	3	authors	author	NOUN
dpc-3032	14	4	have	have	VERB
dpc-3032	14	5	nothing	nothing	PRON
dpc-3032	14	6	to	to	PART
dpc-3032	14	7	declare	declare	VERB
dpc-3032	14	8	.	.	PUNCT
dpc-3032	15	1	authorship	authorship	NOUN
dpc-3032	15	2	:	:	PUNCT
dpc-3032	15	3	all	all	DET
dpc-3032	15	4	authors	author	NOUN
dpc-3032	15	5	have	have	AUX
dpc-3032	15	6	contributed	contribute	VERB
dpc-3032	15	7	significantly	significantly	ADV
dpc-3032	15	8	to	to	ADP
dpc-3032	15	9	this	this	DET
dpc-3032	15	10	publication	publication	NOUN
dpc-3032	15	11	.	.	PUNCT
dpc-3032	16	1	corresponding	correspond	VERB
dpc-3032	16	2	author	author	NOUN
dpc-3032	16	3	:	:	PUNCT
dpc-3032	16	4	john	john	PROPN
dpc-3032	16	5	paoli	paoli	PROPN
dpc-3032	16	6	,	,	PUNCT
dpc-3032	16	7	m.d	m.d	PROPN
dpc-3032	16	8	.	.	PROPN
dpc-3032	16	9	,	,	PUNCT
dpc-3032	16	10	professor	professor	NOUN
dpc-3032	16	11	;	;	PUNCT
dpc-3032	16	12	department	department	NOUN
dpc-3032	16	13	of	of	ADP
dpc-3032	16	14	dermatology	dermatology	NOUN
dpc-3032	16	15	and	and	CCONJ
dpc-3032	16	16	venereology	venereology	NOUN
dpc-3032	16	17	,	,	PUNCT
dpc-3032	16	18	institute	institute	NOUN
dpc-3032	16	19	of	of	ADP
dpc-3032	16	20	clinical	clinical	ADJ
dpc-3032	16	21	sciences	science	NOUN
dpc-3032	16	22	,	,	PUNCT
dpc-3032	16	23	sahlgrenska	sahlgrenska	PROPN
dpc-3032	16	24	academy	academy	PROPN
dpc-3032	16	25	,	,	PUNCT
dpc-3032	16	26	university	university	PROPN
dpc-3032	16	27	of	of	ADP
dpc-3032	16	28	gothenburg	gothenburg	PROPN
dpc-3032	16	29	,	,	PUNCT
dpc-3032	16	30	gothenburg	gothenburg	PROPN
dpc-3032	16	31	,	,	PUNCT
dpc-3032	16	32	sweden	sweden	PROPN
dpc-3032	16	33	;	;	PUNCT
dpc-3032	16	34	tel	tel	PROPN
dpc-3032	16	35	:	:	PUNCT
dpc-3032	16	36	+46730404044	+46730404044	NUM
dpc-3032	16	37	e	e	NOUN
dpc-3032	16	38	-	-	NOUN
dpc-3032	16	39	mail	mail	NOUN
dpc-3032	16	40	:	:	PUNCT
dpc-3032	16	41	john.paoli@gu.se	john.paoli@gu.se	NOUN
dpc-3032	16	42	introduction	introduction	NOUN
dpc-3032	16	43	:	:	PUNCT
dpc-3032	16	44	real	real	ADJ
dpc-3032	16	45	-	-	PUNCT
dpc-3032	16	46	life	life	NOUN
dpc-3032	16	47	data	datum	NOUN
dpc-3032	16	48	on	on	ADP
dpc-3032	16	49	vismodegib	vismodegib	NOUN
dpc-3032	16	50	in	in	ADP
dpc-3032	16	51	advanced	advanced	ADJ
dpc-3032	16	52	basal	basal	NOUN
dpc-3032	16	53	cell	cell	NOUN
dpc-3032	16	54	carcinoma	carcinoma	NOUN
dpc-3032	16	55	(	(	PUNCT
dpc-3032	16	56	abcc	abcc	NOUN
dpc-3032	16	57	)	)	PUNCT
dpc-3032	16	58	are	be	AUX
dpc-3032	16	59	limited	limited	ADJ
dpc-3032	16	60	.	.	PUNCT
dpc-3032	17	1	optimal	optimal	ADJ
dpc-3032	17	2	treatment	treatment	NOUN
dpc-3032	17	3	duration	duration	NOUN
dpc-3032	17	4	is	be	AUX
dpc-3032	17	5	left	leave	VERB
dpc-3032	17	6	to	to	ADP
dpc-3032	17	7	the	the	DET
dpc-3032	17	8	discretion	discretion	NOUN
dpc-3032	17	9	of	of	ADP
dpc-3032	17	10	the	the	DET
dpc-3032	17	11	physician	physician	NOUN
dpc-3032	17	12	.	.	PUNCT
dpc-3032	18	1	objectives	objective	NOUN
dpc-3032	18	2	:	:	PUNCT
dpc-3032	18	3	to	to	PART
dpc-3032	18	4	assess	assess	VERB
dpc-3032	18	5	the	the	DET
dpc-3032	18	6	effectiveness	effectiveness	NOUN
dpc-3032	18	7	,	,	PUNCT
dpc-3032	18	8	safety	safety	NOUN
dpc-3032	18	9	and	and	CCONJ
dpc-3032	18	10	treatment	treatment	NOUN
dpc-3032	18	11	pattern	pattern	NOUN
dpc-3032	18	12	for	for	ADP
dpc-3032	18	13	vismodegib	vismodegib	NOUN
dpc-3032	18	14	in	in	ADP
dpc-3032	18	15	abcc	abcc	NOUN
dpc-3032	18	16	in	in	ADP
dpc-3032	18	17	clinical	clinical	ADJ
dpc-3032	18	18	practice	practice	NOUN
dpc-3032	18	19	.	.	PUNCT
dpc-3032	19	1	methods	method	NOUN
dpc-3032	19	2	:	:	PUNCT
dpc-3032	19	3	in	in	ADP
dpc-3032	19	4	this	this	DET
dpc-3032	19	5	multicenter	multicenter	NOUN
dpc-3032	19	6	,	,	PUNCT
dpc-3032	19	7	non	non	ADJ
dpc-3032	19	8	-	-	ADJ
dpc-3032	19	9	interventional	interventional	ADJ
dpc-3032	19	10	,	,	PUNCT
dpc-3032	19	11	prospective	prospective	ADJ
dpc-3032	19	12	study	study	NOUN
dpc-3032	19	13	,	,	PUNCT
dpc-3032	19	14	49	49	NUM
dpc-3032	19	15	swedish	swedish	ADJ
dpc-3032	19	16	patients	patient	NOUN
dpc-3032	19	17	planned	plan	VERB
dpc-3032	19	18	for	for	ADP
dpc-3032	19	19	vismodegib	vismodegib	NOUN
dpc-3032	19	20	treatment	treatment	NOUN
dpc-3032	19	21	were	be	AUX
dpc-3032	19	22	included	include	VERB
dpc-3032	19	23	.	.	PUNCT
dpc-3032	20	1	the	the	DET
dpc-3032	20	2	treatment	treatment	NOUN
dpc-3032	20	3	pattern	pattern	NOUN
dpc-3032	20	4	observed	observe	VERB
dpc-3032	20	5	was	be	AUX
dpc-3032	20	6	treatment	treatment	NOUN
dpc-3032	20	7	until	until	ADP
dpc-3032	20	8	remission	remission	NOUN
dpc-3032	20	9	,	,	PUNCT
dpc-3032	20	10	allowing	allow	VERB
dpc-3032	20	11	unlimited	unlimited	ADJ
dpc-3032	20	12	discontinuations	discontinuation	NOUN
dpc-3032	20	13	/	/	SYM
dpc-3032	20	14	pauses	pause	NOUN
dpc-3032	20	15	.	.	PUNCT
dpc-3032	21	1	results	result	NOUN
dpc-3032	21	2	:	:	PUNCT
dpc-3032	21	3	the	the	DET
dpc-3032	21	4	majority	majority	NOUN
dpc-3032	21	5	of	of	ADP
dpc-3032	21	6	patients	patient	NOUN
dpc-3032	21	7	(	(	PUNCT
dpc-3032	21	8	93.8	93.8	NUM
dpc-3032	21	9	%	%	NOUN
dpc-3032	21	10	)	)	PUNCT
dpc-3032	21	11	,	,	PUNCT
dpc-3032	21	12	discontinued	discontinue	VERB
dpc-3032	21	13	at	at	ADP
dpc-3032	21	14	least	least	ADJ
dpc-3032	21	15	once	once	ADV
dpc-3032	21	16	during	during	ADP
dpc-3032	21	17	the	the	DET
dpc-3032	21	18	study	study	NOUN
dpc-3032	21	19	.	.	PUNCT
dpc-3032	22	1	compared	compare	VERB
dpc-3032	22	2	to	to	ADP
dpc-3032	22	3	earlier	early	ADJ
dpc-3032	22	4	studies	study	NOUN
dpc-3032	22	5	there	there	PRON
dpc-3032	22	6	was	be	VERB
dpc-3032	22	7	a	a	DET
dpc-3032	22	8	decrease	decrease	NOUN
dpc-3032	22	9	of	of	ADP
dpc-3032	22	10	more	more	ADJ
dpc-3032	22	11	than	than	ADP
dpc-3032	22	12	2	2	NUM
dpc-3032	22	13	months	month	NOUN
dpc-3032	22	14	with	with	ADP
dpc-3032	22	15	actual	actual	ADJ
dpc-3032	22	16	drug	drug	NOUN
dpc-3032	22	17	intake	intake	NOUN
dpc-3032	22	18	,	,	PUNCT
dpc-3032	22	19	reducing	reduce	VERB
dpc-3032	22	20	the	the	DET
dpc-3032	22	21	patients	patient	NOUN
dpc-3032	22	22	burden	burden	NOUN
dpc-3032	22	23	and	and	CCONJ
dpc-3032	22	24	costs	cost	NOUN
dpc-3032	22	25	,	,	PUNCT
dpc-3032	22	26	at	at	ADP
dpc-3032	22	27	the	the	DET
dpc-3032	22	28	same	same	ADJ
dpc-3032	22	29	time	time	NOUN
dpc-3032	22	30	as	as	SCONJ
dpc-3032	22	31	a	a	DET
dpc-3032	22	32	high	high	ADJ
dpc-3032	22	33	number	number	NOUN
dpc-3032	22	34	of	of	ADP
dpc-3032	22	35	responses	response	NOUN
dpc-3032	22	36	were	be	AUX
dpc-3032	22	37	seen	see	VERB
dpc-3032	22	38	(	(	PUNCT
dpc-3032	22	39	87.8	87.8	NUM
dpc-3032	22	40	%	%	NOUN
dpc-3032	22	41	)	)	PUNCT
dpc-3032	22	42	.	.	PUNCT
dpc-3032	23	1	median	median	ADJ
dpc-3032	23	2	progression	progression	NOUN
dpc-3032	23	3	-	-	PUNCT
dpc-3032	23	4	free	free	ADJ
dpc-3032	23	5	-	-	PUNCT
dpc-3032	23	6	survival	survival	NOUN
dpc-3032	23	7	was	be	AUX
dpc-3032	23	8	16.7	16.7	NUM
dpc-3032	23	9	months	month	NOUN
dpc-3032	23	10	,	,	PUNCT
dpc-3032	23	11	and	and	CCONJ
dpc-3032	23	12	90	90	NUM
dpc-3032	23	13	%	%	NOUN
dpc-3032	23	14	of	of	ADP
dpc-3032	23	15	the	the	DET
dpc-3032	23	16	patients	patient	NOUN
dpc-3032	23	17	were	be	AUX
dpc-3032	23	18	alive	alive	ADJ
dpc-3032	23	19	at	at	ADP
dpc-3032	23	20	13.3	13.3	NUM
dpc-3032	23	21	months	month	NOUN
dpc-3032	23	22	.	.	PUNCT
dpc-3032	24	1	ten	ten	NUM
dpc-3032	24	2	patients	patient	NOUN
dpc-3032	24	3	were	be	AUX
dpc-3032	24	4	re	re	VERB
dpc-3032	24	5	-	-	VERB
dpc-3032	24	6	challenged	challenge	VERB
dpc-3032	24	7	with	with	ADP
dpc-3032	24	8	vismodegib	vismodegib	NOUN
dpc-3032	24	9	at	at	ADP
dpc-3032	24	10	recurrence	recurrence	NOUN
dpc-3032	24	11	or	or	CCONJ
dpc-3032	24	12	progression	progression	NOUN
dpc-3032	24	13	,	,	PUNCT
dpc-3032	24	14	resulting	result	VERB
dpc-3032	24	15	in	in	ADP
dpc-3032	24	16	five	five	NUM
dpc-3032	24	17	partial	partial	ADJ
dpc-3032	24	18	remissions	remission	NOUN
dpc-3032	24	19	and	and	CCONJ
dpc-3032	24	20	three	three	NUM
dpc-3032	24	21	complete	complete	ADJ
dpc-3032	24	22	remissions	remission	NOUN
dpc-3032	24	23	.	.	PUNCT
dpc-3032	25	1	abstract	abstract	ADJ
dpc-3032	25	2	2	2	NUM
dpc-3032	25	3	original	original	ADJ
dpc-3032	25	4	article	article	NOUN
dpc-3032	25	5	|	|	ADV
dpc-3032	25	6	dermatol	dermatol	ADJ
dpc-3032	25	7	pract	pract	NOUN
dpc-3032	25	8	concept	concept	NOUN
dpc-3032	25	9	.	.	PUNCT
dpc-3032	26	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	26	2	introduction	introduction	NOUN
dpc-3032	26	3	basal	basal	NOUN
dpc-3032	26	4	cell	cell	NOUN
dpc-3032	26	5	carcinoma	carcinoma	NOUN
dpc-3032	26	6	(	(	PUNCT
dpc-3032	26	7	bcc	bcc	PROPN
dpc-3032	26	8	)	)	PUNCT
dpc-3032	26	9	is	be	AUX
dpc-3032	26	10	the	the	DET
dpc-3032	26	11	most	most	ADV
dpc-3032	26	12	common	common	ADJ
dpc-3032	26	13	human	human	ADJ
dpc-3032	26	14	cancer	cancer	NOUN
dpc-3032	26	15	.	.	PUNCT
dpc-3032	27	1	in	in	ADP
dpc-3032	27	2	sweden	sweden	PROPN
dpc-3032	27	3	,	,	PUNCT
dpc-3032	27	4	the	the	DET
dpc-3032	27	5	number	number	NOUN
dpc-3032	27	6	of	of	ADP
dpc-3032	27	7	histopathologically	histopathologically	ADV
dpc-3032	27	8	verified	verify	VERB
dpc-3032	27	9	bcc	bcc	PROPN
dpc-3032	27	10	cases	case	NOUN
dpc-3032	27	11	have	have	AUX
dpc-3032	27	12	increased	increase	VERB
dpc-3032	27	13	10	10	NUM
dpc-3032	27	14	-	-	NOUN
dpc-3032	27	15	fold	fold	ADJ
dpc-3032	27	16	during	during	ADP
dpc-3032	27	17	the	the	DET
dpc-3032	27	18	last	last	ADJ
dpc-3032	27	19	30	30	NUM
dpc-3032	27	20	years	year	NOUN
dpc-3032	27	21	.	.	PUNCT
dpc-3032	28	1	in	in	ADP
dpc-3032	28	2	2019	2019	NUM
dpc-3032	28	3	,	,	PUNCT
dpc-3032	28	4	the	the	DET
dpc-3032	28	5	number	number	NOUN
dpc-3032	28	6	of	of	ADP
dpc-3032	28	7	patients	patient	NOUN
dpc-3032	28	8	reported	report	VERB
dpc-3032	28	9	to	to	ADP
dpc-3032	28	10	the	the	DET
dpc-3032	28	11	swedish	swedish	PROPN
dpc-3032	28	12	cancer	cancer	NOUN
dpc-3032	28	13	registry	registry	NOUN
dpc-3032	28	14	were	be	AUX
dpc-3032	28	15	>	>	X
dpc-3032	28	16	61	61	NUM
dpc-3032	28	17	000	000	NUM
dpc-3032	28	18	,	,	PUNCT
dpc-3032	28	19	compared	compare	VERB
dpc-3032	28	20	to	to	ADP
dpc-3032	28	21	36	36	NUM
dpc-3032	28	22	500	500	NUM
dpc-3032	28	23	in	in	ADP
dpc-3032	28	24	2008	2008	NUM
dpc-3032	29	1	[	[	X
dpc-3032	29	2	1	1	NUM
dpc-3032	29	3	]	]	PUNCT
dpc-3032	29	4	.	.	PUNCT
dpc-3032	30	1	the	the	DET
dpc-3032	30	2	most	most	ADV
dpc-3032	30	3	common	common	ADJ
dpc-3032	30	4	reason	reason	NOUN
dpc-3032	30	5	for	for	ADP
dpc-3032	30	6	bcc	bcc	PROPN
dpc-3032	30	7	is	be	AUX
dpc-3032	30	8	chronic	chronic	ADJ
dpc-3032	30	9	or	or	CCONJ
dpc-3032	30	10	intermittent	intermittent	ADJ
dpc-3032	30	11	exposure	exposure	NOUN
dpc-3032	30	12	of	of	ADP
dpc-3032	30	13	uv	uv	NOUN
dpc-3032	30	14	-	-	PUNCT
dpc-3032	30	15	radiation	radiation	NOUN
dpc-3032	30	16	,	,	PUNCT
dpc-3032	30	17	where	where	SCONJ
dpc-3032	30	18	the	the	DET
dpc-3032	30	19	disease	disease	NOUN
dpc-3032	30	20	development	development	NOUN
dpc-3032	30	21	is	be	AUX
dpc-3032	30	22	driven	drive	VERB
dpc-3032	30	23	by	by	ADP
dpc-3032	30	24	an	an	DET
dpc-3032	30	25	abnormal	abnormal	ADJ
dpc-3032	30	26	activation	activation	NOUN
dpc-3032	30	27	of	of	ADP
dpc-3032	30	28	the	the	DET
dpc-3032	30	29	hedgehog	hedgehog	NOUN
dpc-3032	30	30	signaling	signal	VERB
dpc-3032	30	31	pathway	pathway	NOUN
dpc-3032	31	1	[	[	X
dpc-3032	31	2	2	2	NUM
dpc-3032	31	3	-	-	SYM
dpc-3032	31	4	6	6	NUM
dpc-3032	31	5	]	]	PUNCT
dpc-3032	31	6	.	.	PUNCT
dpc-3032	32	1	the	the	DET
dpc-3032	32	2	majority	majority	NOUN
dpc-3032	32	3	of	of	ADP
dpc-3032	32	4	bccs	bccs	PROPN
dpc-3032	32	5	occur	occur	VERB
dpc-3032	32	6	sporadically	sporadically	ADV
dpc-3032	32	7	,	,	PUNCT
dpc-3032	32	8	but	but	CCONJ
dpc-3032	32	9	a	a	DET
dpc-3032	32	10	rare	rare	ADJ
dpc-3032	32	11	autosomal	autosomal	ADJ
dpc-3032	32	12	dominant	dominant	ADJ
dpc-3032	32	13	inherited	inherit	VERB
dpc-3032	32	14	condition	condition	NOUN
dpc-3032	32	15	,	,	PUNCT
dpc-3032	32	16	gorlin	gorlin	NOUN
dpc-3032	32	17	syndrome	syndrome	PROPN
dpc-3032	32	18	,	,	PUNCT
dpc-3032	32	19	also	also	ADV
dpc-3032	32	20	exists	exist	VERB
dpc-3032	32	21	[	[	X
dpc-3032	32	22	7	7	NUM
dpc-3032	32	23	-	-	SYM
dpc-3032	32	24	9	9	NUM
dpc-3032	32	25	]	]	PUNCT
dpc-3032	32	26	.	.	PUNCT
dpc-3032	33	1	vismodegib	vismodegib	PROPN
dpc-3032	33	2	(	(	PUNCT
dpc-3032	33	3	erivedge	erivedge	PROPN
dpc-3032	33	4	®	®	PROPN
dpc-3032	33	5	,	,	PUNCT
dpc-3032	33	6	hoffmann	hoffmann	PROPN
dpc-3032	33	7	-	-	PUNCT
dpc-3032	33	8	la	la	PROPN
dpc-3032	33	9	roche	roche	PROPN
dpc-3032	33	10	ltd	ltd	PROPN
dpc-3032	33	11	,	,	PUNCT
dpc-3032	33	12	basel	basel	PROPN
dpc-3032	33	13	,	,	PUNCT
dpc-3032	33	14	switzerland	switzerland	PROPN
dpc-3032	33	15	)	)	PUNCT
dpc-3032	33	16	is	be	AUX
dpc-3032	33	17	a	a	DET
dpc-3032	33	18	first	first	ADJ
dpc-3032	33	19	-	-	PUNCT
dpc-3032	33	20	in	in	ADP
dpc-3032	33	21	-	-	PUNCT
dpc-3032	33	22	class	class	NOUN
dpc-3032	33	23	,	,	PUNCT
dpc-3032	33	24	oral	oral	ADJ
dpc-3032	33	25	small	small	ADJ
dpc-3032	33	26	molecule	molecule	NOUN
dpc-3032	33	27	inhibitor	inhibitor	NOUN
dpc-3032	33	28	of	of	ADP
dpc-3032	33	29	the	the	DET
dpc-3032	33	30	hedgehog	hedgehog	NOUN
dpc-3032	33	31	signaling	signal	VERB
dpc-3032	33	32	pathway	pathway	NOUN
dpc-3032	33	33	,	,	PUNCT
dpc-3032	33	34	developed	develop	VERB
dpc-3032	33	35	to	to	PART
dpc-3032	33	36	treat	treat	VERB
dpc-3032	33	37	hedgehog	hedgehog	ADJ
dpc-3032	33	38	mutated	mutate	VERB
dpc-3032	33	39	tumors	tumor	NOUN
dpc-3032	33	40	.	.	PUNCT
dpc-3032	34	1	the	the	DET
dpc-3032	34	2	european	european	ADJ
dpc-3032	34	3	approval	approval	NOUN
dpc-3032	34	4	of	of	ADP
dpc-3032	34	5	vismodegib	vismodegib	NOUN
dpc-3032	34	6	was	be	AUX
dpc-3032	34	7	based	base	VERB
dpc-3032	34	8	on	on	ADP
dpc-3032	34	9	the	the	DET
dpc-3032	34	10	pivotal	pivotal	ADJ
dpc-3032	34	11	study	study	NOUN
dpc-3032	34	12	erivance	erivance	NOUN
dpc-3032	34	13	,	,	PUNCT
dpc-3032	34	14	an	an	DET
dpc-3032	34	15	international	international	ADJ
dpc-3032	34	16	,	,	PUNCT
dpc-3032	34	17	phase-2	phase-2	PROPN
dpc-3032	34	18	,	,	PUNCT
dpc-3032	34	19	open	open	ADJ
dpc-3032	34	20	-	-	PUNCT
dpc-3032	34	21	label	label	NOUN
dpc-3032	34	22	,	,	PUNCT
dpc-3032	34	23	non	non	ADJ
dpc-3032	34	24	-	-	ADJ
dpc-3032	34	25	comparative	comparative	ADJ
dpc-3032	34	26	clinical	clinical	ADJ
dpc-3032	34	27	trial	trial	NOUN
dpc-3032	34	28	that	that	PRON
dpc-3032	34	29	showed	show	VERB
dpc-3032	34	30	high	high	ADJ
dpc-3032	34	31	efficacy	efficacy	NOUN
dpc-3032	34	32	and	and	CCONJ
dpc-3032	34	33	acceptable	acceptable	ADJ
dpc-3032	34	34	tolerability	tolerability	NOUN
dpc-3032	34	35	in	in	ADP
dpc-3032	34	36	patients	patient	NOUN
dpc-3032	34	37	with	with	ADP
dpc-3032	34	38	metastatic	metastatic	ADJ
dpc-3032	34	39	or	or	CCONJ
dpc-3032	34	40	locally	locally	ADV
dpc-3032	34	41	advanced	advanced	ADJ
dpc-3032	34	42	bcc	bcc	PROPN
dpc-3032	34	43	with	with	ADP
dpc-3032	34	44	or	or	CCONJ
dpc-3032	34	45	without	without	ADP
dpc-3032	34	46	gorlin	gorlin	PROPN
dpc-3032	34	47	syndrome	syndrome	PROPN
dpc-3032	35	1	[	[	X
dpc-3032	35	2	10	10	NUM
dpc-3032	35	3	,	,	PUNCT
dpc-3032	35	4	11	11	NUM
dpc-3032	35	5	]	]	PUNCT
dpc-3032	35	6	.	.	PUNCT
dpc-3032	36	1	the	the	DET
dpc-3032	36	2	results	result	NOUN
dpc-3032	36	3	were	be	AUX
dpc-3032	36	4	confirmed	confirm	VERB
dpc-3032	36	5	in	in	ADP
dpc-3032	36	6	a	a	DET
dpc-3032	36	7	larger	large	ADJ
dpc-3032	36	8	multicenter	multicenter	NOUN
dpc-3032	36	9	safety	safety	NOUN
dpc-3032	36	10	study	study	NOUN
dpc-3032	36	11	,	,	PUNCT
dpc-3032	36	12	stevie	stevie	PROPN
dpc-3032	37	1	[	[	X
dpc-3032	37	2	12	12	NUM
dpc-3032	37	3	]	]	PUNCT
dpc-3032	37	4	.	.	PUNCT
dpc-3032	38	1	both	both	DET
dpc-3032	38	2	trials	trial	NOUN
dpc-3032	38	3	included	include	VERB
dpc-3032	38	4	continuous	continuous	ADJ
dpc-3032	38	5	treatment	treatment	NOUN
dpc-3032	38	6	with	with	ADP
dpc-3032	38	7	vismodegib	vismodegib	NOUN
dpc-3032	38	8	150	150	NUM
dpc-3032	38	9	mg	mg	NOUN
dpc-3032	38	10	once	once	ADV
dpc-3032	38	11	daily	daily	ADV
dpc-3032	38	12	,	,	PUNCT
dpc-3032	38	13	until	until	ADP
dpc-3032	38	14	disease	disease	NOUN
dpc-3032	38	15	progression	progression	NOUN
dpc-3032	38	16	or	or	CCONJ
dpc-3032	38	17	intolerable	intolerable	ADJ
dpc-3032	38	18	toxicity	toxicity	NOUN
dpc-3032	38	19	.	.	PUNCT
dpc-3032	39	1	thirty	thirty	NUM
dpc-3032	39	2	-	-	PUNCT
dpc-3032	39	3	one	one	NUM
dpc-3032	39	4	percent	percent	NOUN
dpc-3032	39	5	of	of	ADP
dpc-3032	39	6	the	the	DET
dpc-3032	39	7	patients	patient	NOUN
dpc-3032	39	8	discontinued	discontinue	VERB
dpc-3032	39	9	treatment	treatment	NOUN
dpc-3032	39	10	due	due	ADP
dpc-3032	39	11	to	to	ADP
dpc-3032	39	12	toxicity	toxicity	NOUN
dpc-3032	39	13	,	,	PUNCT
dpc-3032	39	14	although	although	SCONJ
dpc-3032	39	15	treatment	treatment	NOUN
dpc-3032	39	16	interruptions	interruption	NOUN
dpc-3032	39	17	/	/	SYM
dpc-3032	39	18	pauses	pause	VERB
dpc-3032	39	19	up	up	ADP
dpc-3032	39	20	to	to	PART
dpc-3032	39	21	4	4	NUM
dpc-3032	39	22	-	-	SYM
dpc-3032	39	23	8	8	NUM
dpc-3032	39	24	weeks	week	NOUN
dpc-3032	39	25	were	be	AUX
dpc-3032	39	26	allowed	allow	VERB
dpc-3032	39	27	.	.	PUNCT
dpc-3032	40	1	to	to	PART
dpc-3032	40	2	overcome	overcome	VERB
dpc-3032	40	3	the	the	DET
dpc-3032	40	4	toxicity	toxicity	NOUN
dpc-3032	40	5	with	with	ADP
dpc-3032	40	6	maintained	maintain	VERB
dpc-3032	40	7	efficacy	efficacy	NOUN
dpc-3032	40	8	,	,	PUNCT
dpc-3032	40	9	the	the	DET
dpc-3032	40	10	dosing	dose	VERB
dpc-3032	40	11	regimen	regimen	NOUN
dpc-3032	40	12	has	have	AUX
dpc-3032	40	13	been	be	AUX
dpc-3032	40	14	further	far	ADV
dpc-3032	40	15	evaluated	evaluate	VERB
dpc-3032	40	16	in	in	ADP
dpc-3032	40	17	several	several	ADJ
dpc-3032	40	18	trials	trial	NOUN
dpc-3032	40	19	,	,	PUNCT
dpc-3032	40	20	as	as	ADP
dpc-3032	40	21	intermittent	intermittent	ADJ
dpc-3032	40	22	dosing	dosing	NOUN
dpc-3032	40	23	,	,	PUNCT
dpc-3032	40	24	or	or	CCONJ
dpc-3032	40	25	reduced	reduce	VERB
dpc-3032	40	26	dosing	dose	VERB
dpc-3032	40	27	[	[	X
dpc-3032	40	28	1316	1316	NUM
dpc-3032	40	29	]	]	PUNCT
dpc-3032	40	30	.	.	PUNCT
dpc-3032	41	1	however	however	ADV
dpc-3032	41	2	,	,	PUNCT
dpc-3032	41	3	there	there	PRON
dpc-3032	41	4	is	be	VERB
dpc-3032	41	5	no	no	DET
dpc-3032	41	6	established	establish	VERB
dpc-3032	41	7	guideline	guideline	NOUN
dpc-3032	41	8	for	for	ADP
dpc-3032	41	9	optimal	optimal	ADJ
dpc-3032	41	10	treatment	treatment	NOUN
dpc-3032	41	11	duration	duration	NOUN
dpc-3032	41	12	with	with	ADP
dpc-3032	41	13	vismodegib	vismodegib	NOUN
dpc-3032	41	14	.	.	PUNCT
dpc-3032	42	1	at	at	ADP
dpc-3032	42	2	the	the	DET
dpc-3032	42	3	time	time	NOUN
dpc-3032	42	4	of	of	ADP
dpc-3032	42	5	initiation	initiation	NOUN
dpc-3032	42	6	of	of	ADP
dpc-3032	42	7	this	this	DET
dpc-3032	42	8	non	non	ADJ
dpc-3032	42	9	-	-	ADJ
dpc-3032	42	10	interventional	interventional	ADJ
dpc-3032	42	11	study	study	NOUN
dpc-3032	42	12	(	(	PUNCT
dpc-3032	42	13	nis	nis	NOUN
dpc-3032	42	14	)	)	PUNCT
dpc-3032	42	15	,	,	PUNCT
dpc-3032	42	16	data	datum	NOUN
dpc-3032	42	17	on	on	ADP
dpc-3032	42	18	treatment	treatment	NOUN
dpc-3032	42	19	in	in	ADP
dpc-3032	42	20	a	a	DET
dpc-3032	42	21	real	real	ADJ
dpc-3032	42	22	-	-	PUNCT
dpc-3032	42	23	life	life	NOUN
dpc-3032	42	24	setting	setting	NOUN
dpc-3032	42	25	was	be	AUX
dpc-3032	42	26	lacking	lack	VERB
dpc-3032	42	27	in	in	ADP
dpc-3032	42	28	sweden	sweden	PROPN
dpc-3032	42	29	as	as	ADV
dpc-3032	42	30	well	well	ADV
dpc-3032	42	31	as	as	ADP
dpc-3032	42	32	world	world	NOUN
dpc-3032	42	33	-	-	PUNCT
dpc-3032	42	34	wide	wide	ADV
dpc-3032	42	35	.	.	PUNCT
dpc-3032	43	1	implementing	implement	VERB
dpc-3032	43	2	a	a	DET
dpc-3032	43	3	systematic	systematic	ADJ
dpc-3032	43	4	data	datum	NOUN
dpc-3032	43	5	collection	collection	NOUN
dpc-3032	43	6	was	be	AUX
dpc-3032	43	7	encouraged	encourage	VERB
dpc-3032	43	8	by	by	ADP
dpc-3032	43	9	the	the	DET
dpc-3032	43	10	necessity	necessity	NOUN
dpc-3032	43	11	to	to	PART
dpc-3032	43	12	increase	increase	VERB
dpc-3032	43	13	knowledge	knowledge	NOUN
dpc-3032	43	14	of	of	ADP
dpc-3032	43	15	current	current	ADJ
dpc-3032	43	16	treatment	treatment	NOUN
dpc-3032	43	17	patterns	pattern	NOUN
dpc-3032	43	18	,	,	PUNCT
dpc-3032	43	19	effectiveness	effectiveness	NOUN
dpc-3032	43	20	and	and	CCONJ
dpc-3032	43	21	safety	safety	NOUN
dpc-3032	43	22	.	.	PUNCT
dpc-3032	44	1	since	since	SCONJ
dpc-3032	44	2	then	then	ADV
dpc-3032	44	3	,	,	PUNCT
dpc-3032	44	4	three	three	NUM
dpc-3032	44	5	similar	similar	ADJ
dpc-3032	44	6	european	european	ADJ
dpc-3032	44	7	studies	study	NOUN
dpc-3032	44	8	with	with	ADP
dpc-3032	44	9	data	datum	NOUN
dpc-3032	44	10	collected	collect	VERB
dpc-3032	44	11	both	both	CCONJ
dpc-3032	44	12	retrospectively	retrospectively	ADV
dpc-3032	44	13	and	and	CCONJ
dpc-3032	44	14	prospectively	prospectively	ADV
dpc-3032	44	15	have	have	AUX
dpc-3032	44	16	been	be	AUX
dpc-3032	44	17	published	publish	VERB
dpc-3032	44	18	:	:	PUNCT
dpc-3032	44	19	one	one	NUM
dpc-3032	44	20	from	from	ADP
dpc-3032	44	21	greece	greece	PROPN
dpc-3032	44	22	with	with	ADP
dpc-3032	44	23	67	67	NUM
dpc-3032	44	24	patients	patient	NOUN
dpc-3032	44	25	and	and	CCONJ
dpc-3032	44	26	two	two	NUM
dpc-3032	44	27	from	from	ADP
dpc-3032	44	28	germany	germany	PROPN
dpc-3032	44	29	with	with	ADP
dpc-3032	44	30	66	66	NUM
dpc-3032	44	31	and	and	CCONJ
dpc-3032	44	32	53	53	NUM
dpc-3032	44	33	patients	patient	NOUN
dpc-3032	44	34	,	,	PUNCT
dpc-3032	44	35	respectively	respectively	ADV
dpc-3032	44	36	,	,	PUNCT
dpc-3032	44	37	have	have	AUX
dpc-3032	44	38	been	be	AUX
dpc-3032	44	39	published	publish	VERB
dpc-3032	44	40	[	[	PUNCT
dpc-3032	44	41	17	17	NUM
dpc-3032	44	42	-	-	SYM
dpc-3032	44	43	19	19	NUM
dpc-3032	44	44	]	]	PUNCT
dpc-3032	44	45	.	.	PUNCT
dpc-3032	45	1	the	the	DET
dpc-3032	45	2	current	current	ADJ
dpc-3032	45	3	study	study	NOUN
dpc-3032	45	4	intends	intend	VERB
dpc-3032	45	5	to	to	PART
dpc-3032	45	6	add	add	VERB
dpc-3032	45	7	more	more	ADJ
dpc-3032	45	8	data	datum	NOUN
dpc-3032	45	9	to	to	ADP
dpc-3032	45	10	the	the	DET
dpc-3032	45	11	growing	grow	VERB
dpc-3032	45	12	collection	collection	NOUN
dpc-3032	45	13	of	of	ADP
dpc-3032	45	14	evidence	evidence	NOUN
dpc-3032	45	15	on	on	ADP
dpc-3032	45	16	real	real	ADJ
dpc-3032	45	17	-	-	PUNCT
dpc-3032	45	18	life	life	NOUN
dpc-3032	45	19	treatment	treatment	NOUN
dpc-3032	45	20	with	with	ADP
dpc-3032	45	21	vismodegib	vismodegib	NOUN
dpc-3032	45	22	.	.	PUNCT
dpc-3032	46	1	methods	method	NOUN
dpc-3032	46	2	study	study	VERB
dpc-3032	46	3	population	population	NOUN
dpc-3032	46	4	,	,	PUNCT
dpc-3032	46	5	cohorts	cohort	NOUN
dpc-3032	46	6	and	and	CCONJ
dpc-3032	46	7	data	datum	NOUN
dpc-3032	46	8	collection	collection	NOUN
dpc-3032	46	9	this	this	DET
dpc-3032	46	10	study	study	NOUN
dpc-3032	46	11	was	be	AUX
dpc-3032	46	12	a	a	DET
dpc-3032	46	13	non	non	ADJ
dpc-3032	46	14	-	-	ADJ
dpc-3032	46	15	interventional	interventional	ADJ
dpc-3032	46	16	,	,	PUNCT
dpc-3032	46	17	prospective	prospective	ADJ
dpc-3032	46	18	cohort	cohort	NOUN
dpc-3032	46	19	study	study	NOUN
dpc-3032	46	20	in	in	ADP
dpc-3032	46	21	adult	adult	NOUN
dpc-3032	46	22	patients	patient	NOUN
dpc-3032	46	23	with	with	ADP
dpc-3032	46	24	abcc	abcc	NOUN
dpc-3032	46	25	.	.	PUNCT
dpc-3032	47	1	all	all	DET
dpc-3032	47	2	patients	patient	NOUN
dpc-3032	47	3	were	be	AUX
dpc-3032	47	4	planned	plan	VERB
dpc-3032	47	5	for	for	ADP
dpc-3032	47	6	vismodegib	vismodegib	NOUN
dpc-3032	47	7	treatment	treatment	NOUN
dpc-3032	47	8	within	within	ADP
dpc-3032	47	9	normal	normal	ADJ
dpc-3032	47	10	routine	routine	ADJ
dpc-3032	47	11	practice	practice	NOUN
dpc-3032	47	12	according	accord	VERB
dpc-3032	47	13	to	to	ADP
dpc-3032	47	14	the	the	DET
dpc-3032	47	15	current	current	ADJ
dpc-3032	47	16	product	product	NOUN
dpc-3032	47	17	label	label	NOUN
dpc-3032	47	18	.	.	PUNCT
dpc-3032	48	1	following	follow	VERB
dpc-3032	48	2	non	non	ADJ
dpc-3032	48	3	interventional	interventional	ADJ
dpc-3032	48	4	study	study	NOUN
dpc-3032	48	5	guidelines	guideline	NOUN
dpc-3032	48	6	,	,	PUNCT
dpc-3032	48	7	study	study	NOUN
dpc-3032	48	8	assessments	assessment	NOUN
dpc-3032	48	9	and	and	CCONJ
dpc-3032	48	10	timing	timing	NOUN
dpc-3032	48	11	of	of	ADP
dpc-3032	48	12	visits	visit	NOUN
dpc-3032	48	13	were	be	AUX
dpc-3032	48	14	not	not	PART
dpc-3032	48	15	mandatory	mandatory	ADJ
dpc-3032	48	16	,	,	PUNCT
dpc-3032	48	17	but	but	CCONJ
dpc-3032	48	18	performed	perform	VERB
dpc-3032	48	19	according	accord	VERB
dpc-3032	48	20	to	to	ADP
dpc-3032	48	21	routine	routine	ADJ
dpc-3032	48	22	care	care	NOUN
dpc-3032	48	23	at	at	ADP
dpc-3032	48	24	each	each	DET
dpc-3032	48	25	participating	participate	VERB
dpc-3032	48	26	clinic	clinic	NOUN
dpc-3032	48	27	(	(	PUNCT
dpc-3032	48	28	www.encepp	www.encepp	X
dpc-3032	48	29	.	.	PUNCT
dpc-3032	49	1	eu	eu	PROPN
dpc-3032	49	2	2011	2011	NUM
dpc-3032	49	3	)	)	PUNCT
dpc-3032	49	4	.	.	PUNCT
dpc-3032	50	1	guidelines	guideline	NOUN
dpc-3032	50	2	for	for	ADP
dpc-3032	50	3	good	good	ADJ
dpc-3032	50	4	pharmaco	pharmaco	NOUN
dpc-3032	50	5	-	-	PUNCT
dpc-3032	50	6	epidemiological	epidemiological	ADJ
dpc-3032	50	7	practice	practice	NOUN
dpc-3032	50	8	(	(	PUNCT
dpc-3032	50	9	gpp	gpp	NOUN
dpc-3032	50	10	)	)	PUNCT
dpc-3032	50	11	were	be	AUX
dpc-3032	50	12	followed	follow	VERB
dpc-3032	50	13	and	and	CCONJ
dpc-3032	50	14	approval	approval	NOUN
dpc-3032	50	15	by	by	ADP
dpc-3032	50	16	the	the	DET
dpc-3032	50	17	swedish	swedish	PROPN
dpc-3032	50	18	ethical	ethical	PROPN
dpc-3032	50	19	review	review	NOUN
dpc-3032	50	20	authority	authority	NOUN
dpc-3032	50	21	was	be	AUX
dpc-3032	50	22	obtained	obtain	VERB
dpc-3032	50	23	prior	prior	ADV
dpc-3032	50	24	to	to	ADP
dpc-3032	50	25	study	study	NOUN
dpc-3032	50	26	start	start	NOUN
dpc-3032	50	27	in	in	ADP
dpc-3032	50	28	december	december	PROPN
dpc-3032	50	29	2014	2014	NUM
dpc-3032	50	30	(	(	PUNCT
dpc-3032	50	31	www.pharmacoepi.org	www.pharmacoepi.org	NUM
dpc-3032	50	32	)	)	PUNCT
dpc-3032	50	33	.	.	PUNCT
dpc-3032	51	1	an	an	DET
dpc-3032	51	2	overview	overview	NOUN
dpc-3032	51	3	of	of	ADP
dpc-3032	51	4	the	the	DET
dpc-3032	51	5	study	study	NOUN
dpc-3032	51	6	details	detail	NOUN
dpc-3032	51	7	is	be	AUX
dpc-3032	51	8	published	publish	VERB
dpc-3032	51	9	on	on	ADP
dpc-3032	51	10	www.clinicaltrials.gov	www.clinicaltrials.gov	PROPN
dpc-3032	51	11	,	,	PUNCT
dpc-3032	51	12	nct	nct	PROPN
dpc-3032	51	13	02371967	02371967	NUM
dpc-3032	51	14	.	.	PUNCT
dpc-3032	52	1	the	the	DET
dpc-3032	52	2	study	study	NOUN
dpc-3032	52	3	enrolled	enrol	VERB
dpc-3032	52	4	50	50	NUM
dpc-3032	52	5	patients	patient	NOUN
dpc-3032	52	6	at	at	ADP
dpc-3032	52	7	four	four	NUM
dpc-3032	52	8	university	university	NOUN
dpc-3032	52	9	hospitals	hospital	NOUN
dpc-3032	52	10	in	in	ADP
dpc-3032	52	11	sweden	sweden	PROPN
dpc-3032	52	12	between	between	ADP
dpc-3032	52	13	april	april	PROPN
dpc-3032	52	14	2015	2015	NUM
dpc-3032	52	15	and	and	CCONJ
dpc-3032	52	16	september	september	PROPN
dpc-3032	52	17	2017	2017	NUM
dpc-3032	52	18	,	,	PUNCT
dpc-3032	52	19	with	with	ADP
dpc-3032	52	20	a	a	DET
dpc-3032	52	21	follow	follow	VERB
dpc-3032	52	22	-	-	PUNCT
dpc-3032	52	23	up	up	NOUN
dpc-3032	52	24	period	period	NOUN
dpc-3032	52	25	of	of	ADP
dpc-3032	52	26	3	3	NUM
dpc-3032	52	27	years	year	NOUN
dpc-3032	52	28	.	.	PUNCT
dpc-3032	53	1	the	the	DET
dpc-3032	53	2	trial	trial	NOUN
dpc-3032	53	3	sites	site	NOUN
dpc-3032	53	4	were	be	AUX
dpc-3032	53	5	two	two	NUM
dpc-3032	53	6	dermatology	dermatology	NOUN
dpc-3032	53	7	clinics	clinic	NOUN
dpc-3032	53	8	(	(	PUNCT
dpc-3032	53	9	skåne	skåne	PROPN
dpc-3032	53	10	university	university	PROPN
dpc-3032	53	11	hospital	hospital	PROPN
dpc-3032	53	12	and	and	CCONJ
dpc-3032	53	13	sahlgrenska	sahlgrenska	PROPN
dpc-3032	53	14	university	university	NOUN
dpc-3032	53	15	hospital	hospital	NOUN
dpc-3032	53	16	)	)	PUNCT
dpc-3032	53	17	and	and	CCONJ
dpc-3032	53	18	two	two	NUM
dpc-3032	53	19	oncology	oncology	NOUN
dpc-3032	53	20	clinics	clinic	NOUN
dpc-3032	53	21	(	(	PUNCT
dpc-3032	53	22	karolinska	karolinska	PROPN
dpc-3032	53	23	university	university	PROPN
dpc-3032	53	24	hospital	hospital	NOUN
dpc-3032	53	25	and	and	CCONJ
dpc-3032	53	26	norrland	norrland	PROPN
dpc-3032	53	27	university	university	NOUN
dpc-3032	53	28	hospital	hospital	NOUN
dpc-3032	53	29	)	)	PUNCT
dpc-3032	53	30	.	.	PUNCT
dpc-3032	54	1	patients	patient	NOUN
dpc-3032	54	2	included	include	VERB
dpc-3032	54	3	were	be	AUX
dpc-3032	54	4	≥18	≥18	NUM
dpc-3032	54	5	years	year	NOUN
dpc-3032	54	6	old	old	ADJ
dpc-3032	54	7	,	,	PUNCT
dpc-3032	54	8	with	with	ADP
dpc-3032	54	9	a	a	DET
dpc-3032	54	10	diagnosed	diagnose	VERB
dpc-3032	54	11	abcc	abcc	NOUN
dpc-3032	54	12	,	,	PUNCT
dpc-3032	54	13	defined	define	VERB
dpc-3032	54	14	as	as	ADP
dpc-3032	54	15	metastatic	metastatic	ADJ
dpc-3032	54	16	or	or	CCONJ
dpc-3032	54	17	locally	locally	ADV
dpc-3032	54	18	advanced	advanced	ADJ
dpc-3032	54	19	(	(	PUNCT
dpc-3032	54	20	where	where	SCONJ
dpc-3032	54	21	other	other	ADJ
dpc-3032	54	22	therapy	therapy	NOUN
dpc-3032	54	23	such	such	ADJ
dpc-3032	54	24	as	as	ADP
dpc-3032	54	25	surgery	surgery	NOUN
dpc-3032	54	26	or	or	CCONJ
dpc-3032	54	27	radiotherapy	radiotherapy	NOUN
dpc-3032	54	28	were	be	AUX
dpc-3032	54	29	not	not	PART
dpc-3032	54	30	an	an	DET
dpc-3032	54	31	option	option	NOUN
dpc-3032	54	32	)	)	PUNCT
dpc-3032	54	33	,	,	PUNCT
dpc-3032	54	34	or	or	CCONJ
dpc-3032	54	35	gorlin	gorlin	PROPN
dpc-3032	54	36	syndrome	syndrome	NOUN
dpc-3032	54	37	requiring	require	VERB
dpc-3032	54	38	systemic	systemic	ADJ
dpc-3032	54	39	treatment	treatment	NOUN
dpc-3032	54	40	and	and	CCONJ
dpc-3032	54	41	planned	plan	VERB
dpc-3032	54	42	for	for	ADP
dpc-3032	54	43	treatment	treatment	NOUN
dpc-3032	54	44	with	with	ADP
dpc-3032	54	45	vismodegib	vismodegib	NOUN
dpc-3032	54	46	.	.	PUNCT
dpc-3032	55	1	a	a	DET
dpc-3032	55	2	signed	sign	VERB
dpc-3032	55	3	informed	informed	ADJ
dpc-3032	55	4	consent	consent	NOUN
dpc-3032	55	5	for	for	ADP
dpc-3032	55	6	collection	collection	NOUN
dpc-3032	55	7	of	of	ADP
dpc-3032	55	8	data	datum	NOUN
dpc-3032	55	9	was	be	AUX
dpc-3032	55	10	obtained	obtain	VERB
dpc-3032	55	11	from	from	ADP
dpc-3032	55	12	all	all	DET
dpc-3032	55	13	patients	patient	NOUN
dpc-3032	55	14	before	before	ADP
dpc-3032	55	15	enrolment	enrolment	NOUN
dpc-3032	55	16	.	.	PUNCT
dpc-3032	56	1	all	all	DET
dpc-3032	56	2	patients	patient	NOUN
dpc-3032	56	3	were	be	AUX
dpc-3032	56	4	divided	divide	VERB
dpc-3032	56	5	into	into	ADP
dpc-3032	56	6	three	three	NUM
dpc-3032	56	7	cohorts	cohort	NOUN
dpc-3032	56	8	:	:	PUNCT
dpc-3032	56	9	cohort	cohort	NOUN
dpc-3032	56	10	1	1	NUM
dpc-3032	56	11	included	include	VERB
dpc-3032	56	12	patients	patient	NOUN
dpc-3032	56	13	with	with	ADP
dpc-3032	56	14	abcc	abcc	NOUN
dpc-3032	56	15	without	without	ADP
dpc-3032	56	16	gorlin	gorlin	PROPN
dpc-3032	56	17	syndrome	syndrome	PROPN
dpc-3032	56	18	and	and	CCONJ
dpc-3032	56	19	not	not	PART
dpc-3032	56	20	previously	previously	ADV
dpc-3032	56	21	exposed	expose	VERB
dpc-3032	56	22	to	to	ADP
dpc-3032	56	23	a	a	DET
dpc-3032	56	24	hedgehog	hedgehog	NOUN
dpc-3032	56	25	pathway	pathway	NOUN
dpc-3032	56	26	inhibitor	inhibitor	NOUN
dpc-3032	56	27	(	(	PUNCT
dpc-3032	56	28	hpi	hpi	PROPN
dpc-3032	56	29	)	)	PUNCT
dpc-3032	56	30	,	,	PUNCT
dpc-3032	56	31	cohort	cohort	NOUN
dpc-3032	56	32	2	2	NUM
dpc-3032	56	33	included	include	VERB
dpc-3032	56	34	patients	patient	NOUN
dpc-3032	56	35	with	with	ADP
dpc-3032	56	36	abcc	abcc	NOUN
dpc-3032	56	37	without	without	ADP
dpc-3032	56	38	gorlin	gorlin	PROPN
dpc-3032	56	39	syndrome	syndrome	PROPN
dpc-3032	56	40	that	that	PRON
dpc-3032	56	41	previously	previously	ADV
dpc-3032	56	42	had	have	AUX
dpc-3032	56	43	been	be	AUX
dpc-3032	56	44	exposed	expose	VERB
dpc-3032	56	45	to	to	ADP
dpc-3032	56	46	an	an	DET
dpc-3032	56	47	hpi	hpi	NOUN
dpc-3032	56	48	and	and	CCONJ
dpc-3032	56	49	cohort	cohort	PROPN
dpc-3032	56	50	3	3	NUM
dpc-3032	56	51	included	include	VERB
dpc-3032	56	52	patients	patient	NOUN
dpc-3032	56	53	with	with	ADP
dpc-3032	56	54	gorlin	gorlin	PROPN
dpc-3032	56	55	syndrome	syndrome	PROPN
dpc-3032	56	56	independent	independent	ADJ
dpc-3032	56	57	of	of	ADP
dpc-3032	56	58	previous	previous	ADJ
dpc-3032	56	59	exposure	exposure	NOUN
dpc-3032	56	60	to	to	ADP
dpc-3032	56	61	an	an	DET
dpc-3032	56	62	hpi	hpi	NOUN
dpc-3032	56	63	.	.	PUNCT
dpc-3032	57	1	patients	patient	NOUN
dpc-3032	57	2	previously	previously	ADV
dpc-3032	57	3	included	include	VERB
dpc-3032	57	4	in	in	ADP
dpc-3032	57	5	other	other	ADJ
dpc-3032	57	6	clinical	clinical	ADJ
dpc-3032	57	7	trials	trial	NOUN
dpc-3032	57	8	within	within	ADP
dpc-3032	57	9	90	90	NUM
dpc-3032	57	10	days	day	NOUN
dpc-3032	57	11	were	be	AUX
dpc-3032	57	12	excluded	exclude	VERB
dpc-3032	57	13	,	,	PUNCT
dpc-3032	57	14	with	with	ADP
dpc-3032	57	15	exceptions	exception	NOUN
dpc-3032	57	16	for	for	ADP
dpc-3032	57	17	patients	patient	NOUN
dpc-3032	57	18	in	in	ADP
dpc-3032	57	19	cohort	cohort	NOUN
dpc-3032	57	20	2	2	NUM
dpc-3032	57	21	.	.	PUNCT
dpc-3032	58	1	the	the	DET
dpc-3032	58	2	aim	aim	NOUN
dpc-3032	58	3	of	of	ADP
dpc-3032	58	4	the	the	DET
dpc-3032	58	5	study	study	NOUN
dpc-3032	58	6	was	be	AUX
dpc-3032	58	7	to	to	PART
dpc-3032	58	8	assess	assess	VERB
dpc-3032	58	9	effectiveness	effectiveness	NOUN
dpc-3032	58	10	,	,	PUNCT
dpc-3032	58	11	safety	safety	NOUN
dpc-3032	58	12	and	and	CCONJ
dpc-3032	58	13	treatment	treatment	NOUN
dpc-3032	58	14	patterns	pattern	NOUN
dpc-3032	58	15	of	of	ADP
dpc-3032	58	16	vismodegib	vismodegib	NOUN
dpc-3032	58	17	treatment	treatment	NOUN
dpc-3032	58	18	in	in	ADP
dpc-3032	58	19	a	a	DET
dpc-3032	58	20	real	real	ADJ
dpc-3032	58	21	-	-	PUNCT
dpc-3032	58	22	life	life	NOUN
dpc-3032	58	23	setting	setting	NOUN
dpc-3032	58	24	.	.	PUNCT
dpc-3032	59	1	clinical	clinical	ADJ
dpc-3032	59	2	outcomes	outcome	NOUN
dpc-3032	59	3	included	include	VERB
dpc-3032	59	4	:	:	PUNCT
dpc-3032	59	5	clinical	clinical	ADJ
dpc-3032	59	6	response	response	NOUN
dpc-3032	59	7	,	,	PUNCT
dpc-3032	59	8	time	time	NOUN
dpc-3032	59	9	to	to	PART
dpc-3032	59	10	response	response	VERB
dpc-3032	59	11	,	,	PUNCT
dpc-3032	59	12	duration	duration	NOUN
dpc-3032	59	13	of	of	ADP
dpc-3032	59	14	response	response	NOUN
dpc-3032	59	15	,	,	PUNCT
dpc-3032	59	16	recurrence	recurrence	NOUN
dpc-3032	59	17	rate	rate	NOUN
dpc-3032	59	18	,	,	PUNCT
dpc-3032	59	19	progression	progression	NOUN
dpc-3032	59	20	-	-	PUNCT
dpc-3032	59	21	free	free	ADJ
dpc-3032	59	22	survival	survival	NOUN
dpc-3032	59	23	and	and	CCONJ
dpc-3032	59	24	overall	overall	ADJ
dpc-3032	59	25	survival	survival	NOUN
dpc-3032	59	26	.	.	PUNCT
dpc-3032	60	1	safety	safety	NOUN
dpc-3032	60	2	objectives	objective	NOUN
dpc-3032	60	3	included	include	VERB
dpc-3032	60	4	:	:	PUNCT
dpc-3032	60	5	incidence	incidence	NOUN
dpc-3032	60	6	,	,	PUNCT
dpc-3032	60	7	severity	severity	NOUN
dpc-3032	60	8	,	,	PUNCT
dpc-3032	60	9	and	and	CCONJ
dpc-3032	60	10	relationship	relationship	NOUN
dpc-3032	60	11	of	of	ADP
dpc-3032	60	12	adverse	adverse	ADJ
dpc-3032	60	13	and	and	CCONJ
dpc-3032	60	14	serious	serious	ADJ
dpc-3032	60	15	adverse	adverse	ADJ
dpc-3032	60	16	events	event	NOUN
dpc-3032	60	17	(	(	PUNCT
dpc-3032	60	18	saes	sae	NOUN
dpc-3032	60	19	)	)	PUNCT
dpc-3032	60	20	including	include	VERB
dpc-3032	60	21	pregnancies	pregnancy	NOUN
dpc-3032	60	22	,	,	PUNCT
dpc-3032	60	23	and	and	CCONJ
dpc-3032	60	24	adverse	adverse	ADJ
dpc-3032	60	25	events	event	NOUN
dpc-3032	60	26	leading	lead	VERB
dpc-3032	60	27	to	to	ADP
dpc-3032	60	28	treatment	treatment	NOUN
dpc-3032	60	29	interruption	interruption	NOUN
dpc-3032	60	30	or	or	CCONJ
dpc-3032	60	31	conclusions	conclusion	NOUN
dpc-3032	60	32	:	:	PUNCT
dpc-3032	60	33	clinical	clinical	ADJ
dpc-3032	60	34	response	response	NOUN
dpc-3032	60	35	rates	rate	NOUN
dpc-3032	60	36	with	with	ADP
dpc-3032	60	37	vismodegib	vismodegib	NOUN
dpc-3032	60	38	for	for	ADP
dpc-3032	60	39	abcc	abcc	NOUN
dpc-3032	60	40	were	be	AUX
dpc-3032	60	41	comparable	comparable	ADJ
dpc-3032	60	42	to	to	ADP
dpc-3032	60	43	those	those	PRON
dpc-3032	60	44	of	of	ADP
dpc-3032	60	45	similar	similar	ADJ
dpc-3032	60	46	trials	trial	NOUN
dpc-3032	60	47	despite	despite	SCONJ
dpc-3032	60	48	a	a	DET
dpc-3032	60	49	shorter	short	ADJ
dpc-3032	60	50	and	and	CCONJ
dpc-3032	60	51	more	more	ADV
dpc-3032	60	52	intermittent	intermittent	ADJ
dpc-3032	60	53	treatment	treatment	NOUN
dpc-3032	60	54	duration	duration	NOUN
dpc-3032	60	55	.	.	PUNCT
dpc-3032	61	1	the	the	DET
dpc-3032	61	2	majority	majority	NOUN
dpc-3032	61	3	of	of	ADP
dpc-3032	61	4	re	re	NOUN
dpc-3032	61	5	-	-	NOUN
dpc-3032	61	6	challenges	challenge	NOUN
dpc-3032	61	7	lead	lead	VERB
dpc-3032	61	8	to	to	ADP
dpc-3032	61	9	partial	partial	ADJ
dpc-3032	61	10	or	or	CCONJ
dpc-3032	61	11	complete	complete	ADJ
dpc-3032	61	12	remissions	remission	NOUN
dpc-3032	61	13	.	.	PUNCT
dpc-3032	62	1	original	original	ADJ
dpc-3032	62	2	article	article	NOUN
dpc-3032	62	3	|	|	ADV
dpc-3032	62	4	dermatol	dermatol	ADJ
dpc-3032	62	5	pract	pract	NOUN
dpc-3032	62	6	concept	concept	NOUN
dpc-3032	62	7	.	.	PUNCT
dpc-3032	63	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	63	2	3	3	NUM
dpc-3032	63	3	discontinuation	discontinuation	NOUN
dpc-3032	63	4	.	.	PUNCT
dpc-3032	64	1	toxicity	toxicity	NOUN
dpc-3032	64	2	was	be	AUX
dpc-3032	64	3	graded	grade	VERB
dpc-3032	64	4	using	use	VERB
dpc-3032	64	5	national	national	ADJ
dpc-3032	64	6	cancer	cancer	PROPN
dpc-3032	64	7	institute	institute	PROPN
dpc-3032	64	8	common	common	ADJ
dpc-3032	64	9	terminology	terminology	NOUN
dpc-3032	64	10	criteria	criterion	NOUN
dpc-3032	64	11	for	for	ADP
dpc-3032	64	12	adverse	adverse	ADJ
dpc-3032	64	13	events	event	NOUN
dpc-3032	64	14	(	(	PUNCT
dpc-3032	64	15	nci	nci	PROPN
dpc-3032	64	16	ctcae	ctcae	PROPN
dpc-3032	64	17	)	)	PUNCT
dpc-3032	64	18	version	version	NOUN
dpc-3032	64	19	4	4	NUM
dpc-3032	64	20	.	.	PUNCT
dpc-3032	65	1	adverse	adverse	ADJ
dpc-3032	65	2	events	event	NOUN
dpc-3032	65	3	of	of	ADP
dpc-3032	65	4	special	special	ADJ
dpc-3032	65	5	interest	interest	NOUN
dpc-3032	65	6	(	(	PUNCT
dpc-3032	65	7	aesi	aesi	ADJ
dpc-3032	65	8	)	)	PUNCT
dpc-3032	65	9	included	include	VERB
dpc-3032	65	10	:	:	PUNCT
dpc-3032	65	11	muscle	muscle	NOUN
dpc-3032	65	12	spasms	spasm	NOUN
dpc-3032	65	13	,	,	PUNCT
dpc-3032	65	14	alopecia	alopecia	NOUN
dpc-3032	65	15	,	,	PUNCT
dpc-3032	65	16	dysgeusia	dysgeusia	PROPN
dpc-3032	65	17	/	/	SYM
dpc-3032	65	18	ageusia	ageusia	NOUN
dpc-3032	65	19	,	,	PUNCT
dpc-3032	65	20	weight	weight	NOUN
dpc-3032	65	21	loss	loss	NOUN
dpc-3032	65	22	,	,	PUNCT
dpc-3032	65	23	fatigue	fatigue	NOUN
dpc-3032	65	24	of	of	ADP
dpc-3032	65	25	grade	grade	NOUN
dpc-3032	65	26	≥2	≥2	PROPN
dpc-3032	65	27	,	,	PUNCT
dpc-3032	65	28	amenorrhea	amenorrhea	NOUN
dpc-3032	65	29	,	,	PUNCT
dpc-3032	65	30	gastrointestinal	gastrointestinal	ADJ
dpc-3032	65	31	events	event	NOUN
dpc-3032	65	32	grade	grade	NOUN
dpc-3032	65	33	≥2	≥2	NOUN
dpc-3032	65	34	,	,	PUNCT
dpc-3032	65	35	cardiovascular	cardiovascular	ADJ
dpc-3032	65	36	events	event	NOUN
dpc-3032	65	37	and	and	CCONJ
dpc-3032	65	38	secondary	secondary	ADJ
dpc-3032	65	39	malignancies	malignancy	NOUN
dpc-3032	65	40	.	.	PUNCT
dpc-3032	66	1	patient	patient	ADJ
dpc-3032	66	2	data	datum	NOUN
dpc-3032	66	3	were	be	AUX
dpc-3032	66	4	collected	collect	VERB
dpc-3032	66	5	from	from	ADP
dpc-3032	66	6	the	the	DET
dpc-3032	66	7	patient	patient	NOUN
dpc-3032	66	8	’s	’s	PART
dpc-3032	66	9	medical	medical	ADJ
dpc-3032	66	10	records	record	NOUN
dpc-3032	66	11	into	into	ADP
dpc-3032	66	12	an	an	DET
dpc-3032	66	13	electronic	electronic	ADJ
dpc-3032	66	14	case	case	NOUN
dpc-3032	66	15	report	report	NOUN
dpc-3032	66	16	form	form	NOUN
dpc-3032	66	17	(	(	PUNCT
dpc-3032	66	18	crf	crf	NOUN
dpc-3032	66	19	)	)	PUNCT
dpc-3032	66	20	(	(	PUNCT
dpc-3032	66	21	viedoc	viedoc	NOUN
dpc-3032	66	22	™	™	ADJ
dpc-3032	66	23	,	,	PUNCT
dpc-3032	66	24	viedoc	viedoc	NOUN
dpc-3032	66	25	technologies	technology	NOUN
dpc-3032	66	26	,	,	PUNCT
dpc-3032	66	27	uppsala	uppsala	PROPN
dpc-3032	66	28	,	,	PUNCT
dpc-3032	66	29	sweden	sweden	PROPN
dpc-3032	66	30	)	)	PUNCT
dpc-3032	66	31	and	and	CCONJ
dpc-3032	66	32	data	datum	NOUN
dpc-3032	66	33	quality	quality	NOUN
dpc-3032	66	34	was	be	AUX
dpc-3032	66	35	checked	check	VERB
dpc-3032	66	36	by	by	ADP
dpc-3032	66	37	on	on	ADP
dpc-3032	66	38	-	-	PUNCT
dpc-3032	66	39	site	site	NOUN
dpc-3032	66	40	and	and	CCONJ
dpc-3032	66	41	remote	remote	ADJ
dpc-3032	66	42	monitoring	monitoring	NOUN
dpc-3032	66	43	.	.	PUNCT
dpc-3032	67	1	analysis	analysis	NOUN
dpc-3032	67	2	of	of	ADP
dpc-3032	67	3	data	datum	NOUN
dpc-3032	67	4	was	be	AUX
dpc-3032	67	5	done	do	VERB
dpc-3032	67	6	after	after	ADP
dpc-3032	67	7	a	a	DET
dpc-3032	67	8	clean	clean	ADJ
dpc-3032	67	9	file	file	NOUN
dpc-3032	67	10	report	report	NOUN
dpc-3032	67	11	and	and	CCONJ
dpc-3032	67	12	database	database	NOUN
dpc-3032	67	13	lock	lock	NOUN
dpc-3032	67	14	.	.	PUNCT
dpc-3032	68	1	statistical	statistical	ADJ
dpc-3032	68	2	analysis	analysis	NOUN
dpc-3032	68	3	the	the	DET
dpc-3032	68	4	statistical	statistical	ADJ
dpc-3032	68	5	analysis	analysis	NOUN
dpc-3032	68	6	was	be	AUX
dpc-3032	68	7	done	do	VERB
dpc-3032	68	8	according	accord	VERB
dpc-3032	68	9	to	to	ADP
dpc-3032	68	10	the	the	DET
dpc-3032	68	11	ich	ich	NOUN
dpc-3032	68	12	e9	e9	PROPN
dpc-3032	68	13	guideline	guideline	NOUN
dpc-3032	68	14	for	for	ADP
dpc-3032	68	15	statistical	statistical	ADJ
dpc-3032	68	16	principles	principle	NOUN
dpc-3032	68	17	of	of	ADP
dpc-3032	68	18	clinical	clinical	ADJ
dpc-3032	68	19	trials	trial	NOUN
dpc-3032	68	20	using	use	VERB
dpc-3032	68	21	sas	sas	PROPN
dpc-3032	68	22	®	®	NOUN
dpc-3032	68	23	(	(	PUNCT
dpc-3032	68	24	version	version	NOUN
dpc-3032	68	25	9.4	9.4	NUM
dpc-3032	68	26	or	or	CCONJ
dpc-3032	68	27	higher	high	ADJ
dpc-3032	68	28	)	)	PUNCT
dpc-3032	68	29	.	.	PUNCT
dpc-3032	69	1	the	the	DET
dpc-3032	69	2	intention	intention	NOUN
dpc-3032	69	3	-	-	PUNCT
dpc-3032	69	4	to	to	ADP
dpc-3032	69	5	-	-	PUNCT
dpc-3032	69	6	treat	treat	VERB
dpc-3032	69	7	(	(	PUNCT
dpc-3032	69	8	itt	itt	ADJ
dpc-3032	69	9	)	)	PUNCT
dpc-3032	69	10	population	population	NOUN
dpc-3032	69	11	used	use	VERB
dpc-3032	69	12	for	for	ADP
dpc-3032	69	13	the	the	DET
dpc-3032	69	14	effectiveness	effectiveness	NOUN
dpc-3032	69	15	analysis	analysis	NOUN
dpc-3032	69	16	was	be	AUX
dpc-3032	69	17	defined	define	VERB
dpc-3032	69	18	as	as	ADP
dpc-3032	69	19	all	all	DET
dpc-3032	69	20	patients	patient	NOUN
dpc-3032	69	21	enrolled	enrol	VERB
dpc-3032	69	22	in	in	ADP
dpc-3032	69	23	the	the	DET
dpc-3032	69	24	study	study	NOUN
dpc-3032	69	25	.	.	PUNCT
dpc-3032	70	1	the	the	DET
dpc-3032	70	2	safety	safety	NOUN
dpc-3032	70	3	population	population	NOUN
dpc-3032	70	4	was	be	AUX
dpc-3032	70	5	defined	define	VERB
dpc-3032	70	6	as	as	ADP
dpc-3032	70	7	all	all	DET
dpc-3032	70	8	patients	patient	NOUN
dpc-3032	70	9	who	who	PRON
dpc-3032	70	10	received	receive	VERB
dpc-3032	70	11	at	at	ADV
dpc-3032	70	12	least	least	ADV
dpc-3032	70	13	one	one	NUM
dpc-3032	70	14	dose	dose	NOUN
dpc-3032	70	15	of	of	ADP
dpc-3032	70	16	vismodegib	vismodegib	NOUN
dpc-3032	70	17	during	during	ADP
dpc-3032	70	18	the	the	DET
dpc-3032	70	19	study	study	NOUN
dpc-3032	70	20	.	.	PUNCT
dpc-3032	71	1	meddra	meddra	NOUN
dpc-3032	71	2	terminology	terminology	NOUN
dpc-3032	71	3	was	be	AUX
dpc-3032	71	4	used	use	VERB
dpc-3032	71	5	for	for	ADP
dpc-3032	71	6	adverse	adverse	ADJ
dpc-3032	71	7	events	event	NOUN
dpc-3032	71	8	and	and	CCONJ
dpc-3032	71	9	nci	nci	PROPN
dpc-3032	71	10	ctcae	ctcae	PROPN
dpc-3032	71	11	version	version	PROPN
dpc-3032	71	12	4	4	NUM
dpc-3032	71	13	was	be	AUX
dpc-3032	71	14	used	use	VERB
dpc-3032	71	15	for	for	ADP
dpc-3032	71	16	toxicity	toxicity	NOUN
dpc-3032	71	17	grading	grading	NOUN
dpc-3032	71	18	.	.	PUNCT
dpc-3032	72	1	tumor	tumor	NOUN
dpc-3032	72	2	assessments	assessment	NOUN
dpc-3032	72	3	were	be	AUX
dpc-3032	72	4	done	do	VERB
dpc-3032	72	5	by	by	ADP
dpc-3032	72	6	radiological	radiological	ADJ
dpc-3032	72	7	assessment	assessment	NOUN
dpc-3032	72	8	using	use	VERB
dpc-3032	72	9	recist	recist	NOUN
dpc-3032	72	10	v	v	ADP
dpc-3032	72	11	1.1	1.1	NUM
dpc-3032	72	12	.	.	PUNCT
dpc-3032	73	1	and/or	and/or	CCONJ
dpc-3032	73	2	by	by	ADP
dpc-3032	73	3	clinical	clinical	ADJ
dpc-3032	73	4	assessment	assessment	NOUN
dpc-3032	73	5	.	.	PUNCT
dpc-3032	74	1	the	the	DET
dpc-3032	74	2	analysis	analysis	NOUN
dpc-3032	74	3	of	of	ADP
dpc-3032	74	4	the	the	DET
dpc-3032	74	5	study	study	NOUN
dpc-3032	74	6	was	be	AUX
dpc-3032	74	7	exploratory	exploratory	ADJ
dpc-3032	74	8	and	and	CCONJ
dpc-3032	74	9	descriptive	descriptive	ADJ
dpc-3032	74	10	methods	method	NOUN
dpc-3032	74	11	were	be	AUX
dpc-3032	74	12	used	use	VERB
dpc-3032	74	13	,	,	PUNCT
dpc-3032	74	14	presenting	present	VERB
dpc-3032	74	15	data	datum	NOUN
dpc-3032	74	16	by	by	ADP
dpc-3032	74	17	cohort	cohort	NOUN
dpc-3032	74	18	and	and	CCONJ
dpc-3032	74	19	in	in	ADP
dpc-3032	74	20	total	total	NOUN
dpc-3032	74	21	.	.	PUNCT
dpc-3032	75	1	no	no	DET
dpc-3032	75	2	pre	pre	ADJ
dpc-3032	75	3	-	-	ADJ
dpc-3032	75	4	specified	specified	ADJ
dpc-3032	75	5	hypotheses	hypothesis	NOUN
dpc-3032	75	6	were	be	AUX
dpc-3032	75	7	defined	define	VERB
dpc-3032	75	8	,	,	PUNCT
dpc-3032	75	9	the	the	DET
dpc-3032	75	10	sample	sample	NOUN
dpc-3032	75	11	size	size	NOUN
dpc-3032	75	12	of	of	ADP
dpc-3032	75	13	50	50	NUM
dpc-3032	75	14	patients	patient	NOUN
dpc-3032	75	15	was	be	AUX
dpc-3032	75	16	regarded	regard	VERB
dpc-3032	75	17	as	as	ADV
dpc-3032	75	18	sufficient	sufficient	ADJ
dpc-3032	75	19	to	to	PART
dpc-3032	75	20	characterize	characterize	VERB
dpc-3032	75	21	the	the	DET
dpc-3032	75	22	treatment	treatment	NOUN
dpc-3032	75	23	pattern	pattern	NOUN
dpc-3032	75	24	considering	consider	VERB
dpc-3032	75	25	the	the	DET
dpc-3032	75	26	rare	rare	ADJ
dpc-3032	75	27	indication	indication	NOUN
dpc-3032	75	28	of	of	ADP
dpc-3032	75	29	abcc	abcc	NOUN
dpc-3032	75	30	.	.	PUNCT
dpc-3032	76	1	continuous	continuous	ADJ
dpc-3032	76	2	data	datum	NOUN
dpc-3032	76	3	were	be	AUX
dpc-3032	76	4	summarized	summarize	VERB
dpc-3032	76	5	as	as	ADP
dpc-3032	76	6	the	the	DET
dpc-3032	76	7	number	number	NOUN
dpc-3032	76	8	of	of	ADP
dpc-3032	76	9	subjects	subject	NOUN
dpc-3032	76	10	with	with	ADP
dpc-3032	76	11	evaluable	evaluable	ADJ
dpc-3032	76	12	observations	observation	NOUN
dpc-3032	76	13	and	and	CCONJ
dpc-3032	76	14	missing	miss	VERB
dpc-3032	76	15	observations	observation	NOUN
dpc-3032	76	16	,	,	PUNCT
dpc-3032	76	17	arithmetic	arithmetic	ADJ
dpc-3032	76	18	mean	mean	NOUN
dpc-3032	76	19	and	and	CCONJ
dpc-3032	76	20	standard	standard	ADJ
dpc-3032	76	21	deviation	deviation	NOUN
dpc-3032	76	22	,	,	PUNCT
dpc-3032	76	23	median	median	NOUN
dpc-3032	76	24	with	with	ADP
dpc-3032	76	25	first	first	ADJ
dpc-3032	76	26	and	and	CCONJ
dpc-3032	76	27	third	third	ADJ
dpc-3032	76	28	quartiles	quartile	NOUN
dpc-3032	76	29	,	,	PUNCT
dpc-3032	76	30	minimum	minimum	NOUN
dpc-3032	76	31	and	and	CCONJ
dpc-3032	76	32	maximum	maximum	ADJ
dpc-3032	76	33	.	.	PUNCT
dpc-3032	77	1	categorical	categorical	ADJ
dpc-3032	77	2	data	datum	NOUN
dpc-3032	77	3	were	be	AUX
dpc-3032	77	4	presented	present	VERB
dpc-3032	77	5	using	use	VERB
dpc-3032	77	6	frequency	frequency	NOUN
dpc-3032	77	7	and	and	CCONJ
dpc-3032	77	8	percentage	percentage	NOUN
dpc-3032	77	9	.	.	PUNCT
dpc-3032	78	1	confidence	confidence	NOUN
dpc-3032	78	2	intervals	interval	NOUN
dpc-3032	78	3	were	be	AUX
dpc-3032	78	4	2	2	NUM
dpc-3032	78	5	-	-	NUM
dpc-3032	78	6	sided	sided	ADJ
dpc-3032	78	7	with	with	ADP
dpc-3032	78	8	a	a	DET
dpc-3032	78	9	95	95	NUM
dpc-3032	78	10	%	%	NOUN
dpc-3032	78	11	confidence	confidence	NOUN
dpc-3032	78	12	interval	interval	NOUN
dpc-3032	78	13	.	.	PUNCT
dpc-3032	79	1	drug	drug	NOUN
dpc-3032	79	2	exposure	exposure	NOUN
dpc-3032	79	3	was	be	AUX
dpc-3032	79	4	summarized	summarize	VERB
dpc-3032	79	5	with	with	ADP
dpc-3032	79	6	number	number	NOUN
dpc-3032	79	7	and	and	CCONJ
dpc-3032	79	8	percentage	percentage	NOUN
dpc-3032	79	9	of	of	ADP
dpc-3032	79	10	patients	patient	NOUN
dpc-3032	79	11	for	for	ADP
dpc-3032	79	12	the	the	DET
dpc-3032	79	13	total	total	ADJ
dpc-3032	79	14	exposure	exposure	NOUN
dpc-3032	79	15	,	,	PUNCT
dpc-3032	79	16	maximum	maximum	ADJ
dpc-3032	79	17	treatment	treatment	NOUN
dpc-3032	79	18	duration	duration	NOUN
dpc-3032	79	19	,	,	PUNCT
dpc-3032	79	20	including	include	VERB
dpc-3032	79	21	breakdowns	breakdown	NOUN
dpc-3032	79	22	for	for	ADP
dpc-3032	79	23	treatment	treatment	NOUN
dpc-3032	79	24	pauses	pause	NOUN
dpc-3032	79	25	and	and	CCONJ
dpc-3032	79	26	dose	dose	NOUN
dpc-3032	79	27	modifications	modification	NOUN
dpc-3032	79	28	.	.	PUNCT
dpc-3032	80	1	more	more	ADJ
dpc-3032	80	2	than	than	ADP
dpc-3032	80	3	one	one	NUM
dpc-3032	80	4	treatment	treatment	NOUN
dpc-3032	80	5	discontinuation	discontinuation	NOUN
dpc-3032	80	6	or	or	CCONJ
dpc-3032	80	7	dose	dose	NOUN
dpc-3032	80	8	modification	modification	NOUN
dpc-3032	80	9	could	could	AUX
dpc-3032	80	10	be	be	AUX
dpc-3032	80	11	reported	report	VERB
dpc-3032	80	12	for	for	ADP
dpc-3032	80	13	each	each	DET
dpc-3032	80	14	patient	patient	NOUN
dpc-3032	80	15	.	.	PUNCT
dpc-3032	81	1	results	result	NOUN
dpc-3032	81	2	in	in	ADP
dpc-3032	81	3	total	total	ADJ
dpc-3032	81	4	,	,	PUNCT
dpc-3032	81	5	50	50	NUM
dpc-3032	81	6	patients	patient	NOUN
dpc-3032	81	7	were	be	AUX
dpc-3032	81	8	enrolled	enrol	VERB
dpc-3032	81	9	.	.	PUNCT
dpc-3032	82	1	one	one	NUM
dpc-3032	82	2	patient	patient	NOUN
dpc-3032	82	3	was	be	AUX
dpc-3032	82	4	found	find	VERB
dpc-3032	82	5	non	non	ADJ
dpc-3032	82	6	-	-	ADJ
dpc-3032	82	7	eligible	eligible	ADJ
dpc-3032	82	8	prior	prior	ADV
dpc-3032	82	9	to	to	ADP
dpc-3032	82	10	drug	drug	NOUN
dpc-3032	82	11	intake	intake	NOUN
dpc-3032	82	12	and	and	CCONJ
dpc-3032	82	13	excluded	exclude	VERB
dpc-3032	82	14	from	from	ADP
dpc-3032	82	15	the	the	DET
dpc-3032	82	16	study	study	NOUN
dpc-3032	82	17	.	.	PUNCT
dpc-3032	83	1	the	the	DET
dpc-3032	83	2	remaining	remain	VERB
dpc-3032	83	3	49	49	NUM
dpc-3032	83	4	patients	patient	NOUN
dpc-3032	83	5	comprised	comprise	VERB
dpc-3032	83	6	the	the	DET
dpc-3032	83	7	itt	itt	ADJ
dpc-3032	83	8	population	population	NOUN
dpc-3032	83	9	.	.	PUNCT
dpc-3032	84	1	one	one	NUM
dpc-3032	84	2	of	of	ADP
dpc-3032	84	3	these	these	DET
dpc-3032	84	4	patients	patient	NOUN
dpc-3032	84	5	withdrew	withdraw	VERB
dpc-3032	84	6	consent	consent	NOUN
dpc-3032	84	7	prior	prior	ADV
dpc-3032	84	8	to	to	ADP
dpc-3032	84	9	first	first	ADJ
dpc-3032	84	10	administration	administration	NOUN
dpc-3032	84	11	of	of	ADP
dpc-3032	84	12	vismodegib	vismodegib	PROPN
dpc-3032	84	13	.	.	PUNCT
dpc-3032	85	1	thus	thus	ADV
dpc-3032	85	2	,	,	PUNCT
dpc-3032	85	3	the	the	DET
dpc-3032	85	4	remaining	remain	VERB
dpc-3032	85	5	48	48	NUM
dpc-3032	85	6	  	  	SPACE
dpc-3032	85	7	patients	patient	NOUN
dpc-3032	85	8	constituted	constitute	VERB
dpc-3032	85	9	the	the	DET
dpc-3032	85	10	safety	safety	NOUN
dpc-3032	85	11	population	population	NOUN
dpc-3032	85	12	.	.	PUNCT
dpc-3032	86	1	in	in	ADP
dpc-3032	86	2	total	total	ADJ
dpc-3032	86	3	,	,	PUNCT
dpc-3032	86	4	40	40	NUM
dpc-3032	86	5	patients	patient	NOUN
dpc-3032	86	6	were	be	AUX
dpc-3032	86	7	diagnosed	diagnose	VERB
dpc-3032	86	8	with	with	ADP
dpc-3032	86	9	abcc	abcc	NOUN
dpc-3032	86	10	without	without	ADP
dpc-3032	86	11	gorlin	gorlin	PROPN
dpc-3032	86	12	syndrome	syndrome	PROPN
dpc-3032	86	13	.	.	PUNCT
dpc-3032	87	1	the	the	DET
dpc-3032	87	2	majority	majority	NOUN
dpc-3032	87	3	of	of	ADP
dpc-3032	87	4	these	these	PRON
dpc-3032	87	5	,	,	PUNCT
dpc-3032	87	6	37	37	NUM
dpc-3032	87	7	patients	patient	NOUN
dpc-3032	87	8	,	,	PUNCT
dpc-3032	87	9	were	be	AUX
dpc-3032	87	10	not	not	PART
dpc-3032	87	11	previously	previously	ADV
dpc-3032	87	12	exposed	expose	VERB
dpc-3032	87	13	to	to	ADP
dpc-3032	87	14	an	an	DET
dpc-3032	87	15	hpi	hpi	NOUN
dpc-3032	87	16	and	and	CCONJ
dpc-3032	87	17	allocated	allocate	VERB
dpc-3032	87	18	to	to	PART
dpc-3032	87	19	cohort	cohort	VERB
dpc-3032	87	20	1	1	NUM
dpc-3032	87	21	.	.	PUNCT
dpc-3032	88	1	thus	thus	ADV
dpc-3032	88	2	,	,	PUNCT
dpc-3032	88	3	three	three	NUM
dpc-3032	88	4	patients	patient	NOUN
dpc-3032	88	5	were	be	AUX
dpc-3032	88	6	allocated	allocate	VERB
dpc-3032	88	7	to	to	PART
dpc-3032	88	8	cohort	cohort	VERB
dpc-3032	88	9	2	2	NUM
dpc-3032	88	10	.	.	NOUN
dpc-3032	88	11	nine	nine	NUM
dpc-3032	88	12	patients	patient	NOUN
dpc-3032	88	13	with	with	ADP
dpc-3032	88	14	gorlin	gorlin	PROPN
dpc-3032	88	15	syndrome	syndrome	PROPN
dpc-3032	88	16	were	be	AUX
dpc-3032	88	17	allocated	allocate	VERB
dpc-3032	88	18	to	to	PART
dpc-3032	88	19	cohort	cohort	VERB
dpc-3032	88	20	3	3	NUM
dpc-3032	88	21	independent	independent	NOUN
dpc-3032	88	22	of	of	ADP
dpc-3032	88	23	previous	previous	ADJ
dpc-3032	88	24	exposure	exposure	NOUN
dpc-3032	88	25	to	to	ADP
dpc-3032	88	26	an	an	DET
dpc-3032	88	27	hpi	hpi	PROPN
dpc-3032	88	28	.	.	PUNCT
dpc-3032	89	1	baseline	baseline	PROPN
dpc-3032	89	2	patient	patient	ADJ
dpc-3032	89	3	characteristics	characteristic	NOUN
dpc-3032	89	4	can	can	AUX
dpc-3032	89	5	be	be	AUX
dpc-3032	89	6	found	find	VERB
dpc-3032	89	7	in	in	ADP
dpc-3032	89	8	table	table	NOUN
dpc-3032	89	9	1	1	NUM
dpc-3032	89	10	.	.	PUNCT
dpc-3032	90	1	one	one	NUM
dpc-3032	90	2	patient	patient	NOUN
dpc-3032	90	3	of	of	ADP
dpc-3032	90	4	childbearing	childbeare	VERB
dpc-3032	90	5	potential	potential	NOUN
dpc-3032	90	6	was	be	AUX
dpc-3032	90	7	included	include	VERB
dpc-3032	90	8	and	and	CCONJ
dpc-3032	90	9	followed	follow	VERB
dpc-3032	90	10	with	with	ADP
dpc-3032	90	11	monthly	monthly	ADJ
dpc-3032	90	12	pregnancy	pregnancy	NOUN
dpc-3032	90	13	tests	test	VERB
dpc-3032	90	14	up	up	ADP
dpc-3032	90	15	to	to	PART
dpc-3032	90	16	1	1	NUM
dpc-3032	90	17	year	year	NOUN
dpc-3032	90	18	after	after	ADP
dpc-3032	90	19	treatment	treatment	NOUN
dpc-3032	90	20	completion	completion	NOUN
dpc-3032	90	21	.	.	PUNCT
dpc-3032	91	1	all	all	DET
dpc-3032	91	2	tests	test	NOUN
dpc-3032	91	3	were	be	AUX
dpc-3032	91	4	negative	negative	ADJ
dpc-3032	91	5	.	.	PUNCT
dpc-3032	92	1	all	all	DET
dpc-3032	92	2	patients	patient	NOUN
dpc-3032	92	3	had	have	VERB
dpc-3032	92	4	an	an	DET
dpc-3032	92	5	ongoing	ongoing	ADJ
dpc-3032	92	6	locally	locally	ADV
dpc-3032	92	7	advanced	advanced	ADJ
dpc-3032	92	8	or	or	CCONJ
dpc-3032	92	9	metastatic	metastatic	ADJ
dpc-3032	92	10	bcc	bcc	PROPN
dpc-3032	92	11	or	or	CCONJ
dpc-3032	92	12	gorlin	gorlin	PROPN
dpc-3032	92	13	syndrome	syndrome	PROPN
dpc-3032	92	14	at	at	ADP
dpc-3032	92	15	enrollment	enrollment	NOUN
dpc-3032	92	16	,	,	PUNCT
dpc-3032	92	17	and	and	CCONJ
dpc-3032	92	18	two	two	NUM
dpc-3032	92	19	patients	patient	NOUN
dpc-3032	92	20	had	have	VERB
dpc-3032	92	21	recurrent	recurrent	ADJ
dpc-3032	92	22	disease	disease	NOUN
dpc-3032	92	23	following	follow	VERB
dpc-3032	92	24	previous	previous	ADJ
dpc-3032	92	25	treatment	treatment	NOUN
dpc-3032	92	26	.	.	PUNCT
dpc-3032	93	1	six	six	NUM
dpc-3032	93	2	patients	patient	NOUN
dpc-3032	93	3	(	(	PUNCT
dpc-3032	93	4	12.2	12.2	NUM
dpc-3032	93	5	%	%	NOUN
dpc-3032	93	6	)	)	PUNCT
dpc-3032	93	7	had	have	VERB
dpc-3032	93	8	other	other	ADJ
dpc-3032	93	9	prior	prior	ADJ
dpc-3032	93	10	cancer	cancer	NOUN
dpc-3032	93	11	history	history	NOUN
dpc-3032	93	12	(	(	PUNCT
dpc-3032	93	13	fibrosarcoma	fibrosarcoma	ADJ
dpc-3032	93	14	,	,	PUNCT
dpc-3032	93	15	lymphoma	lymphoma	NOUN
dpc-3032	93	16	,	,	PUNCT
dpc-3032	93	17	melanoma	melanoma	NOUN
dpc-3032	93	18	,	,	PUNCT
dpc-3032	93	19	nasopharyngeal	nasopharyngeal	ADJ
dpc-3032	93	20	cancer	cancer	NOUN
dpc-3032	93	21	,	,	PUNCT
dpc-3032	93	22	prostate	prostate	NOUN
dpc-3032	93	23	cancer	cancer	NOUN
dpc-3032	93	24	and	and	CCONJ
dpc-3032	93	25	squamous	squamous	ADJ
dpc-3032	93	26	cell	cell	NOUN
dpc-3032	93	27	carcinoma	carcinoma	NOUN
dpc-3032	93	28	)	)	PUNCT
dpc-3032	93	29	.	.	PUNCT
dpc-3032	94	1	the	the	DET
dpc-3032	94	2	most	most	ADV
dpc-3032	94	3	frequent	frequent	ADJ
dpc-3032	94	4	non	non	ADJ
dpc-3032	94	5	-	-	ADJ
dpc-3032	94	6	cancer	cancer	ADJ
dpc-3032	94	7	condition	condition	NOUN
dpc-3032	94	8	was	be	AUX
dpc-3032	94	9	hypertension	hypertension	NOUN
dpc-3032	94	10	.	.	PUNCT
dpc-3032	95	1	six	six	NUM
dpc-3032	95	2	patients	patient	NOUN
dpc-3032	95	3	(	(	PUNCT
dpc-3032	95	4	12.2	12.2	NUM
dpc-3032	95	5	%	%	NOUN
dpc-3032	95	6	)	)	PUNCT
dpc-3032	95	7	were	be	AUX
dpc-3032	95	8	reported	report	VERB
dpc-3032	95	9	to	to	PART
dpc-3032	95	10	have	have	AUX
dpc-3032	95	11	received	receive	VERB
dpc-3032	95	12	vismodegib	vismodegib	NOUN
dpc-3032	95	13	previously	previously	ADV
dpc-3032	95	14	,	,	PUNCT
dpc-3032	95	15	all	all	DET
dpc-3032	95	16	patients	patient	NOUN
dpc-3032	95	17	in	in	ADP
dpc-3032	95	18	cohort	cohort	NOUN
dpc-3032	95	19	2	2	NUM
dpc-3032	95	20	and	and	CCONJ
dpc-3032	95	21	three	three	NUM
dpc-3032	95	22	patients	patient	NOUN
dpc-3032	95	23	in	in	ADP
dpc-3032	95	24	cohort	cohort	NOUN
dpc-3032	95	25	3	3	NUM
dpc-3032	95	26	.	.	PUNCT
dpc-3032	96	1	at	at	ADP
dpc-3032	96	2	baseline	baseline	NOUN
dpc-3032	96	3	,	,	PUNCT
dpc-3032	96	4	the	the	DET
dpc-3032	96	5	extent	extent	NOUN
dpc-3032	96	6	of	of	ADP
dpc-3032	96	7	the	the	DET
dpc-3032	96	8	disease	disease	NOUN
dpc-3032	96	9	was	be	AUX
dpc-3032	96	10	clinically	clinically	ADV
dpc-3032	96	11	assessed	assess	VERB
dpc-3032	96	12	in	in	ADP
dpc-3032	96	13	34	34	NUM
dpc-3032	96	14	patients	patient	NOUN
dpc-3032	96	15	whereas	whereas	SCONJ
dpc-3032	96	16	14	14	NUM
dpc-3032	96	17	patients	patient	NOUN
dpc-3032	96	18	also	also	ADV
dpc-3032	96	19	required	require	VERB
dpc-3032	96	20	radiological	radiological	ADJ
dpc-3032	96	21	assessment	assessment	NOUN
dpc-3032	96	22	.	.	PUNCT
dpc-3032	97	1	more	more	ADJ
dpc-3032	97	2	than	than	ADP
dpc-3032	97	3	half	half	NOUN
dpc-3032	97	4	of	of	ADP
dpc-3032	97	5	the	the	DET
dpc-3032	97	6	study	study	NOUN
dpc-3032	97	7	population	population	NOUN
dpc-3032	97	8	,	,	PUNCT
dpc-3032	97	9	28	28	NUM
dpc-3032	97	10	patients	patient	NOUN
dpc-3032	97	11	(	(	PUNCT
dpc-3032	97	12	57.1	57.1	NUM
dpc-3032	97	13	%	%	NOUN
dpc-3032	97	14	)	)	PUNCT
dpc-3032	97	15	completed	complete	VERB
dpc-3032	97	16	the	the	DET
dpc-3032	97	17	study	study	NOUN
dpc-3032	97	18	with	with	ADP
dpc-3032	97	19	a	a	DET
dpc-3032	97	20	3	3	NUM
dpc-3032	97	21	-	-	PUNCT
dpc-3032	97	22	year	year	NOUN
dpc-3032	97	23	follow	follow	NOUN
dpc-3032	97	24	-	-	PUNCT
dpc-3032	97	25	up	up	NOUN
dpc-3032	97	26	period	period	NOUN
dpc-3032	97	27	.	.	PUNCT
dpc-3032	98	1	the	the	DET
dpc-3032	98	2	remaining	remain	VERB
dpc-3032	98	3	study	study	NOUN
dpc-3032	98	4	population	population	NOUN
dpc-3032	98	5	(	(	PUNCT
dpc-3032	98	6	21	21	NUM
dpc-3032	98	7	patients	patient	NOUN
dpc-3032	98	8	,	,	PUNCT
dpc-3032	98	9	42.9	42.9	NUM
dpc-3032	98	10	%	%	NOUN
dpc-3032	98	11	)	)	PUNCT
dpc-3032	98	12	withdrew	withdraw	VERB
dpc-3032	98	13	prematurely	prematurely	ADV
dpc-3032	98	14	from	from	ADP
dpc-3032	98	15	the	the	DET
dpc-3032	98	16	study	study	NOUN
dpc-3032	98	17	.	.	PUNCT
dpc-3032	99	1	the	the	DET
dpc-3032	99	2	most	most	ADV
dpc-3032	99	3	common	common	ADJ
dpc-3032	99	4	reasons	reason	NOUN
dpc-3032	99	5	were	be	AUX
dpc-3032	99	6	death	death	NOUN
dpc-3032	99	7	(	(	PUNCT
dpc-3032	99	8	not	not	PART
dpc-3032	99	9	related	relate	VERB
dpc-3032	99	10	to	to	ADP
dpc-3032	99	11	treatment	treatment	NOUN
dpc-3032	99	12	)	)	PUNCT
dpc-3032	99	13	or	or	CCONJ
dpc-3032	99	14	progressive	progressive	ADJ
dpc-3032	99	15	disease	disease	NOUN
dpc-3032	99	16	.	.	PUNCT
dpc-3032	100	1	treatment	treatment	NOUN
dpc-3032	100	2	discontinuations	discontinuation	NOUN
dpc-3032	100	3	and	and	CCONJ
dpc-3032	100	4	pauses	pause	NOUN
dpc-3032	100	5	were	be	AUX
dpc-3032	100	6	frequent	frequent	ADJ
dpc-3032	100	7	and	and	CCONJ
dpc-3032	100	8	reported	report	VERB
dpc-3032	100	9	at	at	ADP
dpc-3032	100	10	least	least	ADJ
dpc-3032	100	11	once	once	ADV
dpc-3032	100	12	by	by	ADP
dpc-3032	100	13	45	45	NUM
dpc-3032	100	14	patients	patient	NOUN
dpc-3032	100	15	(	(	PUNCT
dpc-3032	100	16	93.8	93.8	NUM
dpc-3032	100	17	%	%	NOUN
dpc-3032	100	18	)	)	PUNCT
dpc-3032	100	19	during	during	ADP
dpc-3032	100	20	the	the	DET
dpc-3032	100	21	study	study	NOUN
dpc-3032	100	22	.	.	PUNCT
dpc-3032	101	1	the	the	DET
dpc-3032	101	2	most	most	ADV
dpc-3032	101	3	common	common	ADJ
dpc-3032	101	4	reasons	reason	NOUN
dpc-3032	101	5	were	be	AUX
dpc-3032	101	6	complete	complete	ADJ
dpc-3032	101	7	remissions	remission	NOUN
dpc-3032	101	8	(	(	PUNCT
dpc-3032	101	9	22	22	NUM
dpc-3032	101	10	patients	patient	NOUN
dpc-3032	101	11	)	)	PUNCT
dpc-3032	101	12	and	and	CCONJ
dpc-3032	101	13	adverse	adverse	ADJ
dpc-3032	101	14	events	event	NOUN
dpc-3032	101	15	(	(	PUNCT
dpc-3032	101	16	14	14	NUM
dpc-3032	101	17	patients	patient	NOUN
dpc-3032	101	18	)	)	PUNCT
dpc-3032	101	19	.	.	PUNCT
dpc-3032	102	1	median	median	ADJ
dpc-3032	102	2	duration	duration	NOUN
dpc-3032	102	3	of	of	ADP
dpc-3032	102	4	exposure	exposure	NOUN
dpc-3032	102	5	(	(	PUNCT
dpc-3032	102	6	including	include	VERB
dpc-3032	102	7	days	day	NOUN
dpc-3032	102	8	off	off	ADP
dpc-3032	102	9	treatment	treatment	NOUN
dpc-3032	102	10	)	)	PUNCT
dpc-3032	102	11	was	be	AUX
dpc-3032	102	12	5.7	5.7	NUM
dpc-3032	102	13	months	month	NOUN
dpc-3032	102	14	(	(	PUNCT
dpc-3032	102	15	range	range	NOUN
dpc-3032	102	16	1	1	NUM
dpc-3032	102	17	-	-	SYM
dpc-3032	102	18	35.9	35.9	NUM
dpc-3032	102	19	months	month	NOUN
dpc-3032	102	20	)	)	PUNCT
dpc-3032	102	21	and	and	CCONJ
dpc-3032	102	22	5.2	5.2	NUM
dpc-3032	102	23	months	month	NOUN
dpc-3032	102	24	(	(	PUNCT
dpc-3032	102	25	range	range	NOUN
dpc-3032	102	26	1	1	NUM
dpc-3032	102	27	-	-	SYM
dpc-3032	102	28	35.5	35.5	NUM
dpc-3032	102	29	months	month	NOUN
dpc-3032	102	30	)	)	PUNCT
dpc-3032	102	31	excluding	exclude	VERB
dpc-3032	102	32	days	day	NOUN
dpc-3032	102	33	off	off	ADP
dpc-3032	102	34	treatment	treatment	NOUN
dpc-3032	102	35	(	(	PUNCT
dpc-3032	102	36	table	table	NOUN
dpc-3032	102	37	2	2	NUM
dpc-3032	102	38	)	)	PUNCT
dpc-3032	102	39	.	.	PUNCT
dpc-3032	103	1	the	the	DET
dpc-3032	103	2	overall	overall	ADJ
dpc-3032	103	3	treatment	treatment	NOUN
dpc-3032	103	4	pattern	pattern	NOUN
dpc-3032	103	5	with	with	ADP
dpc-3032	103	6	number	number	NOUN
dpc-3032	103	7	of	of	ADP
dpc-3032	103	8	days	day	NOUN
dpc-3032	103	9	of	of	ADP
dpc-3032	103	10	treatment	treatment	NOUN
dpc-3032	103	11	and	and	CCONJ
dpc-3032	103	12	pauses	pause	VERB
dpc-3032	103	13	from	from	ADP
dpc-3032	103	14	treatment	treatment	NOUN
dpc-3032	103	15	per	per	ADP
dpc-3032	103	16	patient	patient	NOUN
dpc-3032	103	17	showed	show	VERB
dpc-3032	103	18	high	high	ADJ
dpc-3032	103	19	variability	variability	NOUN
dpc-3032	103	20	(	(	PUNCT
dpc-3032	103	21	table	table	NOUN
dpc-3032	103	22	3	3	NUM
dpc-3032	103	23	)	)	PUNCT
dpc-3032	103	24	.	.	PUNCT
dpc-3032	104	1	of	of	ADP
dpc-3032	104	2	the	the	DET
dpc-3032	104	3	49	49	NUM
dpc-3032	104	4	included	include	VERB
dpc-3032	104	5	patients	patient	NOUN
dpc-3032	104	6	,	,	PUNCT
dpc-3032	104	7	43	43	NUM
dpc-3032	104	8	(	(	PUNCT
dpc-3032	104	9	87.8	87.8	NUM
dpc-3032	104	10	%	%	NOUN
dpc-3032	104	11	)	)	PUNCT
dpc-3032	104	12	achieved	achieve	VERB
dpc-3032	104	13	a	a	DET
dpc-3032	104	14	clinical	clinical	ADJ
dpc-3032	104	15	response	response	NOUN
dpc-3032	104	16	(	(	PUNCT
dpc-3032	104	17	95	95	NUM
dpc-3032	104	18	%	%	NOUN
dpc-3032	104	19	ci	ci	NOUN
dpc-3032	104	20	;	;	PUNCT
dpc-3032	104	21	75.2	75.2	NUM
dpc-3032	104	22	-	-	SYM
dpc-3032	104	23	95.4	95.4	NUM
dpc-3032	104	24	%	%	NOUN
dpc-3032	104	25	)	)	PUNCT
dpc-3032	104	26	.	.	PUNCT
dpc-3032	105	1	clinical	clinical	ADJ
dpc-3032	105	2	response	response	NOUN
dpc-3032	105	3	was	be	AUX
dpc-3032	105	4	observed	observe	VERB
dpc-3032	105	5	in	in	ADP
dpc-3032	105	6	34	34	NUM
dpc-3032	105	7	patients	patient	NOUN
dpc-3032	105	8	(	(	PUNCT
dpc-3032	105	9	91.9	91.9	NUM
dpc-3032	105	10	%	%	NOUN
dpc-3032	105	11	)	)	PUNCT
dpc-3032	105	12	in	in	ADP
dpc-3032	105	13	cohort	cohort	NOUN
dpc-3032	105	14	1	1	NUM
dpc-3032	105	15	,	,	PUNCT
dpc-3032	105	16	two	two	NUM
dpc-3032	105	17	patients	patient	NOUN
dpc-3032	105	18	(	(	PUNCT
dpc-3032	105	19	66.7	66.7	NUM
dpc-3032	105	20	%	%	NOUN
dpc-3032	105	21	)	)	PUNCT
dpc-3032	105	22	in	in	ADP
dpc-3032	105	23	cohort	cohort	NOUN
dpc-3032	105	24	2	2	NUM
dpc-3032	105	25	and	and	CCONJ
dpc-3032	105	26	seven	seven	NUM
dpc-3032	105	27	patients	patient	NOUN
dpc-3032	105	28	(	(	PUNCT
dpc-3032	105	29	77.8	77.8	NUM
dpc-3032	105	30	%	%	NOUN
dpc-3032	105	31	)	)	PUNCT
dpc-3032	105	32	in	in	ADP
dpc-3032	105	33	cohort	cohort	NOUN
dpc-3032	105	34	3	3	NUM
dpc-3032	105	35	.	.	PUNCT
dpc-3032	105	36	approximately	approximately	ADV
dpc-3032	105	37	half	half	NOUN
dpc-3032	105	38	of	of	ADP
dpc-3032	105	39	the	the	DET
dpc-3032	105	40	responses	response	NOUN
dpc-3032	105	41	were	be	AUX
dpc-3032	105	42	complete	complete	ADJ
dpc-3032	105	43	remissions	remission	NOUN
dpc-3032	105	44	as	as	ADP
dpc-3032	105	45	best	good	ADJ
dpc-3032	105	46	response	response	NOUN
dpc-3032	105	47	.	.	PUNCT
dpc-3032	106	1	at	at	ADP
dpc-3032	106	2	2	2	NUM
dpc-3032	106	3	months	month	NOUN
dpc-3032	106	4	of	of	ADP
dpc-3032	106	5	treatment	treatment	NOUN
dpc-3032	106	6	(	(	PUNCT
dpc-3032	106	7	60	60	NUM
dpc-3032	106	8	days	day	NOUN
dpc-3032	106	9	)	)	PUNCT
dpc-3032	106	10	,	,	PUNCT
dpc-3032	106	11	approximately	approximately	ADV
dpc-3032	106	12	half	half	NOUN
dpc-3032	106	13	of	of	ADP
dpc-3032	106	14	the	the	DET
dpc-3032	106	15	study	study	NOUN
dpc-3032	106	16	population	population	NOUN
dpc-3032	106	17	had	have	AUX
dpc-3032	106	18	achieved	achieve	VERB
dpc-3032	106	19	a	a	DET
dpc-3032	106	20	clinical	clinical	ADJ
dpc-3032	106	21	response	response	NOUN
dpc-3032	106	22	,	,	PUNCT
dpc-3032	106	23	and	and	CCONJ
dpc-3032	106	24	at	at	ADP
dpc-3032	106	25	3.3	3.3	NUM
dpc-3032	106	26	months	month	NOUN
dpc-3032	106	27	(	(	PUNCT
dpc-3032	106	28	100	100	NUM
dpc-3032	106	29	days	day	NOUN
dpc-3032	106	30	)	)	PUNCT
dpc-3032	106	31	,	,	PUNCT
dpc-3032	106	32	80	80	NUM
dpc-3032	106	33	%	%	NOUN
dpc-3032	106	34	of	of	ADP
dpc-3032	106	35	the	the	DET
dpc-3032	106	36	patients	patient	NOUN
dpc-3032	106	37	had	have	AUX
dpc-3032	106	38	achieved	achieve	VERB
dpc-3032	106	39	a	a	DET
dpc-3032	106	40	clinical	clinical	ADJ
dpc-3032	106	41	response	response	NOUN
dpc-3032	106	42	.	.	PUNCT
dpc-3032	107	1	median	median	ADJ
dpc-3032	107	2	duration	duration	NOUN
dpc-3032	107	3	of	of	ADP
dpc-3032	107	4	response	response	NOUN
dpc-3032	107	5	was	be	AUX
dpc-3032	107	6	approximately	approximately	ADV
dpc-3032	107	7	14.3	14.3	NUM
dpc-3032	107	8	months	month	NOUN
dpc-3032	107	9	(	(	PUNCT
dpc-3032	107	10	430	430	NUM
dpc-3032	107	11	days	day	NOUN
dpc-3032	107	12	)	)	PUNCT
dpc-3032	107	13	.	.	PUNCT
dpc-3032	108	1	recurrence	recurrence	NOUN
dpc-3032	108	2	during	during	ADP
dpc-3032	108	3	the	the	DET
dpc-3032	108	4	study	study	NOUN
dpc-3032	108	5	occurred	occur	VERB
dpc-3032	108	6	in	in	ADP
dpc-3032	108	7	14	14	NUM
dpc-3032	108	8	patients	patient	NOUN
dpc-3032	108	9	(	(	PUNCT
dpc-3032	108	10	28.6	28.6	NUM
dpc-3032	108	11	%	%	NOUN
dpc-3032	108	12	)	)	PUNCT
dpc-3032	108	13	,	,	PUNCT
dpc-3032	108	14	11	11	NUM
dpc-3032	108	15	of	of	ADP
dpc-3032	108	16	these	these	DET
dpc-3032	108	17	patients	patient	NOUN
dpc-3032	108	18	were	be	AUX
dpc-3032	108	19	in	in	ADP
dpc-3032	108	20	cohort	cohort	NOUN
dpc-3032	108	21	1	1	NUM
dpc-3032	108	22	and	and	CCONJ
dpc-3032	108	23	three	three	NUM
dpc-3032	108	24	patients	patient	NOUN
dpc-3032	108	25	were	be	AUX
dpc-3032	108	26	in	in	ADP
dpc-3032	108	27	cohort	cohort	NOUN
dpc-3032	108	28	3	3	NUM
dpc-3032	108	29	.	.	PUNCT
dpc-3032	109	1	the	the	DET
dpc-3032	109	2	median	median	ADJ
dpc-3032	109	3	time	time	NOUN
dpc-3032	109	4	to	to	ADP
dpc-3032	109	5	recurrence	recurrence	NOUN
dpc-3032	109	6	was	be	AUX
dpc-3032	109	7	4	4	NUM
dpc-3032	109	8	original	original	ADJ
dpc-3032	109	9	article	article	NOUN
dpc-3032	109	10	|	|	ADV
dpc-3032	109	11	dermatol	dermatol	ADJ
dpc-3032	109	12	pract	pract	NOUN
dpc-3032	109	13	concept	concept	NOUN
dpc-3032	109	14	.	.	PUNCT
dpc-3032	110	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	110	2	events	event	NOUN
dpc-3032	110	3	(	(	PUNCT
dpc-3032	110	4	77.3	77.3	NUM
dpc-3032	110	5	%	%	NOUN
dpc-3032	110	6	)	)	PUNCT
dpc-3032	110	7	were	be	AUX
dpc-3032	110	8	regarded	regard	VERB
dpc-3032	110	9	to	to	PART
dpc-3032	110	10	be	be	AUX
dpc-3032	110	11	at	at	ADV
dpc-3032	110	12	least	least	ADV
dpc-3032	110	13	possibly	possibly	ADV
dpc-3032	110	14	related	relate	VERB
dpc-3032	110	15	to	to	ADP
dpc-3032	110	16	vismodegib	vismodegib	NOUN
dpc-3032	110	17	treatment	treatment	NOUN
dpc-3032	110	18	.	.	PUNCT
dpc-3032	111	1	most	most	ADJ
dpc-3032	111	2	adverse	adverse	ADJ
dpc-3032	111	3	events	event	NOUN
dpc-3032	111	4	were	be	AUX
dpc-3032	111	5	mild	mild	ADJ
dpc-3032	111	6	or	or	CCONJ
dpc-3032	111	7	moderate	moderate	ADJ
dpc-3032	111	8	and	and	CCONJ
dpc-3032	111	9	commonly	commonly	ADV
dpc-3032	111	10	reported	report	VERB
dpc-3032	111	11	as	as	ADP
dpc-3032	111	12	muscle	muscle	NOUN
dpc-3032	111	13	spasms	spasm	NOUN
dpc-3032	111	14	,	,	PUNCT
dpc-3032	111	15	dysgeusia	dysgeusia	NOUN
dpc-3032	111	16	and	and	CCONJ
dpc-3032	111	17	alopecia	alopecia	NOUN
dpc-3032	111	18	.	.	PUNCT
dpc-3032	112	1	severe	severe	ADJ
dpc-3032	112	2	adverse	adverse	ADJ
dpc-3032	112	3	events	event	NOUN
dpc-3032	112	4	were	be	AUX
dpc-3032	112	5	reported	report	VERB
dpc-3032	112	6	on	on	ADP
dpc-3032	112	7	17	17	NUM
dpc-3032	112	8	occasions	occasion	NOUN
dpc-3032	112	9	,	,	PUNCT
dpc-3032	112	10	where	where	SCONJ
dpc-3032	112	11	three	three	NUM
dpc-3032	112	12	events	event	NOUN
dpc-3032	112	13	(	(	PUNCT
dpc-3032	112	14	ageusia	ageusia	NOUN
dpc-3032	112	15	,	,	PUNCT
dpc-3032	112	16	dysgeusia	dysgeusia	NOUN
dpc-3032	112	17	and	and	CCONJ
dpc-3032	112	18	fatigue	fatigue	NOUN
dpc-3032	112	19	)	)	PUNCT
dpc-3032	112	20	were	be	AUX
dpc-3032	112	21	deemed	deem	VERB
dpc-3032	112	22	as	as	ADV
dpc-3032	112	23	related	relate	VERB
dpc-3032	112	24	to	to	ADP
dpc-3032	112	25	vismodegib	vismodegib	NOUN
dpc-3032	112	26	treatment	treatment	NOUN
dpc-3032	112	27	.	.	PUNCT
dpc-3032	113	1	the	the	DET
dpc-3032	113	2	frequencies	frequency	NOUN
dpc-3032	113	3	of	of	ADP
dpc-3032	113	4	predefined	predefine	VERB
dpc-3032	113	5	aesis	aesis	NOUN
dpc-3032	113	6	can	can	AUX
dpc-3032	113	7	be	be	AUX
dpc-3032	113	8	found	find	VERB
dpc-3032	113	9	in	in	ADP
dpc-3032	113	10	table	table	NOUN
dpc-3032	113	11	4	4	NUM
dpc-3032	113	12	.	.	PUNCT
dpc-3032	114	1	a	a	DET
dpc-3032	114	2	total	total	NOUN
dpc-3032	114	3	of	of	ADP
dpc-3032	114	4	19	19	NUM
dpc-3032	114	5	saes	sae	NOUN
dpc-3032	114	6	were	be	AUX
dpc-3032	114	7	reported	report	VERB
dpc-3032	114	8	during	during	ADP
dpc-3032	114	9	the	the	DET
dpc-3032	114	10	entire	entire	ADJ
dpc-3032	114	11	study	study	NOUN
dpc-3032	114	12	period	period	NOUN
dpc-3032	114	13	by	by	ADP
dpc-3032	114	14	16	16	NUM
dpc-3032	114	15	patients	patient	NOUN
dpc-3032	114	16	(	(	PUNCT
dpc-3032	114	17	33.3	33.3	NUM
dpc-3032	114	18	%	%	NOUN
dpc-3032	114	19	)	)	PUNCT
dpc-3032	114	20	.	.	PUNCT
dpc-3032	115	1	of	of	ADP
dpc-3032	115	2	these	these	PRON
dpc-3032	115	3	,	,	PUNCT
dpc-3032	115	4	11	11	NUM
dpc-3032	115	5	saes	sae	NOUN
dpc-3032	115	6	had	have	VERB
dpc-3032	115	7	a	a	DET
dpc-3032	115	8	fatal	fatal	ADJ
dpc-3032	115	9	outcome	outcome	NOUN
dpc-3032	115	10	.	.	PUNCT
dpc-3032	116	1	causes	cause	NOUN
dpc-3032	116	2	of	of	ADP
dpc-3032	116	3	death	death	NOUN
dpc-3032	116	4	included	include	VERB
dpc-3032	116	5	natural	natural	ADJ
dpc-3032	116	6	causes	cause	NOUN
dpc-3032	116	7	(	(	PUNCT
dpc-3032	116	8	3	3	NUM
dpc-3032	116	9	patients	patient	NOUN
dpc-3032	116	10	)	)	PUNCT
dpc-3032	116	11	,	,	PUNCT
dpc-3032	116	12	cardiac	cardiac	ADJ
dpc-3032	116	13	failure	failure	NOUN
dpc-3032	116	14	(	(	PUNCT
dpc-3032	116	15	2	2	NUM
dpc-3032	116	16	patients	patient	NOUN
dpc-3032	116	17	)	)	PUNCT
dpc-3032	116	18	,	,	PUNCT
dpc-3032	116	19	stroke	stroke	NOUN
dpc-3032	116	20	,	,	PUNCT
dpc-3032	116	21	complications	complication	NOUN
dpc-3032	116	22	after	after	ADP
dpc-3032	116	23	brain	brain	NOUN
dpc-3032	116	24	surgery	surgery	NOUN
dpc-3032	116	25	,	,	PUNCT
dpc-3032	116	26	gastrointestinal	gastrointestinal	ADJ
dpc-3032	116	27	bleeding	bleeding	NOUN
dpc-3032	116	28	,	,	PUNCT
dpc-3032	116	29	metastatic	metastatic	ADJ
dpc-3032	116	30	disease	disease	NOUN
dpc-3032	116	31	and	and	CCONJ
dpc-3032	116	32	in	in	ADP
dpc-3032	116	33	two	two	NUM
dpc-3032	116	34	patients	patient	NOUN
dpc-3032	116	35	the	the	DET
dpc-3032	116	36	cause	cause	NOUN
dpc-3032	116	37	was	be	AUX
dpc-3032	116	38	unknown	unknown	ADJ
dpc-3032	116	39	.	.	PUNCT
dpc-3032	117	1	one	one	NUM
dpc-3032	117	2	patient	patient	NOUN
dpc-3032	117	3	died	die	VERB
dpc-3032	117	4	while	while	SCONJ
dpc-3032	117	5	on	on	ADP
dpc-3032	117	6	treatment	treatment	NOUN
dpc-3032	117	7	due	due	ADP
dpc-3032	117	8	to	to	ADP
dpc-3032	117	9	natural	natural	ADJ
dpc-3032	117	10	causes	cause	NOUN
dpc-3032	117	11	and	and	CCONJ
dpc-3032	117	12	10	10	NUM
dpc-3032	117	13	approximately	approximately	ADV
dpc-3032	117	14	20	20	NUM
dpc-3032	117	15	months	month	NOUN
dpc-3032	117	16	(	(	PUNCT
dpc-3032	117	17	600	600	NUM
dpc-3032	117	18	days	day	NOUN
dpc-3032	117	19	)	)	PUNCT
dpc-3032	117	20	and	and	CCONJ
dpc-3032	117	21	there	there	PRON
dpc-3032	117	22	was	be	VERB
dpc-3032	117	23	a	a	DET
dpc-3032	117	24	20	20	NUM
dpc-3032	117	25	%	%	NOUN
dpc-3032	117	26	probability	probability	NOUN
dpc-3032	117	27	of	of	ADP
dpc-3032	117	28	an	an	DET
dpc-3032	117	29	early	early	ADJ
dpc-3032	117	30	recurrence	recurrence	NOUN
dpc-3032	117	31	at	at	ADP
dpc-3032	117	32	6.7	6.7	NUM
dpc-3032	117	33	months	month	NOUN
dpc-3032	117	34	(	(	PUNCT
dpc-3032	117	35	200	200	NUM
dpc-3032	117	36	days	day	NOUN
dpc-3032	117	37	)	)	PUNCT
dpc-3032	117	38	.	.	PUNCT
dpc-3032	118	1	ten	ten	NUM
dpc-3032	118	2	patients	patient	NOUN
dpc-3032	118	3	were	be	AUX
dpc-3032	118	4	re	re	VERB
dpc-3032	118	5	-	-	VERB
dpc-3032	118	6	challenged	challenge	VERB
dpc-3032	118	7	due	due	ADP
dpc-3032	118	8	to	to	ADP
dpc-3032	118	9	progression	progression	NOUN
dpc-3032	118	10	after	after	ADP
dpc-3032	118	11	an	an	DET
dpc-3032	118	12	initially	initially	ADV
dpc-3032	118	13	achieved	achieve	VERB
dpc-3032	118	14	response	response	NOUN
dpc-3032	118	15	.	.	PUNCT
dpc-3032	119	1	eight	eight	NUM
dpc-3032	119	2	reached	reach	VERB
dpc-3032	119	3	new	new	ADJ
dpc-3032	119	4	remissions	remission	NOUN
dpc-3032	119	5	,	,	PUNCT
dpc-3032	119	6	five	five	NUM
dpc-3032	119	7	with	with	ADP
dpc-3032	119	8	partial	partial	ADJ
dpc-3032	119	9	remissions	remission	NOUN
dpc-3032	119	10	and	and	CCONJ
dpc-3032	119	11	three	three	NUM
dpc-3032	119	12	with	with	ADP
dpc-3032	119	13	complete	complete	ADJ
dpc-3032	119	14	remissions	remission	NOUN
dpc-3032	119	15	.	.	PUNCT
dpc-3032	120	1	both	both	DET
dpc-3032	120	2	complete	complete	ADJ
dpc-3032	120	3	and	and	CCONJ
dpc-3032	120	4	partial	partial	ADJ
dpc-3032	120	5	responses	response	NOUN
dpc-3032	120	6	were	be	AUX
dpc-3032	120	7	achieved	achieve	VERB
dpc-3032	120	8	.	.	PUNCT
dpc-3032	121	1	two	two	NUM
dpc-3032	121	2	patients	patient	NOUN
dpc-3032	121	3	were	be	AUX
dpc-3032	121	4	even	even	ADV
dpc-3032	121	5	re	re	VERB
dpc-3032	121	6	-	-	VERB
dpc-3032	121	7	challenged	challenge	VERB
dpc-3032	121	8	twice	twice	ADV
dpc-3032	121	9	with	with	ADP
dpc-3032	121	10	repeated	repeat	VERB
dpc-3032	121	11	partial	partial	ADJ
dpc-3032	121	12	remissions	remission	NOUN
dpc-3032	121	13	as	as	ADP
dpc-3032	121	14	response	response	NOUN
dpc-3032	121	15	.	.	PUNCT
dpc-3032	122	1	the	the	DET
dpc-3032	122	2	median	median	ADJ
dpc-3032	122	3	progression	progression	NOUN
dpc-3032	122	4	-	-	PUNCT
dpc-3032	122	5	free	free	ADJ
dpc-3032	122	6	survival	survival	NOUN
dpc-3032	122	7	(	(	PUNCT
dpc-3032	122	8	pfs	pfs	PROPN
dpc-3032	122	9	)	)	PUNCT
dpc-3032	122	10	was	be	AUX
dpc-3032	122	11	estimated	estimate	VERB
dpc-3032	122	12	to	to	PART
dpc-3032	122	13	be	be	AUX
dpc-3032	122	14	16.6	16.6	NUM
dpc-3032	122	15	months	month	NOUN
dpc-3032	122	16	(	(	PUNCT
dpc-3032	122	17	500	500	NUM
dpc-3032	122	18	days	day	NOUN
dpc-3032	122	19	)	)	PUNCT
dpc-3032	122	20	.	.	PUNCT
dpc-3032	123	1	the	the	DET
dpc-3032	123	2	80	80	NUM
dpc-3032	123	3	%	%	NOUN
dpc-3032	123	4	overall	overall	ADJ
dpc-3032	123	5	survival	survival	NOUN
dpc-3032	123	6	rate	rate	NOUN
dpc-3032	123	7	was	be	AUX
dpc-3032	123	8	2.7	2.7	NUM
dpc-3032	123	9	years	year	NOUN
dpc-3032	123	10	and	and	CCONJ
dpc-3032	123	11	the	the	DET
dpc-3032	123	12	90	90	NUM
dpc-3032	123	13	%	%	NOUN
dpc-3032	123	14	overall	overall	ADJ
dpc-3032	123	15	survival	survival	NOUN
dpc-3032	123	16	rate	rate	NOUN
dpc-3032	123	17	(	(	PUNCT
dpc-3032	123	18	os	os	NOUN
dpc-3032	123	19	)	)	PUNCT
dpc-3032	123	20	was	be	AUX
dpc-3032	123	21	13	13	NUM
dpc-3032	123	22	months	month	NOUN
dpc-3032	123	23	.	.	PUNCT
dpc-3032	124	1	a	a	DET
dpc-3032	124	2	median	median	ADJ
dpc-3032	124	3	overall	overall	ADJ
dpc-3032	124	4	survival	survival	NOUN
dpc-3032	124	5	was	be	AUX
dpc-3032	124	6	not	not	PART
dpc-3032	124	7	reached	reach	VERB
dpc-3032	124	8	within	within	ADP
dpc-3032	124	9	the	the	DET
dpc-3032	124	10	study	study	NOUN
dpc-3032	124	11	period	period	NOUN
dpc-3032	124	12	(	(	PUNCT
dpc-3032	124	13	figure	figure	VERB
dpc-3032	124	14	i	i	PROPN
dpc-3032	124	15	)	)	PUNCT
dpc-3032	124	16	.	.	PUNCT
dpc-3032	125	1	there	there	PRON
dpc-3032	125	2	were	be	VERB
dpc-3032	125	3	45	45	NUM
dpc-3032	125	4	patients	patient	NOUN
dpc-3032	125	5	(	(	PUNCT
dpc-3032	125	6	93.8	93.8	NUM
dpc-3032	125	7	%	%	NOUN
dpc-3032	125	8	)	)	PUNCT
dpc-3032	125	9	that	that	PRON
dpc-3032	125	10	experienced	experience	VERB
dpc-3032	125	11	at	at	ADV
dpc-3032	125	12	least	least	ADV
dpc-3032	125	13	one	one	NUM
dpc-3032	125	14	adverse	adverse	ADJ
dpc-3032	125	15	event	event	NOUN
dpc-3032	125	16	,	,	PUNCT
dpc-3032	125	17	with	with	ADP
dpc-3032	125	18	a	a	DET
dpc-3032	125	19	total	total	NOUN
dpc-3032	125	20	of	of	ADP
dpc-3032	125	21	194	194	NUM
dpc-3032	125	22	events	event	NOUN
dpc-3032	125	23	.	.	PUNCT
dpc-3032	126	1	of	of	ADP
dpc-3032	126	2	these	these	PRON
dpc-3032	126	3	,	,	PUNCT
dpc-3032	126	4	150	150	NUM
dpc-3032	126	5	table	table	NOUN
dpc-3032	126	6	1	1	NUM
dpc-3032	126	7	.	.	PUNCT
dpc-3032	126	8	baseline	baseline	PROPN
dpc-3032	126	9	characteristics	characteristic	NOUN
dpc-3032	126	10	.	.	PUNCT
dpc-3032	127	1	cohort	cohort	NOUN
dpc-3032	127	2	1	1	NUM
dpc-3032	127	3	(	(	PUNCT
dpc-3032	127	4	n=37	n=37	NOUN
dpc-3032	127	5	)	)	PUNCT
dpc-3032	127	6	cohort	cohort	NOUN
dpc-3032	127	7	2	2	NUM
dpc-3032	127	8	(	(	PUNCT
dpc-3032	127	9	n=3	n=3	NOUN
dpc-3032	127	10	)	)	PUNCT
dpc-3032	127	11	cohort	cohort	NOUN
dpc-3032	127	12	3	3	NUM
dpc-3032	127	13	(	(	PUNCT
dpc-3032	127	14	n=9	n=9	NOUN
dpc-3032	127	15	)	)	PUNCT
dpc-3032	127	16	total	total	NOUN
dpc-3032	127	17	(	(	PUNCT
dpc-3032	127	18	n=49	n=49	NUM
dpc-3032	127	19	)	)	PUNCT
dpc-3032	127	20	age	age	NOUN
dpc-3032	127	21	,	,	PUNCT
dpc-3032	127	22	years	year	NOUN
dpc-3032	127	23	,	,	PUNCT
dpc-3032	127	24	mean	mean	INTJ
dpc-3032	127	25	(	(	PUNCT
dpc-3032	127	26	sd	sd	NOUN
dpc-3032	127	27	)	)	PUNCT
dpc-3032	127	28	78	78	NUM
dpc-3032	127	29	(	(	PUNCT
dpc-3032	127	30	11	11	NUM
dpc-3032	127	31	)	)	PUNCT
dpc-3032	127	32	66	66	NUM
dpc-3032	127	33	(	(	PUNCT
dpc-3032	127	34	20	20	NUM
dpc-3032	127	35	)	)	PUNCT
dpc-3032	127	36	56	56	NUM
dpc-3032	127	37	(	(	PUNCT
dpc-3032	127	38	11	11	NUM
dpc-3032	127	39	)	)	SYM
dpc-3032	127	40	73	73	NUM
dpc-3032	127	41	(	(	PUNCT
dpc-3032	127	42	14	14	NUM
dpc-3032	127	43	)	)	PUNCT
dpc-3032	127	44	age	age	NOUN
dpc-3032	127	45	,	,	PUNCT
dpc-3032	127	46	years	year	NOUN
dpc-3032	127	47	,	,	PUNCT
dpc-3032	127	48	min	min	PROPN
dpc-3032	127	49	-	-	ADJ
dpc-3032	127	50	max	max	PROPN
dpc-3032	127	51	50	50	NUM
dpc-3032	127	52	-	-	SYM
dpc-3032	127	53	97	97	NUM
dpc-3032	127	54	46	46	NUM
dpc-3032	127	55	-	-	SYM
dpc-3032	127	56	85	85	NUM
dpc-3032	127	57	43	43	NUM
dpc-3032	127	58	-	-	SYM
dpc-3032	127	59	74	74	NUM
dpc-3032	127	60	43	43	NUM
dpc-3032	127	61	-	-	SYM
dpc-3032	127	62	97	97	NUM
dpc-3032	127	63	female	female	NOUN
dpc-3032	127	64	,	,	PUNCT
dpc-3032	127	65	n	n	CCONJ
dpc-3032	127	66	(	(	PUNCT
dpc-3032	127	67	%	%	INTJ
dpc-3032	127	68	)	)	PUNCT
dpc-3032	127	69	16	16	NUM
dpc-3032	127	70	(	(	PUNCT
dpc-3032	127	71	43	43	NUM
dpc-3032	127	72	)	)	PUNCT
dpc-3032	127	73	0	0	NUM
dpc-3032	127	74	2	2	NUM
dpc-3032	127	75	(	(	PUNCT
dpc-3032	127	76	22	22	NUM
dpc-3032	127	77	)	)	PUNCT
dpc-3032	127	78	18	18	NUM
dpc-3032	127	79	(	(	PUNCT
dpc-3032	127	80	37	37	NUM
dpc-3032	127	81	)	)	PUNCT
dpc-3032	127	82	male	male	NOUN
dpc-3032	127	83	,	,	PUNCT
dpc-3032	127	84	n	n	CCONJ
dpc-3032	127	85	(	(	PUNCT
dpc-3032	127	86	%	%	INTJ
dpc-3032	127	87	)	)	PUNCT
dpc-3032	127	88	21	21	NUM
dpc-3032	127	89	(	(	PUNCT
dpc-3032	127	90	57	57	NUM
dpc-3032	127	91	)	)	PUNCT
dpc-3032	127	92	3	3	NUM
dpc-3032	127	93	(	(	PUNCT
dpc-3032	127	94	100	100	NUM
dpc-3032	127	95	)	)	PUNCT
dpc-3032	127	96	7	7	NUM
dpc-3032	127	97	(	(	PUNCT
dpc-3032	127	98	78	78	NUM
dpc-3032	127	99	)	)	PUNCT
dpc-3032	127	100	31	31	NUM
dpc-3032	127	101	(	(	PUNCT
dpc-3032	127	102	63	63	NUM
dpc-3032	127	103	)	)	PUNCT
dpc-3032	127	104	height	height	NOUN
dpc-3032	127	105	,	,	PUNCT
dpc-3032	127	106	mean	mean	INTJ
dpc-3032	127	107	(	(	PUNCT
dpc-3032	127	108	sd	sd	NOUN
dpc-3032	127	109	)	)	PUNCT
dpc-3032	127	110	,	,	PUNCT
dpc-3032	127	111	cm	cm	NOUN
dpc-3032	127	112	171	171	NUM
dpc-3032	127	113	(	(	PUNCT
dpc-3032	127	114	11	11	NUM
dpc-3032	127	115	)	)	SYM
dpc-3032	127	116	179	179	NUM
dpc-3032	127	117	(	(	PUNCT
dpc-3032	127	118	8)	8)	NUM
dpc-3032	127	119	184	184	NUM
dpc-3032	127	120	(	(	PUNCT
dpc-3032	127	121	9	9	NUM
dpc-3032	127	122	)	)	PUNCT
dpc-3032	127	123	173	173	NUM
dpc-3032	127	124	(	(	PUNCT
dpc-3032	127	125	11	11	NUM
dpc-3032	127	126	)	)	PUNCT
dpc-3032	127	127	weight	weight	NOUN
dpc-3032	127	128	,	,	PUNCT
dpc-3032	127	129	mean	mean	NOUN
dpc-3032	127	130	(	(	PUNCT
dpc-3032	127	131	sd	sd	NOUN
dpc-3032	127	132	)	)	PUNCT
dpc-3032	127	133	,	,	PUNCT
dpc-3032	127	134	kg	kg	PROPN
dpc-3032	127	135	76	76	NUM
dpc-3032	127	136	(	(	PUNCT
dpc-3032	127	137	19	19	NUM
dpc-3032	127	138	)	)	SYM
dpc-3032	127	139	91	91	NUM
dpc-3032	127	140	(	(	PUNCT
dpc-3032	127	141	11	11	NUM
dpc-3032	127	142	)	)	SYM
dpc-3032	127	143	96	96	NUM
dpc-3032	127	144	(	(	PUNCT
dpc-3032	127	145	25	25	NUM
dpc-3032	127	146	)	)	PUNCT
dpc-3032	127	147	80	80	NUM
dpc-3032	127	148	(	(	PUNCT
dpc-3032	127	149	21	21	NUM
dpc-3032	127	150	)	)	PUNCT
dpc-3032	127	151	ecog	ecog	VERB
dpc-3032	127	152	performance	performance	NOUN
dpc-3032	127	153	status	status	NOUN
dpc-3032	127	154	,	,	PUNCT
dpc-3032	127	155	n	n	PROPN
dpc-3032	127	156	(	(	PUNCT
dpc-3032	127	157	%	%	INTJ
dpc-3032	127	158	)	)	PUNCT
dpc-3032	127	159	ecog	ecog	VERB
dpc-3032	127	160	0	0	NUM
dpc-3032	127	161	-	-	SYM
dpc-3032	127	162	1	1	NUM
dpc-3032	127	163	31	31	NUM
dpc-3032	127	164	(	(	PUNCT
dpc-3032	127	165	84	84	NUM
dpc-3032	127	166	)	)	PUNCT
dpc-3032	127	167	3	3	NUM
dpc-3032	127	168	(	(	PUNCT
dpc-3032	127	169	100	100	NUM
dpc-3032	127	170	)	)	PUNCT
dpc-3032	127	171	8	8	NUM
dpc-3032	127	172	(	(	PUNCT
dpc-3032	127	173	89	89	NUM
dpc-3032	127	174	)	)	SYM
dpc-3032	127	175	42	42	NUM
dpc-3032	127	176	(	(	PUNCT
dpc-3032	127	177	86	86	NUM
dpc-3032	127	178	)	)	PUNCT
dpc-3032	127	179	ecog	ecog	VERB
dpc-3032	127	180	2	2	NUM
dpc-3032	127	181	1	1	NUM
dpc-3032	127	182	(	(	PUNCT
dpc-3032	127	183	3	3	NUM
dpc-3032	127	184	)	)	PUNCT
dpc-3032	127	185	0	0	NUM
dpc-3032	127	186	1	1	NUM
dpc-3032	127	187	(	(	PUNCT
dpc-3032	127	188	11	11	NUM
dpc-3032	127	189	)	)	SYM
dpc-3032	127	190	2	2	NUM
dpc-3032	127	191	(	(	PUNCT
dpc-3032	127	192	4	4	NUM
dpc-3032	127	193	)	)	PUNCT
dpc-3032	127	194	ecog	ecog	VERB
dpc-3032	127	195	3	3	NUM
dpc-3032	127	196	4	4	NUM
dpc-3032	127	197	(	(	PUNCT
dpc-3032	127	198	11	11	NUM
dpc-3032	127	199	)	)	PUNCT
dpc-3032	127	200	0	0	NUM
dpc-3032	127	201	0	0	NUM
dpc-3032	127	202	4	4	NUM
dpc-3032	127	203	(	(	PUNCT
dpc-3032	127	204	8)	8)	NUM
dpc-3032	127	205	ecog	ecog	VERB
dpc-3032	127	206	4	4	NUM
dpc-3032	127	207	1	1	NUM
dpc-3032	127	208	(	(	PUNCT
dpc-3032	127	209	3	3	NUM
dpc-3032	127	210	)	)	PUNCT
dpc-3032	127	211	0	0	NUM
dpc-3032	127	212	0	0	NUM
dpc-3032	127	213	1	1	NUM
dpc-3032	127	214	(	(	PUNCT
dpc-3032	127	215	2	2	NUM
dpc-3032	127	216	)	)	PUNCT
dpc-3032	127	217	bcc	bcc	PROPN
dpc-3032	127	218	assessment	assessment	NOUN
dpc-3032	127	219	at	at	ADP
dpc-3032	127	220	time	time	NOUN
dpc-3032	127	221	of	of	ADP
dpc-3032	127	222	diagnose	diagnose	NOUN
dpc-3032	127	223	,	,	PUNCT
dpc-3032	127	224	n	n	CCONJ
dpc-3032	127	225	(	(	PUNCT
dpc-3032	127	226	%	%	INTJ
dpc-3032	127	227	)	)	PUNCT
dpc-3032	127	228	clinical	clinical	ADJ
dpc-3032	127	229	,	,	PUNCT
dpc-3032	127	230	histopathology	histopathology	NOUN
dpc-3032	127	231	0	0	NUM
dpc-3032	127	232	0	0	NUM
dpc-3032	127	233	2	2	NUM
dpc-3032	127	234	(	(	PUNCT
dpc-3032	127	235	22	22	NUM
dpc-3032	127	236	)	)	PUNCT
dpc-3032	127	237	2	2	NUM
dpc-3032	127	238	(	(	PUNCT
dpc-3032	127	239	4	4	NUM
dpc-3032	127	240	)	)	PUNCT
dpc-3032	127	241	clinical	clinical	ADJ
dpc-3032	127	242	2	2	NUM
dpc-3032	127	243	(	(	PUNCT
dpc-3032	127	244	5	5	NUM
dpc-3032	127	245	)	)	PUNCT
dpc-3032	127	246	0	0	NUM
dpc-3032	127	247	2	2	NUM
dpc-3032	127	248	(	(	PUNCT
dpc-3032	127	249	22	22	NUM
dpc-3032	127	250	)	)	PUNCT
dpc-3032	127	251	4	4	NUM
dpc-3032	127	252	(	(	PUNCT
dpc-3032	127	253	8)	8)	NUM
dpc-3032	127	254	histopathology	histopathology	NOUN
dpc-3032	127	255	23	23	NUM
dpc-3032	127	256	(	(	PUNCT
dpc-3032	127	257	62	62	NUM
dpc-3032	127	258	)	)	SYM
dpc-3032	127	259	1	1	NUM
dpc-3032	127	260	(	(	PUNCT
dpc-3032	127	261	33	33	NUM
dpc-3032	127	262	)	)	PUNCT
dpc-3032	127	263	0	0	NUM
dpc-3032	127	264	24	24	NUM
dpc-3032	127	265	(	(	PUNCT
dpc-3032	127	266	49	49	NUM
dpc-3032	127	267	)	)	PUNCT
dpc-3032	127	268	unknown	unknown	ADJ
dpc-3032	127	269	10	10	NUM
dpc-3032	127	270	(	(	PUNCT
dpc-3032	127	271	27	27	NUM
dpc-3032	127	272	)	)	SYM
dpc-3032	127	273	2	2	NUM
dpc-3032	127	274	(	(	PUNCT
dpc-3032	127	275	67	67	NUM
dpc-3032	127	276	)	)	SYM
dpc-3032	127	277	5	5	NUM
dpc-3032	127	278	(	(	PUNCT
dpc-3032	127	279	56	56	NUM
dpc-3032	127	280	)	)	PUNCT
dpc-3032	127	281	17	17	NUM
dpc-3032	127	282	(	(	PUNCT
dpc-3032	127	283	35	35	NUM
dpc-3032	127	284	)	)	PUNCT
dpc-3032	127	285	missing	miss	VERB
dpc-3032	127	286	data	datum	NOUN
dpc-3032	127	287	2	2	NUM
dpc-3032	127	288	(	(	PUNCT
dpc-3032	127	289	5	5	NUM
dpc-3032	127	290	)	)	PUNCT
dpc-3032	127	291	0	0	NUM
dpc-3032	127	292	0	0	NUM
dpc-3032	127	293	2	2	NUM
dpc-3032	127	294	(	(	PUNCT
dpc-3032	127	295	4	4	NUM
dpc-3032	127	296	)	)	PUNCT
dpc-3032	127	297	previous	previous	ADJ
dpc-3032	127	298	medical	medical	ADJ
dpc-3032	127	299	treatments	treatment	NOUN
dpc-3032	127	300	,	,	PUNCT
dpc-3032	127	301	n	n	CCONJ
dpc-3032	127	302	(	(	PUNCT
dpc-3032	127	303	%	%	INTJ
dpc-3032	127	304	)	)	PUNCT
dpc-3032	127	305	a	a	DET
dpc-3032	127	306	imiquimod	imiquimod	ADJ
dpc-3032	127	307	1	1	NUM
dpc-3032	127	308	(	(	PUNCT
dpc-3032	127	309	3	3	NUM
dpc-3032	127	310	)	)	PUNCT
dpc-3032	127	311	0	0	NUM
dpc-3032	127	312	0	0	NUM
dpc-3032	127	313	1	1	NUM
dpc-3032	127	314	(	(	PUNCT
dpc-3032	127	315	2	2	NUM
dpc-3032	127	316	)	)	PUNCT
dpc-3032	127	317	vismodegib	vismodegib	NOUN
dpc-3032	127	318	0	0	NUM
dpc-3032	127	319	3	3	NUM
dpc-3032	127	320	(	(	PUNCT
dpc-3032	127	321	100	100	NUM
dpc-3032	127	322	)	)	PUNCT
dpc-3032	127	323	3	3	NUM
dpc-3032	127	324	(	(	PUNCT
dpc-3032	127	325	33	33	NUM
dpc-3032	127	326	)	)	PUNCT
dpc-3032	127	327	4	4	NUM
dpc-3032	127	328	previous	previous	ADJ
dpc-3032	127	329	surgical	surgical	ADJ
dpc-3032	127	330	procedures	procedure	NOUN
dpc-3032	127	331	,	,	PUNCT
dpc-3032	127	332	n	n	CCONJ
dpc-3032	127	333	(	(	PUNCT
dpc-3032	127	334	%	%	NOUN
dpc-3032	127	335	)	)	PUNCT
dpc-3032	127	336	b	b	NOUN
dpc-3032	127	337	surgery	surgery	NOUN
dpc-3032	127	338	14	14	NUM
dpc-3032	127	339	(	(	PUNCT
dpc-3032	127	340	37.8	37.8	NUM
dpc-3032	127	341	)	)	PUNCT
dpc-3032	127	342	0	0	NUM
dpc-3032	127	343	1	1	NUM
dpc-3032	127	344	(	(	PUNCT
dpc-3032	127	345	11.1	11.1	NUM
dpc-3032	127	346	)	)	PUNCT
dpc-3032	127	347	15	15	NUM
dpc-3032	127	348	(	(	PUNCT
dpc-3032	127	349	30.6	30.6	NUM
dpc-3032	127	350	)	)	PUNCT
dpc-3032	127	351	cryotherapy	cryotherapy	NOUN
dpc-3032	127	352	2	2	NUM
dpc-3032	127	353	(	(	PUNCT
dpc-3032	127	354	5.4	5.4	NUM
dpc-3032	127	355	)	)	PUNCT
dpc-3032	127	356	0	0	NUM
dpc-3032	127	357	0	0	NUM
dpc-3032	127	358	2	2	NUM
dpc-3032	127	359	(	(	PUNCT
dpc-3032	127	360	4.1	4.1	NUM
dpc-3032	127	361	)	)	PUNCT
dpc-3032	127	362	cryosurgery	cryosurgery	NOUN
dpc-3032	127	363	1	1	NUM
dpc-3032	127	364	(	(	PUNCT
dpc-3032	127	365	2.7	2.7	NUM
dpc-3032	127	366	)	)	PUNCT
dpc-3032	127	367	0	0	NUM
dpc-3032	127	368	0	0	NUM
dpc-3032	127	369	1	1	NUM
dpc-3032	127	370	(	(	PUNCT
dpc-3032	127	371	2.0	2.0	NUM
dpc-3032	127	372	)	)	PUNCT
dpc-3032	127	373	cardiac	cardiac	ADJ
dpc-3032	127	374	pacemaker	pacemaker	NOUN
dpc-3032	127	375	insertion	insertion	NOUN
dpc-3032	127	376	0	0	NUM
dpc-3032	127	377	1	1	NUM
dpc-3032	127	378	(	(	PUNCT
dpc-3032	127	379	33.3	33.3	NUM
dpc-3032	127	380	)	)	PUNCT
dpc-3032	127	381	0	0	NUM
dpc-3032	127	382	1	1	NUM
dpc-3032	127	383	(	(	PUNCT
dpc-3032	127	384	2.0	2.0	NUM
dpc-3032	127	385	)	)	PUNCT
dpc-3032	127	386	previous	previous	ADJ
dpc-3032	127	387	radiotherapy	radiotherapy	NOUN
dpc-3032	127	388	and	and	CCONJ
dpc-3032	127	389	photodynamic	photodynamic	ADJ
dpc-3032	127	390	therapy	therapy	NOUN
dpc-3032	127	391	n	n	CCONJ
dpc-3032	127	392	(	(	PUNCT
dpc-3032	127	393	%	%	INTJ
dpc-3032	127	394	)	)	PUNCT
dpc-3032	127	395	b	b	PROPN
dpc-3032	127	396	radiotherapy	radiotherapy	NOUN
dpc-3032	127	397	5	5	NUM
dpc-3032	127	398	(	(	PUNCT
dpc-3032	127	399	13.5	13.5	NUM
dpc-3032	127	400	)	)	PUNCT
dpc-3032	127	401	0	0	NUM
dpc-3032	127	402	0	0	NUM
dpc-3032	127	403	5	5	NUM
dpc-3032	127	404	(	(	PUNCT
dpc-3032	127	405	10.2	10.2	NUM
dpc-3032	127	406	)	)	PUNCT
dpc-3032	127	407	photodynamic	photodynamic	ADJ
dpc-3032	127	408	therapy	therapy	NOUN
dpc-3032	127	409	1	1	NUM
dpc-3032	127	410	(	(	PUNCT
dpc-3032	127	411	2.7	2.7	NUM
dpc-3032	127	412	)	)	PUNCT
dpc-3032	127	413	0	0	NUM
dpc-3032	127	414	0	0	NUM
dpc-3032	127	415	1	1	NUM
dpc-3032	127	416	(	(	PUNCT
dpc-3032	127	417	2.0	2.0	NUM
dpc-3032	127	418	)	)	PUNCT
dpc-3032	127	419	areflect	areflect	ADJ
dpc-3032	127	420	at	at	ADV
dpc-3032	127	421	least	least	ADV
dpc-3032	127	422	14	14	NUM
dpc-3032	127	423	days	day	NOUN
dpc-3032	127	424	prior	prior	ADV
dpc-3032	127	425	to	to	PART
dpc-3032	127	426	study	study	VERB
dpc-3032	127	427	start	start	NOUN
dpc-3032	127	428	blast	blast	NOUN
dpc-3032	127	429	10	10	NUM
dpc-3032	127	430	years	year	NOUN
dpc-3032	127	431	prior	prior	ADV
dpc-3032	127	432	to	to	PART
dpc-3032	127	433	study	study	VERB
dpc-3032	127	434	start	start	VERB
dpc-3032	127	435	original	original	ADJ
dpc-3032	127	436	article	article	NOUN
dpc-3032	127	437	|	|	ADV
dpc-3032	127	438	dermatol	dermatol	ADJ
dpc-3032	127	439	pract	pract	NOUN
dpc-3032	127	440	concept	concept	NOUN
dpc-3032	127	441	.	.	PUNCT
dpc-3032	128	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	128	2	5	5	NUM
dpc-3032	128	3	dysgeusia	dysgeusia	NOUN
dpc-3032	128	4	,	,	PUNCT
dpc-3032	128	5	upper	upper	ADJ
dpc-3032	128	6	limb	limb	NOUN
dpc-3032	128	7	fracture	fracture	NOUN
dpc-3032	128	8	,	,	PUNCT
dpc-3032	128	9	loss	loss	NOUN
dpc-3032	128	10	of	of	ADP
dpc-3032	128	11	effect	effect	NOUN
dpc-3032	128	12	and	and	CCONJ
dpc-3032	128	13	weight	weight	NOUN
dpc-3032	128	14	loss	loss	NOUN
dpc-3032	128	15	(	(	PUNCT
dpc-3032	128	16	table	table	NOUN
dpc-3032	128	17	4	4	NUM
dpc-3032	128	18	)	)	PUNCT
dpc-3032	128	19	.	.	PUNCT
dpc-3032	129	1	conclusions	conclusion	NOUN
dpc-3032	129	2	the	the	DET
dpc-3032	129	3	aim	aim	NOUN
dpc-3032	129	4	of	of	ADP
dpc-3032	129	5	the	the	DET
dpc-3032	129	6	current	current	ADJ
dpc-3032	129	7	study	study	NOUN
dpc-3032	129	8	was	be	AUX
dpc-3032	129	9	to	to	PART
dpc-3032	129	10	systematically	systematically	ADV
dpc-3032	129	11	collect	collect	VERB
dpc-3032	129	12	data	datum	NOUN
dpc-3032	129	13	on	on	ADP
dpc-3032	129	14	effect	effect	NOUN
dpc-3032	129	15	,	,	PUNCT
dpc-3032	129	16	safety	safety	NOUN
dpc-3032	129	17	and	and	CCONJ
dpc-3032	129	18	treatment	treatment	NOUN
dpc-3032	129	19	patterns	pattern	NOUN
dpc-3032	129	20	of	of	ADP
dpc-3032	129	21	vismodegib	vismodegib	NOUN
dpc-3032	129	22	in	in	ADP
dpc-3032	129	23	a	a	DET
dpc-3032	129	24	real	real	ADJ
dpc-3032	129	25	-	-	PUNCT
dpc-3032	129	26	world	world	NOUN
dpc-3032	129	27	setting	setting	NOUN
dpc-3032	129	28	.	.	PUNCT
dpc-3032	130	1	the	the	DET
dpc-3032	130	2	resulting	result	VERB
dpc-3032	130	3	study	study	NOUN
dpc-3032	130	4	population	population	NOUN
dpc-3032	130	5	correlates	correlate	VERB
dpc-3032	130	6	well	well	ADV
dpc-3032	130	7	in	in	ADP
dpc-3032	130	8	general	general	ADJ
dpc-3032	130	9	to	to	ADP
dpc-3032	130	10	other	other	ADJ
dpc-3032	130	11	studies	study	NOUN
dpc-3032	130	12	on	on	ADP
dpc-3032	130	13	the	the	DET
dpc-3032	130	14	use	use	NOUN
dpc-3032	130	15	of	of	ADP
dpc-3032	130	16	patients	patient	NOUN
dpc-3032	130	17	died	die	VERB
dpc-3032	130	18	during	during	ADP
dpc-3032	130	19	the	the	DET
dpc-3032	130	20	follow	follow	NOUN
dpc-3032	130	21	-	-	PUNCT
dpc-3032	130	22	up	up	NOUN
dpc-3032	130	23	period	period	NOUN
dpc-3032	130	24	.	.	PUNCT
dpc-3032	131	1	none	none	NOUN
dpc-3032	131	2	of	of	ADP
dpc-3032	131	3	the	the	DET
dpc-3032	131	4	fatal	fatal	ADJ
dpc-3032	131	5	events	event	NOUN
dpc-3032	131	6	were	be	AUX
dpc-3032	131	7	assessed	assess	VERB
dpc-3032	131	8	as	as	ADP
dpc-3032	131	9	related	relate	VERB
dpc-3032	131	10	to	to	ADP
dpc-3032	131	11	vismodegib	vismodegib	NOUN
dpc-3032	131	12	.	.	PUNCT
dpc-3032	132	1	ten	ten	NUM
dpc-3032	132	2	patients	patient	NOUN
dpc-3032	132	3	(	(	PUNCT
dpc-3032	132	4	20.8	20.8	NUM
dpc-3032	132	5	%	%	NOUN
dpc-3032	132	6	)	)	PUNCT
dpc-3032	132	7	withdrew	withdraw	VERB
dpc-3032	132	8	treatment	treatment	NOUN
dpc-3032	132	9	due	due	ADP
dpc-3032	132	10	to	to	ADP
dpc-3032	132	11	an	an	DET
dpc-3032	132	12	adverse	adverse	ADJ
dpc-3032	132	13	event	event	NOUN
dpc-3032	132	14	(	(	PUNCT
dpc-3032	132	15	table	table	NOUN
dpc-3032	132	16	4	4	NUM
dpc-3032	132	17	)	)	PUNCT
dpc-3032	132	18	.	.	PUNCT
dpc-3032	133	1	the	the	DET
dpc-3032	133	2	reasons	reason	NOUN
dpc-3032	133	3	were	be	AUX
dpc-3032	133	4	ageusia	ageusia	NOUN
dpc-3032	133	5	/	/	SYM
dpc-3032	133	6	dysgeusia	dysgeusia	PROPN
dpc-3032	133	7	,	,	PUNCT
dpc-3032	133	8	weight	weight	NOUN
dpc-3032	133	9	loss	loss	NOUN
dpc-3032	133	10	,	,	PUNCT
dpc-3032	133	11	asthenia	asthenia	PROPN
dpc-3032	133	12	,	,	PUNCT
dpc-3032	133	13	fatigue	fatigue	NOUN
dpc-3032	133	14	,	,	PUNCT
dpc-3032	133	15	muscle	muscle	NOUN
dpc-3032	133	16	spasms	spasm	NOUN
dpc-3032	133	17	/	/	SYM
dpc-3032	133	18	weakness	weakness	NOUN
dpc-3032	133	19	,	,	PUNCT
dpc-3032	133	20	nausea	nausea	NOUN
dpc-3032	133	21	,	,	PUNCT
dpc-3032	133	22	pruritus	pruritus	NOUN
dpc-3032	133	23	and	and	CCONJ
dpc-3032	133	24	back	back	ADJ
dpc-3032	133	25	pain	pain	NOUN
dpc-3032	133	26	.	.	PUNCT
dpc-3032	134	1	there	there	PRON
dpc-3032	134	2	were	be	VERB
dpc-3032	134	3	12	12	NUM
dpc-3032	134	4	adverse	adverse	ADJ
dpc-3032	134	5	events	event	NOUN
dpc-3032	134	6	reported	report	VERB
dpc-3032	134	7	by	by	ADP
dpc-3032	134	8	seven	seven	NUM
dpc-3032	134	9	patients	patient	NOUN
dpc-3032	134	10	(	(	PUNCT
dpc-3032	134	11	14.6	14.6	NUM
dpc-3032	134	12	%	%	NOUN
dpc-3032	134	13	)	)	PUNCT
dpc-3032	134	14	that	that	PRON
dpc-3032	134	15	resulted	result	VERB
dpc-3032	134	16	in	in	ADP
dpc-3032	134	17	an	an	DET
dpc-3032	134	18	interruption	interruption	NOUN
dpc-3032	134	19	or	or	CCONJ
dpc-3032	134	20	discontinuation	discontinuation	NOUN
dpc-3032	134	21	of	of	ADP
dpc-3032	134	22	vismodegib	vismodegib	NOUN
dpc-3032	134	23	.	.	PUNCT
dpc-3032	135	1	the	the	DET
dpc-3032	135	2	reasons	reason	NOUN
dpc-3032	135	3	were	be	AUX
dpc-3032	135	4	gastrointestinal	gastrointestinal	ADJ
dpc-3032	135	5	disorders	disorder	NOUN
dpc-3032	135	6	,	,	PUNCT
dpc-3032	135	7	nausea	nausea	NOUN
dpc-3032	135	8	,	,	PUNCT
dpc-3032	135	9	vomiting	vomiting	NOUN
dpc-3032	135	10	,	,	PUNCT
dpc-3032	135	11	diarrhoea	diarrhoea	NOUN
dpc-3032	135	12	,	,	PUNCT
dpc-3032	135	13	fatigue	fatigue	NOUN
dpc-3032	135	14	,	,	PUNCT
dpc-3032	135	15	table	table	NOUN
dpc-3032	135	16	2	2	NUM
dpc-3032	135	17	.	.	NOUN
dpc-3032	135	18	disposition	disposition	NOUN
dpc-3032	135	19	of	of	ADP
dpc-3032	135	20	patients	patient	NOUN
dpc-3032	135	21	,	,	PUNCT
dpc-3032	135	22	exposure	exposure	NOUN
dpc-3032	135	23	of	of	ADP
dpc-3032	135	24	drug	drug	NOUN
dpc-3032	135	25	and	and	CCONJ
dpc-3032	135	26	efficacy	efficacy	NOUN
dpc-3032	135	27	.	.	PUNCT
dpc-3032	136	1	cohort	cohort	NOUN
dpc-3032	136	2	1	1	NUM
dpc-3032	136	3	cohort	cohort	NOUN
dpc-3032	136	4	2	2	NUM
dpc-3032	136	5	cohort	cohort	NOUN
dpc-3032	136	6	3	3	NUM
dpc-3032	136	7	total	total	NOUN
dpc-3032	136	8	patients	patient	NOUN
dpc-3032	136	9	enrolled	enrol	VERB
dpc-3032	136	10	n=37	n=37	PROPN
dpc-3032	136	11	n=3	n=3	PUNCT
dpc-3032	136	12	n=9	n=9	PROPN
dpc-3032	136	13	n=49	n=49	VERB
dpc-3032	136	14	completed	complete	VERB
dpc-3032	136	15	the	the	DET
dpc-3032	136	16	study	study	NOUN
dpc-3032	136	17	,	,	PUNCT
dpc-3032	136	18	n	n	CCONJ
dpc-3032	136	19	(	(	PUNCT
dpc-3032	136	20	%	%	INTJ
dpc-3032	136	21	)	)	PUNCT
dpc-3032	136	22	20	20	NUM
dpc-3032	136	23	(	(	PUNCT
dpc-3032	136	24	54.1	54.1	NUM
dpc-3032	136	25	)	)	SYM
dpc-3032	136	26	2	2	NUM
dpc-3032	136	27	(	(	PUNCT
dpc-3032	136	28	66.7	66.7	NUM
dpc-3032	136	29	)	)	PUNCT
dpc-3032	136	30	6	6	NUM
dpc-3032	136	31	(	(	PUNCT
dpc-3032	136	32	66.7	66.7	NUM
dpc-3032	136	33	)	)	PUNCT
dpc-3032	136	34	28	28	NUM
dpc-3032	136	35	(	(	PUNCT
dpc-3032	136	36	57.1	57.1	NUM
dpc-3032	136	37	)	)	PUNCT
dpc-3032	136	38	prematurely	prematurely	ADV
dpc-3032	136	39	withdrawn	withdraw	VERB
dpc-3032	136	40	from	from	ADP
dpc-3032	136	41	the	the	DET
dpc-3032	136	42	study	study	NOUN
dpc-3032	136	43	,	,	PUNCT
dpc-3032	136	44	n	n	CCONJ
dpc-3032	136	45	(	(	PUNCT
dpc-3032	136	46	%	%	INTJ
dpc-3032	136	47	)	)	PUNCT
dpc-3032	136	48	17	17	NUM
dpc-3032	136	49	(	(	PUNCT
dpc-3032	136	50	45.9	45.9	NUM
dpc-3032	136	51	)	)	PUNCT
dpc-3032	136	52	1	1	NUM
dpc-3032	136	53	(	(	PUNCT
dpc-3032	136	54	33.3	33.3	NUM
dpc-3032	136	55	)	)	PUNCT
dpc-3032	136	56	3	3	NUM
dpc-3032	136	57	(	(	PUNCT
dpc-3032	136	58	33.3	33.3	NUM
dpc-3032	136	59	)	)	PUNCT
dpc-3032	136	60	21	21	NUM
dpc-3032	136	61	(	(	PUNCT
dpc-3032	136	62	42.9	42.9	NUM
dpc-3032	136	63	)	)	PUNCT
dpc-3032	136	64	patients	patient	NOUN
dpc-3032	136	65	treated	treat	VERB
dpc-3032	136	66	n=37	n=37	PROPN
dpc-3032	136	67	n=3	n=3	PUNCT
dpc-3032	136	68	n=8	n=8	ADP
dpc-3032	136	69	n=48	n=48	ADP
dpc-3032	136	70	discontinued	discontinue	VERB
dpc-3032	136	71	treatment	treatment	NOUN
dpc-3032	136	72	at	at	ADP
dpc-3032	136	73	least	least	ADJ
dpc-3032	136	74	once	once	ADV
dpc-3032	136	75	during	during	ADP
dpc-3032	136	76	the	the	DET
dpc-3032	136	77	study	study	NOUN
dpc-3032	136	78	,	,	PUNCT
dpc-3032	136	79	n	n	CCONJ
dpc-3032	136	80	(	(	PUNCT
dpc-3032	136	81	%	%	INTJ
dpc-3032	136	82	)	)	PUNCT
dpc-3032	136	83	35	35	NUM
dpc-3032	136	84	(	(	PUNCT
dpc-3032	136	85	94.6	94.6	NUM
dpc-3032	136	86	)	)	PUNCT
dpc-3032	136	87	3	3	NUM
dpc-3032	136	88	(	(	PUNCT
dpc-3032	136	89	100.0	100.0	NUM
dpc-3032	136	90	)	)	PUNCT
dpc-3032	136	91	7	7	NUM
dpc-3032	136	92	(	(	PUNCT
dpc-3032	136	93	87.5	87.5	NUM
dpc-3032	136	94	)	)	PUNCT
dpc-3032	136	95	45	45	NUM
dpc-3032	136	96	(	(	PUNCT
dpc-3032	136	97	93.8	93.8	NUM
dpc-3032	136	98	)	)	PUNCT
dpc-3032	136	99	reason	reason	NOUN
dpc-3032	136	100	of	of	ADP
dpc-3032	136	101	discontinuation	discontinuation	NOUN
dpc-3032	136	102	from	from	ADP
dpc-3032	136	103	treatment	treatment	NOUN
dpc-3032	136	104	,	,	PUNCT
dpc-3032	136	105	n	n	CCONJ
dpc-3032	136	106	(	(	PUNCT
dpc-3032	136	107	%	%	INTJ
dpc-3032	136	108	)	)	PUNCT
dpc-3032	136	109	complete	complete	ADJ
dpc-3032	136	110	remission	remission	NOUN
dpc-3032	136	111	15	15	NUM
dpc-3032	136	112	(	(	PUNCT
dpc-3032	136	113	42.9	42.9	NUM
dpc-3032	136	114	)	)	PUNCT
dpc-3032	136	115	1	1	NUM
dpc-3032	136	116	(	(	PUNCT
dpc-3032	136	117	33.3	33.3	NUM
dpc-3032	136	118	)	)	PUNCT
dpc-3032	136	119	6	6	NUM
dpc-3032	136	120	(	(	PUNCT
dpc-3032	136	121	85.7	85.7	NUM
dpc-3032	136	122	)	)	PUNCT
dpc-3032	136	123	22	22	NUM
dpc-3032	136	124	(	(	PUNCT
dpc-3032	136	125	48.9	48.9	NUM
dpc-3032	136	126	)	)	PUNCT
dpc-3032	136	127	adverse	adverse	ADJ
dpc-3032	136	128	event	event	NOUN
dpc-3032	136	129	/	/	SYM
dpc-3032	136	130	serious	serious	ADJ
dpc-3032	136	131	adverse	adverse	ADJ
dpc-3032	136	132	event	event	NOUN
dpc-3032	136	133	10	10	NUM
dpc-3032	136	134	(	(	PUNCT
dpc-3032	136	135	28.6	28.6	NUM
dpc-3032	136	136	)	)	SYM
dpc-3032	136	137	1	1	NUM
dpc-3032	136	138	(	(	PUNCT
dpc-3032	136	139	33.3	33.3	NUM
dpc-3032	136	140	)	)	PUNCT
dpc-3032	136	141	3	3	NUM
dpc-3032	136	142	(	(	PUNCT
dpc-3032	136	143	42.9	42.9	NUM
dpc-3032	136	144	)	)	PUNCT
dpc-3032	136	145	14	14	NUM
dpc-3032	136	146	(	(	PUNCT
dpc-3032	136	147	31.1	31.1	NUM
dpc-3032	136	148	)	)	PUNCT
dpc-3032	136	149	death	death	NOUN
dpc-3032	136	150	1	1	NUM
dpc-3032	136	151	(	(	PUNCT
dpc-3032	136	152	2.9	2.9	NUM
dpc-3032	136	153	)	)	PUNCT
dpc-3032	136	154	0	0	NUM
dpc-3032	136	155	0	0	NUM
dpc-3032	136	156	1	1	NUM
dpc-3032	136	157	(	(	PUNCT
dpc-3032	136	158	2.2	2.2	NUM
dpc-3032	136	159	)	)	PUNCT
dpc-3032	136	160	progressive	progressive	ADJ
dpc-3032	136	161	disease	disease	NOUN
dpc-3032	136	162	3	3	NUM
dpc-3032	136	163	(	(	PUNCT
dpc-3032	136	164	8.6	8.6	NUM
dpc-3032	136	165	)	)	PUNCT
dpc-3032	136	166	0	0	NUM
dpc-3032	136	167	0	0	NUM
dpc-3032	136	168	3	3	NUM
dpc-3032	136	169	(	(	PUNCT
dpc-3032	136	170	6.7	6.7	NUM
dpc-3032	136	171	)	)	PUNCT
dpc-3032	136	172	lack	lack	NOUN
dpc-3032	136	173	of	of	ADP
dpc-3032	136	174	efficacy	efficacy	NOUN
dpc-3032	136	175	4	4	NUM
dpc-3032	136	176	(	(	PUNCT
dpc-3032	136	177	11.4	11.4	NUM
dpc-3032	136	178	)	)	PUNCT
dpc-3032	136	179	0	0	NUM
dpc-3032	136	180	1	1	NUM
dpc-3032	136	181	(	(	PUNCT
dpc-3032	136	182	14.3	14.3	NUM
dpc-3032	136	183	)	)	SYM
dpc-3032	136	184	5	5	NUM
dpc-3032	136	185	(	(	PUNCT
dpc-3032	136	186	11.1	11.1	NUM
dpc-3032	136	187	)	)	PUNCT
dpc-3032	136	188	physician	physician	NOUN
dpc-3032	136	189	decision	decision	NOUN
dpc-3032	136	190	5	5	NUM
dpc-3032	136	191	(	(	PUNCT
dpc-3032	136	192	14.3	14.3	NUM
dpc-3032	136	193	)	)	PUNCT
dpc-3032	136	194	1	1	NUM
dpc-3032	136	195	(	(	PUNCT
dpc-3032	136	196	33.3	33.3	NUM
dpc-3032	136	197	)	)	PUNCT
dpc-3032	136	198	0	0	NUM
dpc-3032	136	199	6	6	NUM
dpc-3032	136	200	(	(	PUNCT
dpc-3032	136	201	13.3	13.3	NUM
dpc-3032	136	202	)	)	PUNCT
dpc-3032	136	203	other	other	ADJ
dpc-3032	136	204	4	4	NUM
dpc-3032	136	205	(	(	PUNCT
dpc-3032	136	206	11.4	11.4	NUM
dpc-3032	136	207	)	)	PUNCT
dpc-3032	136	208	0	0	NUM
dpc-3032	136	209	5	5	NUM
dpc-3032	136	210	(	(	PUNCT
dpc-3032	136	211	71.4	71.4	NUM
dpc-3032	136	212	)	)	PUNCT
dpc-3032	136	213	9	9	NUM
dpc-3032	136	214	(	(	PUNCT
dpc-3032	136	215	20	20	NUM
dpc-3032	136	216	)	)	PUNCT
dpc-3032	136	217	exposure	exposure	NOUN
dpc-3032	136	218	of	of	ADP
dpc-3032	136	219	drug	drug	NOUN
dpc-3032	136	220	treatment	treatment	NOUN
dpc-3032	136	221	duration	duration	NOUN
dpc-3032	136	222	,	,	PUNCT
dpc-3032	136	223	(	(	PUNCT
dpc-3032	136	224	incl	incl	NOUN
dpc-3032	136	225	days	day	NOUN
dpc-3032	136	226	off	off	ADP
dpc-3032	136	227	treatment	treatment	NOUN
dpc-3032	136	228	)	)	PUNCT
dpc-3032	136	229	,	,	PUNCT
dpc-3032	136	230	months	month	NOUN
dpc-3032	136	231	mean	mean	VERB
dpc-3032	136	232	(	(	PUNCT
dpc-3032	136	233	sd	sd	NOUN
dpc-3032	136	234	)	)	PUNCT
dpc-3032	136	235	11.7	11.7	NUM
dpc-3032	136	236	(	(	PUNCT
dpc-3032	136	237	11.5	11.5	NUM
dpc-3032	136	238	)	)	PUNCT
dpc-3032	136	239	12.5	12.5	NUM
dpc-3032	136	240	(	(	PUNCT
dpc-3032	136	241	19.2	19.2	NUM
dpc-3032	136	242	)	)	PUNCT
dpc-3032	136	243	16.2	16.2	NUM
dpc-3032	136	244	(	(	PUNCT
dpc-3032	136	245	13.3	13.3	NUM
dpc-3032	136	246	)	)	PUNCT
dpc-3032	136	247	12.4	12.4	NUM
dpc-3032	136	248	(	(	PUNCT
dpc-3032	136	249	12.0	12.0	NUM
dpc-3032	136	250	)	)	PUNCT
dpc-3032	136	251	median	median	NOUN
dpc-3032	136	252	(	(	PUNCT
dpc-3032	136	253	range	range	NOUN
dpc-3032	136	254	)	)	PUNCT
dpc-3032	136	255	5.8	5.8	NUM
dpc-3032	136	256	(	(	PUNCT
dpc-3032	136	257	1	1	NUM
dpc-3032	136	258	-	-	NUM
dpc-3032	136	259	35.9	35.9	NUM
dpc-3032	136	260	)	)	PUNCT
dpc-3032	136	261	1.4	1.4	NUM
dpc-3032	136	262	(	(	PUNCT
dpc-3032	136	263	1.4	1.4	NUM
dpc-3032	136	264	-	-	SYM
dpc-3032	136	265	34.8	34.8	NUM
dpc-3032	136	266	)	)	PUNCT
dpc-3032	136	267	15.2	15.2	NUM
dpc-3032	136	268	(	(	PUNCT
dpc-3032	136	269	2.8	2.8	NUM
dpc-3032	136	270	-	-	SYM
dpc-3032	136	271	35.7	35.7	NUM
dpc-3032	136	272	)	)	PUNCT
dpc-3032	136	273	5.7	5.7	NUM
dpc-3032	136	274	(	(	PUNCT
dpc-3032	136	275	1	1	NUM
dpc-3032	136	276	-	-	NUM
dpc-3032	136	277	35.9	35.9	NUM
dpc-3032	136	278	)	)	PUNCT
dpc-3032	136	279	treatment	treatment	NOUN
dpc-3032	136	280	duration	duration	NOUN
dpc-3032	136	281	(	(	PUNCT
dpc-3032	136	282	excl	excl	NOUN
dpc-3032	136	283	days	day	NOUN
dpc-3032	136	284	off	off	ADP
dpc-3032	136	285	treatment	treatment	NOUN
dpc-3032	136	286	)	)	PUNCT
dpc-3032	136	287	,	,	PUNCT
dpc-3032	136	288	months	month	NOUN
dpc-3032	136	289	mean	mean	VERB
dpc-3032	136	290	(	(	PUNCT
dpc-3032	136	291	sd	sd	NOUN
dpc-3032	136	292	)	)	PUNCT
dpc-3032	136	293	8.1	8.1	NUM
dpc-3032	136	294	(	(	PUNCT
dpc-3032	136	295	7.0	7.0	NUM
dpc-3032	136	296	)	)	PUNCT
dpc-3032	136	297	11.1	11.1	NUM
dpc-3032	136	298	(	(	PUNCT
dpc-3032	136	299	16.8	16.8	NUM
dpc-3032	136	300	)	)	PUNCT
dpc-3032	136	301	8.8	8.8	NUM
dpc-3032	136	302	(	(	PUNCT
dpc-3032	136	303	8.2	8.2	NUM
dpc-3032	136	304	)	)	PUNCT
dpc-3032	136	305	8.4	8.4	NUM
dpc-3032	136	306	(	(	PUNCT
dpc-3032	136	307	7.8	7.8	NUM
dpc-3032	136	308	)	)	PUNCT
dpc-3032	136	309	median	median	NOUN
dpc-3032	136	310	(	(	PUNCT
dpc-3032	136	311	range	range	NOUN
dpc-3032	136	312	)	)	PUNCT
dpc-3032	136	313	5.6	5.6	NUM
dpc-3032	136	314	(	(	PUNCT
dpc-3032	136	315	1	1	NUM
dpc-3032	136	316	-	-	SYM
dpc-3032	136	317	35.5	35.5	NUM
dpc-3032	136	318	)	)	PUNCT
dpc-3032	136	319	1.4	1.4	NUM
dpc-3032	136	320	(	(	PUNCT
dpc-3032	136	321	1.4	1.4	NUM
dpc-3032	136	322	-	-	SYM
dpc-3032	136	323	30.6	30.6	NUM
dpc-3032	136	324	)	)	PUNCT
dpc-3032	136	325	4.1	4.1	NUM
dpc-3032	136	326	(	(	PUNCT
dpc-3032	136	327	2.8	2.8	NUM
dpc-3032	136	328	-	-	SYM
dpc-3032	136	329	23.9	23.9	NUM
dpc-3032	136	330	)	)	PUNCT
dpc-3032	136	331	5.2	5.2	NUM
dpc-3032	136	332	(	(	PUNCT
dpc-3032	136	333	1	1	NUM
dpc-3032	136	334	-	-	SYM
dpc-3032	136	335	35.5	35.5	NUM
dpc-3032	136	336	)	)	PUNCT
dpc-3032	136	337	effectiveness	effectiveness	NOUN
dpc-3032	136	338	n=37	n=37	PROPN
dpc-3032	136	339	n=3	n=3	PUNCT
dpc-3032	136	340	n=9	n=9	X
dpc-3032	136	341	n=49	n=49	VERB
dpc-3032	136	342	clinical	clinical	ADJ
dpc-3032	136	343	response	response	NOUN
dpc-3032	136	344	(	(	PUNCT
dpc-3032	136	345	complete	complete	ADJ
dpc-3032	136	346	or	or	CCONJ
dpc-3032	136	347	partial	partial	ADJ
dpc-3032	136	348	remission	remission	NOUN
dpc-3032	136	349	)	)	PUNCT
dpc-3032	136	350	,	,	PUNCT
dpc-3032	136	351	n	n	PROPN
dpc-3032	136	352	(	(	PUNCT
dpc-3032	136	353	%	%	INTJ
dpc-3032	136	354	)	)	PUNCT
dpc-3032	136	355	34	34	NUM
dpc-3032	136	356	(	(	PUNCT
dpc-3032	136	357	91.9	91.9	NUM
dpc-3032	136	358	)	)	SYM
dpc-3032	136	359	2	2	NUM
dpc-3032	136	360	(	(	PUNCT
dpc-3032	136	361	66.7	66.7	NUM
dpc-3032	136	362	)	)	PUNCT
dpc-3032	136	363	7	7	NUM
dpc-3032	136	364	(	(	PUNCT
dpc-3032	136	365	77.8	77.8	NUM
dpc-3032	136	366	)	)	PUNCT
dpc-3032	136	367	43	43	NUM
dpc-3032	136	368	(	(	PUNCT
dpc-3032	136	369	87.8	87.8	NUM
dpc-3032	136	370	)	)	PUNCT
dpc-3032	136	371	95	95	NUM
dpc-3032	136	372	%	%	NOUN
dpc-3032	136	373	ci	ci	NOUN
dpc-3032	136	374	(	(	PUNCT
dpc-3032	136	375	78.1	78.1	NUM
dpc-3032	136	376	-	-	SYM
dpc-3032	136	377	98.3	98.3	NUM
dpc-3032	136	378	)	)	PUNCT
dpc-3032	136	379	(	(	PUNCT
dpc-3032	136	380	9.4	9.4	NUM
dpc-3032	136	381	-	-	SYM
dpc-3032	136	382	99.2	99.2	NUM
dpc-3032	136	383	)	)	PUNCT
dpc-3032	136	384	(	(	PUNCT
dpc-3032	136	385	40.0	40.0	NUM
dpc-3032	136	386	-	-	SYM
dpc-3032	136	387	97.2	97.2	NUM
dpc-3032	136	388	)	)	PUNCT
dpc-3032	136	389	(	(	PUNCT
dpc-3032	136	390	75.2	75.2	NUM
dpc-3032	136	391	-	-	SYM
dpc-3032	136	392	95.4	95.4	NUM
dpc-3032	136	393	)	)	PUNCT
dpc-3032	136	394	recurrence	recurrence	NOUN
dpc-3032	136	395	during	during	ADP
dpc-3032	136	396	the	the	DET
dpc-3032	136	397	study	study	NOUN
dpc-3032	136	398	,	,	PUNCT
dpc-3032	136	399	n	n	CCONJ
dpc-3032	136	400	(	(	PUNCT
dpc-3032	136	401	%	%	INTJ
dpc-3032	136	402	)	)	PUNCT
dpc-3032	136	403	11	11	NUM
dpc-3032	136	404	(	(	PUNCT
dpc-3032	136	405	29.7	29.7	NUM
dpc-3032	136	406	)	)	PUNCT
dpc-3032	136	407	0	0	NUM
dpc-3032	136	408	3	3	NUM
dpc-3032	136	409	(	(	PUNCT
dpc-3032	136	410	33.3	33.3	NUM
dpc-3032	136	411	)	)	PUNCT
dpc-3032	136	412	14	14	NUM
dpc-3032	136	413	(	(	PUNCT
dpc-3032	136	414	28.6	28.6	NUM
dpc-3032	136	415	)	)	PUNCT
dpc-3032	136	416	95	95	NUM
dpc-3032	136	417	%	%	NOUN
dpc-3032	136	418	ci	ci	NOUN
dpc-3032	136	419	(	(	PUNCT
dpc-3032	136	420	15.9	15.9	NUM
dpc-3032	136	421	-	-	SYM
dpc-3032	136	422	47.0	47.0	NUM
dpc-3032	136	423	)	)	PUNCT
dpc-3032	136	424	(	(	PUNCT
dpc-3032	136	425	0.0	0.0	NUM
dpc-3032	136	426	-	-	SYM
dpc-3032	136	427	70.8	70.8	NUM
dpc-3032	136	428	)	)	PUNCT
dpc-3032	136	429	(	(	PUNCT
dpc-3032	136	430	7.5	7.5	NUM
dpc-3032	136	431	-	-	SYM
dpc-3032	136	432	70.1	70.1	NUM
dpc-3032	136	433	)	)	PUNCT
dpc-3032	136	434	(	(	PUNCT
dpc-3032	136	435	16.6	16.6	NUM
dpc-3032	136	436	-	-	SYM
dpc-3032	136	437	43.3	43.3	NUM
dpc-3032	136	438	)	)	PUNCT
dpc-3032	136	439	median	median	ADJ
dpc-3032	136	440	time	time	NOUN
dpc-3032	136	441	to	to	PART
dpc-3032	136	442	response	response	VERB
dpc-3032	136	443	,	,	PUNCT
dpc-3032	136	444	all	all	DET
dpc-3032	136	445	patients	patient	NOUN
dpc-3032	136	446	,	,	PUNCT
dpc-3032	136	447	months	month	NOUN
dpc-3032	136	448	2	2	NUM
dpc-3032	136	449	median	median	NOUN
dpc-3032	136	450	duration	duration	NOUN
dpc-3032	136	451	of	of	ADP
dpc-3032	136	452	response	response	NOUN
dpc-3032	136	453	,	,	PUNCT
dpc-3032	136	454	all	all	DET
dpc-3032	136	455	patients	patient	NOUN
dpc-3032	136	456	,	,	PUNCT
dpc-3032	136	457	months	month	NOUN
dpc-3032	136	458	14.3	14.3	NUM
dpc-3032	136	459	median	median	ADJ
dpc-3032	136	460	time	time	NOUN
dpc-3032	136	461	to	to	PART
dpc-3032	136	462	recurrence	recurrence	VERB
dpc-3032	136	463	,	,	PUNCT
dpc-3032	136	464	all	all	DET
dpc-3032	136	465	patients	patient	NOUN
dpc-3032	136	466	,	,	PUNCT
dpc-3032	136	467	months	month	NOUN
dpc-3032	136	468	20	20	NUM
dpc-3032	136	469	median	median	ADJ
dpc-3032	136	470	progression	progression	NOUN
dpc-3032	136	471	-	-	PUNCT
dpc-3032	136	472	free	free	ADJ
dpc-3032	136	473	survival	survival	NOUN
dpc-3032	136	474	,	,	PUNCT
dpc-3032	136	475	all	all	DET
dpc-3032	136	476	patients	patient	NOUN
dpc-3032	136	477	,	,	PUNCT
dpc-3032	136	478	months	month	NOUN
dpc-3032	136	479	16.6	16.6	NUM
dpc-3032	136	480	median	median	ADJ
dpc-3032	136	481	overall	overall	ADJ
dpc-3032	136	482	survival	survival	NOUN
dpc-3032	136	483	,	,	PUNCT
dpc-3032	136	484	all	all	DET
dpc-3032	136	485	patients	patient	NOUN
dpc-3032	136	486	,	,	PUNCT
dpc-3032	136	487	months	month	NOUN
dpc-3032	136	488	not	not	PART
dpc-3032	136	489	reached	reach	VERB
dpc-3032	136	490	n	n	NUM
dpc-3032	136	491	,	,	PUNCT
dpc-3032	136	492	number	number	NOUN
dpc-3032	136	493	of	of	ADP
dpc-3032	136	494	patients	patient	NOUN
dpc-3032	136	495	;	;	PUNCT
dpc-3032	136	496	sd	sd	NOUN
dpc-3032	136	497	,	,	PUNCT
dpc-3032	136	498	standard	standard	ADJ
dpc-3032	136	499	deviation	deviation	NOUN
dpc-3032	136	500	.	.	PUNCT
dpc-3032	137	1	since	since	SCONJ
dpc-3032	137	2	this	this	PRON
dpc-3032	137	3	was	be	AUX
dpc-3032	137	4	an	an	DET
dpc-3032	137	5	observational	observational	ADJ
dpc-3032	137	6	study	study	NOUN
dpc-3032	137	7	,	,	PUNCT
dpc-3032	137	8	patients	patient	NOUN
dpc-3032	137	9	were	be	AUX
dpc-3032	137	10	taking	take	VERB
dpc-3032	137	11	treatment	treatment	NOUN
dpc-3032	137	12	according	accord	VERB
dpc-3032	137	13	to	to	ADP
dpc-3032	137	14	normal	normal	ADJ
dpc-3032	137	15	routine	routine	ADJ
dpc-3032	137	16	practice	practice	NOUN
dpc-3032	137	17	.	.	PUNCT
dpc-3032	138	1	because	because	SCONJ
dpc-3032	138	2	of	of	ADP
dpc-3032	138	3	this	this	PRON
dpc-3032	138	4	,	,	PUNCT
dpc-3032	138	5	each	each	DET
dpc-3032	138	6	patient	patient	NOUN
dpc-3032	138	7	could	could	AUX
dpc-3032	138	8	report	report	VERB
dpc-3032	138	9	more	more	ADJ
dpc-3032	138	10	than	than	ADP
dpc-3032	138	11	one	one	NUM
dpc-3032	138	12	treatment	treatment	NOUN
dpc-3032	138	13	discontinuation	discontinuation	NOUN
dpc-3032	138	14	(	(	PUNCT
dpc-3032	138	15	i.e.	i.e.	X
dpc-3032	138	16	a	a	DET
dpc-3032	138	17	patient	patient	NOUN
dpc-3032	138	18	can	can	AUX
dpc-3032	138	19	discontinue	discontinue	VERB
dpc-3032	138	20	and	and	CCONJ
dpc-3032	138	21	then	then	ADV
dpc-3032	138	22	restart	restart	VERB
dpc-3032	138	23	treatment	treatment	NOUN
dpc-3032	138	24	several	several	ADJ
dpc-3032	138	25	times	time	NOUN
dpc-3032	138	26	)	)	PUNCT
dpc-3032	138	27	.	.	PUNCT
dpc-3032	139	1	the	the	DET
dpc-3032	139	2	table	table	NOUN
dpc-3032	139	3	summarizes	summarize	VERB
dpc-3032	139	4	the	the	DET
dpc-3032	139	5	number	number	NOUN
dpc-3032	139	6	of	of	ADP
dpc-3032	139	7	patients	patient	NOUN
dpc-3032	139	8	who	who	PRON
dpc-3032	139	9	discontinued	discontinue	VERB
dpc-3032	139	10	at	at	ADP
dpc-3032	139	11	least	least	ADJ
dpc-3032	139	12	once	once	ADV
dpc-3032	139	13	including	include	VERB
dpc-3032	139	14	each	each	DET
dpc-3032	139	15	unique	unique	ADJ
dpc-3032	139	16	reason	reason	NOUN
dpc-3032	139	17	for	for	ADP
dpc-3032	139	18	discontinuation	discontinuation	NOUN
dpc-3032	139	19	.	.	PUNCT
dpc-3032	140	1	6	6	NUM
dpc-3032	140	2	original	original	ADJ
dpc-3032	140	3	article	article	NOUN
dpc-3032	140	4	|	|	ADV
dpc-3032	140	5	dermatol	dermatol	ADJ
dpc-3032	140	6	pract	pract	NOUN
dpc-3032	140	7	concept	concept	NOUN
dpc-3032	140	8	.	.	PUNCT
dpc-3032	141	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	141	2	in	in	ADP
dpc-3032	141	3	the	the	DET
dpc-3032	141	4	pivotal	pivotal	ADJ
dpc-3032	141	5	study	study	NOUN
dpc-3032	141	6	[	[	X
dpc-3032	141	7	11	11	NUM
dpc-3032	141	8	]	]	PUNCT
dpc-3032	141	9	and	and	CCONJ
dpc-3032	141	10	comparable	comparable	ADJ
dpc-3032	141	11	or	or	CCONJ
dpc-3032	141	12	slightly	slightly	ADV
dpc-3032	141	13	shorter	short	ADJ
dpc-3032	141	14	than	than	ADP
dpc-3032	141	15	the	the	DET
dpc-3032	141	16	median	median	ADJ
dpc-3032	141	17	time	time	NOUN
dpc-3032	141	18	to	to	PART
dpc-3032	141	19	response	response	NOUN
dpc-3032	141	20	of	of	ADP
dpc-3032	141	21	2.7	2.7	NUM
dpc-3032	141	22	months	month	NOUN
dpc-3032	141	23	in	in	ADP
dpc-3032	141	24	the	the	DET
dpc-3032	141	25	german	german	ADJ
dpc-3032	141	26	real	real	ADJ
dpc-3032	141	27	-	-	PUNCT
dpc-3032	141	28	world	world	NOUN
dpc-3032	141	29	study	study	NOUN
dpc-3032	141	30	[	[	X
dpc-3032	141	31	18	18	NUM
dpc-3032	141	32	]	]	PUNCT
dpc-3032	141	33	.	.	PUNCT
dpc-3032	142	1	again	again	ADV
dpc-3032	142	2	,	,	PUNCT
dpc-3032	142	3	the	the	DET
dpc-3032	142	4	differences	difference	NOUN
dpc-3032	142	5	between	between	ADP
dpc-3032	142	6	a	a	DET
dpc-3032	142	7	controlled	control	VERB
dpc-3032	142	8	and	and	CCONJ
dpc-3032	142	9	a	a	DET
dpc-3032	142	10	real	real	ADJ
dpc-3032	142	11	-	-	PUNCT
dpc-3032	142	12	world	world	NOUN
dpc-3032	142	13	setting	setting	NOUN
dpc-3032	142	14	is	be	AUX
dpc-3032	142	15	probably	probably	ADV
dpc-3032	142	16	the	the	DET
dpc-3032	142	17	main	main	ADJ
dpc-3032	142	18	reason	reason	NOUN
dpc-3032	142	19	for	for	ADP
dpc-3032	142	20	the	the	DET
dpc-3032	142	21	shorter	short	ADJ
dpc-3032	142	22	time	time	NOUN
dpc-3032	142	23	to	to	ADP
dpc-3032	142	24	response	response	NOUN
dpc-3032	142	25	reported	report	VERB
dpc-3032	142	26	in	in	ADP
dpc-3032	142	27	the	the	DET
dpc-3032	142	28	non	non	ADJ
dpc-3032	142	29	-	-	ADJ
dpc-3032	142	30	interventional	interventional	ADJ
dpc-3032	142	31	studies	study	NOUN
dpc-3032	142	32	.	.	PUNCT
dpc-3032	143	1	the	the	DET
dpc-3032	143	2	results	result	NOUN
dpc-3032	143	3	illustrate	illustrate	VERB
dpc-3032	143	4	the	the	DET
dpc-3032	143	5	relatively	relatively	ADV
dpc-3032	143	6	short	short	ADJ
dpc-3032	143	7	time	time	NOUN
dpc-3032	143	8	to	to	ADP
dpc-3032	143	9	a	a	DET
dpc-3032	143	10	clinically	clinically	ADV
dpc-3032	143	11	relevant	relevant	ADJ
dpc-3032	143	12	effect	effect	NOUN
dpc-3032	143	13	when	when	SCONJ
dpc-3032	143	14	used	use	VERB
dpc-3032	143	15	in	in	ADP
dpc-3032	143	16	everyday	everyday	ADJ
dpc-3032	143	17	healthcare	healthcare	PROPN
dpc-3032	143	18	.	.	PUNCT
dpc-3032	144	1	interestingly	interestingly	ADV
dpc-3032	144	2	,	,	PUNCT
dpc-3032	144	3	ten	ten	NUM
dpc-3032	144	4	patients	patient	NOUN
dpc-3032	144	5	were	be	AUX
dpc-3032	144	6	re	re	VERB
dpc-3032	144	7	-	-	VERB
dpc-3032	144	8	challenged	challenge	VERB
dpc-3032	144	9	with	with	ADP
dpc-3032	144	10	vismodegib	vismodegib	NOUN
dpc-3032	144	11	resulting	result	VERB
dpc-3032	144	12	in	in	ADP
dpc-3032	144	13	five	five	NUM
dpc-3032	144	14	partial	partial	ADJ
dpc-3032	144	15	remissions	remission	NOUN
dpc-3032	144	16	and	and	CCONJ
dpc-3032	144	17	three	three	NUM
dpc-3032	144	18	complete	complete	ADJ
dpc-3032	144	19	remissions	remission	NOUN
dpc-3032	144	20	.	.	PUNCT
dpc-3032	145	1	two	two	NUM
dpc-3032	145	2	patients	patient	NOUN
dpc-3032	145	3	were	be	AUX
dpc-3032	145	4	even	even	ADV
dpc-3032	145	5	re	re	VERB
dpc-3032	145	6	-	-	VERB
dpc-3032	145	7	challenged	challenge	VERB
dpc-3032	145	8	twice	twice	ADV
dpc-3032	145	9	with	with	ADP
dpc-3032	145	10	repeated	repeat	VERB
dpc-3032	145	11	remissions	remission	NOUN
dpc-3032	145	12	.	.	PUNCT
dpc-3032	146	1	these	these	DET
dpc-3032	146	2	data	datum	NOUN
dpc-3032	146	3	are	be	AUX
dpc-3032	146	4	in	in	ADP
dpc-3032	146	5	line	line	NOUN
dpc-3032	146	6	with	with	ADP
dpc-3032	146	7	the	the	DET
dpc-3032	146	8	greek	greek	ADJ
dpc-3032	146	9	study	study	NOUN
dpc-3032	146	10	that	that	PRON
dpc-3032	146	11	reported	report	VERB
dpc-3032	146	12	responses	response	NOUN
dpc-3032	146	13	after	after	ADP
dpc-3032	146	14	re	re	VERB
dpc-3032	146	15	-	-	VERB
dpc-3032	146	16	challenging	challenge	VERB
dpc-3032	146	17	in	in	ADP
dpc-3032	146	18	8	8	NUM
dpc-3032	146	19	patients	patient	NOUN
dpc-3032	146	20	[	[	X
dpc-3032	146	21	17	17	NUM
dpc-3032	146	22	]	]	PUNCT
dpc-3032	146	23	.	.	PUNCT
dpc-3032	147	1	of	of	ADP
dpc-3032	147	2	the	the	DET
dpc-3032	147	3	predefined	predefine	VERB
dpc-3032	147	4	aesis	aesis	NOUN
dpc-3032	147	5	,	,	PUNCT
dpc-3032	147	6	the	the	DET
dpc-3032	147	7	frequencies	frequency	NOUN
dpc-3032	147	8	of	of	ADP
dpc-3032	147	9	alopecia	alopecia	NOUN
dpc-3032	147	10	,	,	PUNCT
dpc-3032	147	11	fatigue	fatigue	NOUN
dpc-3032	147	12	,	,	PUNCT
dpc-3032	147	13	nausea	nausea	NOUN
dpc-3032	147	14	and	and	CCONJ
dpc-3032	147	15	weight	weight	NOUN
dpc-3032	147	16	-	-	PUNCT
dpc-3032	147	17	loss	loss	NOUN
dpc-3032	147	18	were	be	AUX
dpc-3032	147	19	lower	low	ADJ
dpc-3032	147	20	or	or	CCONJ
dpc-3032	147	21	much	much	ADV
dpc-3032	147	22	lower	low	ADJ
dpc-3032	147	23	compared	compare	VERB
dpc-3032	147	24	to	to	ADP
dpc-3032	147	25	those	those	PRON
dpc-3032	147	26	reported	report	VERB
dpc-3032	147	27	in	in	ADP
dpc-3032	147	28	the	the	DET
dpc-3032	147	29	erivance	erivance	NOUN
dpc-3032	147	30	and	and	CCONJ
dpc-3032	147	31	stevie	stevie	PROPN
dpc-3032	147	32	studies	study	NOUN
dpc-3032	147	33	.	.	PUNCT
dpc-3032	148	1	other	other	ADJ
dpc-3032	148	2	adverse	adverse	ADJ
dpc-3032	148	3	events	event	NOUN
dpc-3032	148	4	were	be	AUX
dpc-3032	148	5	as	as	SCONJ
dpc-3032	148	6	expected	expect	VERB
dpc-3032	148	7	in	in	ADP
dpc-3032	148	8	frequency	frequency	NOUN
dpc-3032	148	9	and	and	CCONJ
dpc-3032	148	10	most	most	ADJ
dpc-3032	148	11	events	event	NOUN
dpc-3032	148	12	were	be	AUX
dpc-3032	148	13	mild	mild	ADJ
dpc-3032	148	14	to	to	PART
dpc-3032	148	15	moderate	moderate	VERB
dpc-3032	149	1	[	[	X
dpc-3032	149	2	11	11	NUM
dpc-3032	149	3	,	,	PUNCT
dpc-3032	149	4	12	12	NUM
dpc-3032	149	5	]	]	PUNCT
dpc-3032	149	6	.	.	PUNCT
dpc-3032	150	1	ten	ten	NUM
dpc-3032	150	2	patients	patient	NOUN
dpc-3032	150	3	(	(	PUNCT
dpc-3032	150	4	20.8	20.8	NUM
dpc-3032	150	5	%	%	NOUN
dpc-3032	150	6	)	)	PUNCT
dpc-3032	150	7	discontinued	discontinue	VERB
dpc-3032	150	8	treatment	treatment	NOUN
dpc-3032	150	9	due	due	ADP
dpc-3032	150	10	to	to	ADP
dpc-3032	150	11	adverse	adverse	ADJ
dpc-3032	150	12	events	event	NOUN
dpc-3032	150	13	,	,	PUNCT
dpc-3032	150	14	while	while	SCONJ
dpc-3032	150	15	seven	seven	NUM
dpc-3032	150	16	patients	patient	NOUN
dpc-3032	150	17	(	(	PUNCT
dpc-3032	150	18	14.6	14.6	NUM
dpc-3032	150	19	%	%	NOUN
dpc-3032	150	20	)	)	PUNCT
dpc-3032	150	21	interrupted	interrupted	ADJ
dpc-3032	150	22	or	or	CCONJ
dpc-3032	150	23	discontinued	discontinue	VERB
dpc-3032	150	24	treatment	treatment	NOUN
dpc-3032	150	25	but	but	CCONJ
dpc-3032	150	26	could	could	AUX
dpc-3032	150	27	remain	remain	VERB
dpc-3032	150	28	on	on	ADP
dpc-3032	150	29	treatment	treatment	NOUN
dpc-3032	150	30	regimen	regiman	NOUN
dpc-3032	150	31	.	.	PUNCT
dpc-3032	151	1	compared	compare	VERB
dpc-3032	151	2	to	to	ADP
dpc-3032	151	3	previously	previously	ADV
dpc-3032	151	4	reported	report	VERB
dpc-3032	151	5	trials	trial	NOUN
dpc-3032	151	6	,	,	PUNCT
dpc-3032	151	7	this	this	PRON
dpc-3032	151	8	is	be	AUX
dpc-3032	151	9	a	a	DET
dpc-3032	151	10	low	low	ADJ
dpc-3032	151	11	frequency	frequency	NOUN
dpc-3032	151	12	.	.	PUNCT
dpc-3032	152	1	there	there	PRON
dpc-3032	152	2	were	be	VERB
dpc-3032	152	3	more	more	ADJ
dpc-3032	152	4	saes	sae	NOUN
dpc-3032	152	5	reported	report	VERB
dpc-3032	152	6	in	in	ADP
dpc-3032	152	7	this	this	DET
dpc-3032	152	8	study	study	NOUN
dpc-3032	152	9	(	(	PUNCT
dpc-3032	152	10	33.3	33.3	NUM
dpc-3032	152	11	%	%	NOUN
dpc-3032	152	12	)	)	PUNCT
dpc-3032	152	13	compared	compare	VERB
dpc-3032	152	14	to	to	ADP
dpc-3032	152	15	the	the	DET
dpc-3032	152	16	german	german	ADJ
dpc-3032	152	17	studies	study	NOUN
dpc-3032	152	18	that	that	PRON
dpc-3032	152	19	reported	report	VERB
dpc-3032	152	20	22.7	22.7	NUM
dpc-3032	152	21	%	%	NOUN
dpc-3032	152	22	and	and	CCONJ
dpc-3032	152	23	17.0	17.0	NUM
dpc-3032	152	24	%	%	NOUN
dpc-3032	152	25	,	,	PUNCT
dpc-3032	152	26	respectively	respectively	ADV
dpc-3032	152	27	.	.	PUNCT
dpc-3032	153	1	nevertheless	nevertheless	ADV
dpc-3032	153	2	,	,	PUNCT
dpc-3032	153	3	the	the	DET
dpc-3032	153	4	majority	majority	NOUN
dpc-3032	153	5	of	of	ADP
dpc-3032	153	6	the	the	DET
dpc-3032	153	7	saes	saes	PROPN
dpc-3032	153	8	were	be	AUX
dpc-3032	153	9	not	not	PART
dpc-3032	153	10	related	relate	VERB
dpc-3032	153	11	to	to	ADP
dpc-3032	153	12	vismodegib	vismodegib	NOUN
dpc-3032	153	13	in	in	ADP
dpc-3032	153	14	any	any	PRON
dpc-3032	153	15	of	of	ADP
dpc-3032	153	16	the	the	DET
dpc-3032	153	17	studies	study	NOUN
dpc-3032	153	18	[	[	X
dpc-3032	153	19	18	18	NUM
dpc-3032	153	20	,	,	PUNCT
dpc-3032	153	21	19	19	NUM
dpc-3032	153	22	]	]	PUNCT
dpc-3032	153	23	.	.	PUNCT
dpc-3032	154	1	of	of	ADP
dpc-3032	154	2	the	the	DET
dpc-3032	154	3	vismodegib	vismodegib	NOUN
dpc-3032	154	4	for	for	ADP
dpc-3032	154	5	abcc	abcc	NOUN
dpc-3032	154	6	,	,	PUNCT
dpc-3032	154	7	including	include	VERB
dpc-3032	154	8	the	the	DET
dpc-3032	154	9	pivotal	pivotal	ADJ
dpc-3032	154	10	study	study	NOUN
dpc-3032	154	11	erivance	erivance	NOUN
dpc-3032	155	1	[	[	X
dpc-3032	155	2	10	10	NUM
dpc-3032	155	3	,	,	PUNCT
dpc-3032	155	4	11	11	NUM
dpc-3032	155	5	]	]	PUNCT
dpc-3032	155	6	,	,	PUNCT
dpc-3032	155	7	the	the	DET
dpc-3032	155	8	safety	safety	NOUN
dpc-3032	155	9	study	study	NOUN
dpc-3032	155	10	stevie	stevie	NOUN
dpc-3032	155	11	[	[	X
dpc-3032	155	12	12	12	NUM
dpc-3032	155	13	,	,	PUNCT
dpc-3032	155	14	20	20	NUM
dpc-3032	155	15	]	]	PUNCT
dpc-3032	155	16	and	and	CCONJ
dpc-3032	155	17	the	the	DET
dpc-3032	155	18	more	more	ADV
dpc-3032	155	19	recently	recently	ADV
dpc-3032	155	20	published	publish	VERB
dpc-3032	155	21	non	non	ADJ
dpc-3032	155	22	-	-	ADJ
dpc-3032	155	23	interventional	interventional	ADJ
dpc-3032	155	24	studies	study	NOUN
dpc-3032	155	25	from	from	ADP
dpc-3032	155	26	germany	germany	PROPN
dpc-3032	155	27	[	[	X
dpc-3032	155	28	18	18	NUM
dpc-3032	155	29	,	,	PUNCT
dpc-3032	155	30	19	19	NUM
dpc-3032	155	31	]	]	PUNCT
dpc-3032	155	32	and	and	CCONJ
dpc-3032	155	33	greece	greece	PROPN
dpc-3032	156	1	[	[	X
dpc-3032	156	2	17	17	NUM
dpc-3032	156	3	]	]	PUNCT
dpc-3032	156	4	.	.	PUNCT
dpc-3032	157	1	in	in	ADP
dpc-3032	157	2	the	the	DET
dpc-3032	157	3	current	current	ADJ
dpc-3032	157	4	study	study	NOUN
dpc-3032	157	5	,	,	PUNCT
dpc-3032	157	6	the	the	DET
dpc-3032	157	7	group	group	NOUN
dpc-3032	157	8	with	with	ADP
dpc-3032	157	9	gorlin	gorlin	PROPN
dpc-3032	157	10	syndrome	syndrome	PROPN
dpc-3032	157	11	were	be	AUX
dpc-3032	157	12	markedly	markedly	ADV
dpc-3032	157	13	younger	young	ADJ
dpc-3032	157	14	than	than	ADP
dpc-3032	157	15	the	the	DET
dpc-3032	157	16	overall	overall	ADJ
dpc-3032	157	17	populations	population	NOUN
dpc-3032	157	18	,	,	PUNCT
dpc-3032	157	19	as	as	SCONJ
dpc-3032	157	20	could	could	AUX
dpc-3032	157	21	be	be	AUX
dpc-3032	157	22	expected	expect	VERB
dpc-3032	157	23	with	with	ADP
dpc-3032	157	24	the	the	DET
dpc-3032	157	25	greater	great	ADJ
dpc-3032	157	26	severity	severity	NOUN
dpc-3032	157	27	and	and	CCONJ
dpc-3032	157	28	earlier	early	ADJ
dpc-3032	157	29	onset	onset	NOUN
dpc-3032	157	30	of	of	ADP
dpc-3032	157	31	disease	disease	NOUN
dpc-3032	157	32	for	for	ADP
dpc-3032	157	33	these	these	DET
dpc-3032	157	34	patients	patient	NOUN
dpc-3032	157	35	[	[	X
dpc-3032	157	36	7	7	NUM
dpc-3032	157	37	,	,	PUNCT
dpc-3032	157	38	8	8	NUM
dpc-3032	157	39	]	]	PUNCT
dpc-3032	157	40	.	.	PUNCT
dpc-3032	158	1	the	the	DET
dpc-3032	158	2	predominance	predominance	NOUN
dpc-3032	158	3	of	of	ADP
dpc-3032	158	4	men	man	NOUN
dpc-3032	158	5	compared	compare	VERB
dpc-3032	158	6	to	to	ADP
dpc-3032	158	7	women	woman	NOUN
dpc-3032	158	8	in	in	ADP
dpc-3032	158	9	the	the	DET
dpc-3032	158	10	current	current	ADJ
dpc-3032	158	11	study	study	NOUN
dpc-3032	158	12	is	be	AUX
dpc-3032	158	13	similar	similar	ADJ
dpc-3032	158	14	to	to	ADP
dpc-3032	158	15	most	most	ADJ
dpc-3032	158	16	studies	study	NOUN
dpc-3032	158	17	[	[	X
dpc-3032	158	18	11	11	NUM
dpc-3032	158	19	-	-	SYM
dpc-3032	158	20	13	13	NUM
dpc-3032	158	21	,	,	PUNCT
dpc-3032	158	22	17	17	NUM
dpc-3032	158	23	-	-	SYM
dpc-3032	158	24	19	19	NUM
dpc-3032	158	25	,	,	PUNCT
dpc-3032	158	26	21	21	NUM
dpc-3032	158	27	]	]	PUNCT
dpc-3032	158	28	and	and	CCONJ
dpc-3032	158	29	the	the	DET
dpc-3032	158	30	baseline	baseline	NOUN
dpc-3032	158	31	comorbidity	comorbidity	NOUN
dpc-3032	158	32	and	and	CCONJ
dpc-3032	158	33	concomitant	concomitant	ADJ
dpc-3032	158	34	treatments	treatment	NOUN
dpc-3032	158	35	as	as	SCONJ
dpc-3032	158	36	could	could	AUX
dpc-3032	158	37	be	be	AUX
dpc-3032	158	38	expected	expect	VERB
dpc-3032	158	39	with	with	ADP
dpc-3032	158	40	respect	respect	NOUN
dpc-3032	158	41	to	to	ADP
dpc-3032	158	42	the	the	DET
dpc-3032	158	43	ages	age	NOUN
dpc-3032	158	44	and	and	CCONJ
dpc-3032	158	45	the	the	DET
dpc-3032	158	46	disease	disease	NOUN
dpc-3032	158	47	indication	indication	NOUN
dpc-3032	158	48	.	.	PUNCT
dpc-3032	159	1	the	the	DET
dpc-3032	159	2	obtained	obtain	VERB
dpc-3032	159	3	study	study	NOUN
dpc-3032	159	4	data	datum	NOUN
dpc-3032	159	5	support	support	VERB
dpc-3032	159	6	previous	previous	ADJ
dpc-3032	159	7	knowledge	knowledge	NOUN
dpc-3032	159	8	of	of	ADP
dpc-3032	159	9	vismodegib	vismodegib	NOUN
dpc-3032	159	10	as	as	ADP
dpc-3032	159	11	highly	highly	ADV
dpc-3032	159	12	effective	effective	ADJ
dpc-3032	159	13	;	;	PUNCT
dpc-3032	159	14	the	the	DET
dpc-3032	159	15	pfs	pfs	PROPN
dpc-3032	159	16	and	and	CCONJ
dpc-3032	159	17	os	os	PROPN
dpc-3032	159	18	levels	level	NOUN
dpc-3032	159	19	are	be	AUX
dpc-3032	159	20	in	in	ADP
dpc-3032	159	21	line	line	NOUN
dpc-3032	159	22	with	with	ADP
dpc-3032	159	23	the	the	DET
dpc-3032	159	24	pivotal	pivotal	ADJ
dpc-3032	159	25	erivance	erivance	NOUN
dpc-3032	159	26	and	and	CCONJ
dpc-3032	159	27	stevie	stevie	NOUN
dpc-3032	159	28	trials	trial	NOUN
dpc-3032	159	29	[	[	X
dpc-3032	159	30	18	18	NUM
dpc-3032	159	31	,	,	PUNCT
dpc-3032	159	32	12	12	NUM
dpc-3032	159	33	]	]	PUNCT
dpc-3032	159	34	whereas	whereas	SCONJ
dpc-3032	159	35	the	the	DET
dpc-3032	159	36	clinical	clinical	ADJ
dpc-3032	159	37	response	response	NOUN
dpc-3032	159	38	of	of	ADP
dpc-3032	159	39	95.4	95.4	NUM
dpc-3032	159	40	%	%	NOUN
dpc-3032	159	41	in	in	ADP
dpc-3032	159	42	this	this	DET
dpc-3032	159	43	trial	trial	NOUN
dpc-3032	159	44	is	be	AUX
dpc-3032	159	45	high	high	ADJ
dpc-3032	159	46	compared	compare	VERB
dpc-3032	159	47	to	to	ADP
dpc-3032	159	48	other	other	ADJ
dpc-3032	159	49	studies	study	NOUN
dpc-3032	159	50	,	,	PUNCT
dpc-3032	159	51	where	where	SCONJ
dpc-3032	159	52	50	50	NUM
dpc-3032	159	53	-	-	SYM
dpc-3032	159	54	77	77	NUM
dpc-3032	159	55	%	%	NOUN
dpc-3032	159	56	clinical	clinical	ADJ
dpc-3032	159	57	responders	responder	NOUN
dpc-3032	159	58	were	be	AUX
dpc-3032	159	59	observed	observe	VERB
dpc-3032	159	60	[	[	X
dpc-3032	159	61	11	11	NUM
dpc-3032	159	62	,	,	PUNCT
dpc-3032	159	63	13	13	NUM
dpc-3032	159	64	,	,	PUNCT
dpc-3032	159	65	18	18	NUM
dpc-3032	159	66	,	,	PUNCT
dpc-3032	159	67	19	19	NUM
dpc-3032	159	68	]	]	PUNCT
dpc-3032	159	69	and	and	CCONJ
dpc-3032	159	70	similar	similar	ADJ
dpc-3032	159	71	to	to	ADP
dpc-3032	159	72	the	the	DET
dpc-3032	159	73	greek	greek	ADJ
dpc-3032	159	74	study	study	NOUN
dpc-3032	159	75	that	that	PRON
dpc-3032	159	76	reported	report	VERB
dpc-3032	159	77	95.6	95.6	NUM
dpc-3032	159	78	%	%	NOUN
dpc-3032	159	79	responders	responder	NOUN
dpc-3032	159	80	[	[	X
dpc-3032	159	81	17	17	NUM
dpc-3032	159	82	]	]	PUNCT
dpc-3032	159	83	.	.	PUNCT
dpc-3032	160	1	the	the	DET
dpc-3032	160	2	variability	variability	NOUN
dpc-3032	160	3	in	in	ADP
dpc-3032	160	4	clinical	clinical	ADJ
dpc-3032	160	5	response	response	NOUN
dpc-3032	160	6	rate	rate	NOUN
dpc-3032	160	7	between	between	ADP
dpc-3032	160	8	studies	study	NOUN
dpc-3032	160	9	is	be	AUX
dpc-3032	160	10	most	most	ADV
dpc-3032	160	11	likely	likely	ADJ
dpc-3032	160	12	due	due	ADP
dpc-3032	160	13	to	to	ADP
dpc-3032	160	14	differences	difference	NOUN
dpc-3032	160	15	in	in	ADP
dpc-3032	160	16	response	response	NOUN
dpc-3032	160	17	evaluation	evaluation	NOUN
dpc-3032	160	18	methods	method	NOUN
dpc-3032	160	19	.	.	PUNCT
dpc-3032	161	1	the	the	DET
dpc-3032	161	2	current	current	ADJ
dpc-3032	161	3	study	study	NOUN
dpc-3032	161	4	pragmatically	pragmatically	ADV
dpc-3032	161	5	allowed	allow	VERB
dpc-3032	161	6	for	for	ADP
dpc-3032	161	7	physician	physician	NOUN
dpc-3032	161	8	assessment	assessment	NOUN
dpc-3032	161	9	to	to	PART
dpc-3032	161	10	determine	determine	VERB
dpc-3032	161	11	clinical	clinical	ADJ
dpc-3032	161	12	response	response	NOUN
dpc-3032	161	13	in	in	ADP
dpc-3032	161	14	order	order	NOUN
dpc-3032	161	15	to	to	PART
dpc-3032	161	16	reflect	reflect	VERB
dpc-3032	161	17	the	the	DET
dpc-3032	161	18	real	real	ADJ
dpc-3032	161	19	-	-	PUNCT
dpc-3032	161	20	world	world	NOUN
dpc-3032	161	21	practice	practice	NOUN
dpc-3032	161	22	and	and	CCONJ
dpc-3032	161	23	thus	thus	ADV
dpc-3032	161	24	a	a	DET
dpc-3032	161	25	resulting	result	VERB
dpc-3032	161	26	higher	high	ADJ
dpc-3032	161	27	response	response	NOUN
dpc-3032	161	28	rate	rate	NOUN
dpc-3032	161	29	than	than	SCONJ
dpc-3032	161	30	when	when	SCONJ
dpc-3032	161	31	using	use	VERB
dpc-3032	161	32	strict	strict	ADJ
dpc-3032	161	33	radiologic	radiologic	ADJ
dpc-3032	161	34	criteria	criterion	NOUN
dpc-3032	161	35	is	be	AUX
dpc-3032	161	36	to	to	PART
dpc-3032	161	37	be	be	AUX
dpc-3032	161	38	expected	expect	VERB
dpc-3032	161	39	.	.	PUNCT
dpc-3032	162	1	approximately	approximately	ADV
dpc-3032	162	2	half	half	NOUN
dpc-3032	162	3	of	of	ADP
dpc-3032	162	4	the	the	DET
dpc-3032	162	5	patients	patient	NOUN
dpc-3032	162	6	had	have	AUX
dpc-3032	162	7	reached	reach	VERB
dpc-3032	162	8	a	a	DET
dpc-3032	162	9	clinical	clinical	ADJ
dpc-3032	162	10	response	response	NOUN
dpc-3032	162	11	after	after	ADP
dpc-3032	162	12	2	2	NUM
dpc-3032	162	13	months	month	NOUN
dpc-3032	162	14	(	(	PUNCT
dpc-3032	162	15	60	60	NUM
dpc-3032	162	16	days	day	NOUN
dpc-3032	162	17	)	)	PUNCT
dpc-3032	162	18	,	,	PUNCT
dpc-3032	162	19	and	and	CCONJ
dpc-3032	162	20	80	80	NUM
dpc-3032	162	21	%	%	NOUN
dpc-3032	162	22	after	after	ADP
dpc-3032	162	23	3.3	3.3	NUM
dpc-3032	162	24	months	month	NOUN
dpc-3032	162	25	(	(	PUNCT
dpc-3032	162	26	100	100	NUM
dpc-3032	162	27	days	day	NOUN
dpc-3032	162	28	)	)	PUNCT
dpc-3032	162	29	of	of	ADP
dpc-3032	162	30	treatment	treatment	NOUN
dpc-3032	162	31	.	.	PUNCT
dpc-3032	163	1	this	this	PRON
dpc-3032	163	2	is	be	AUX
dpc-3032	163	3	a	a	DET
dpc-3032	163	4	shorter	short	ADJ
dpc-3032	163	5	time	time	NOUN
dpc-3032	163	6	to	to	PART
dpc-3032	163	7	response	response	VERB
dpc-3032	163	8	,	,	PUNCT
dpc-3032	163	9	compared	compare	VERB
dpc-3032	163	10	to	to	ADP
dpc-3032	163	11	the	the	DET
dpc-3032	163	12	median	median	ADJ
dpc-3032	163	13	time	time	NOUN
dpc-3032	163	14	of	of	ADP
dpc-3032	163	15	5.5	5.5	NUM
dpc-3032	163	16	-	-	SYM
dpc-3032	163	17	6.7	6.7	NUM
dpc-3032	163	18	months	month	NOUN
dpc-3032	163	19	table	table	NOUN
dpc-3032	163	20	3	3	NUM
dpc-3032	163	21	.	.	NOUN
dpc-3032	163	22	extent	extent	NOUN
dpc-3032	163	23	of	of	ADP
dpc-3032	163	24	exposure	exposure	NOUN
dpc-3032	163	25	including	include	VERB
dpc-3032	163	26	duration	duration	NOUN
dpc-3032	163	27	of	of	ADP
dpc-3032	163	28	treatment	treatment	NOUN
dpc-3032	163	29	and	and	CCONJ
dpc-3032	163	30	pauses	pause	NOUN
dpc-3032	163	31	from	from	ADP
dpc-3032	163	32	treatment	treatment	NOUN
dpc-3032	163	33	.	.	PUNCT
dpc-3032	164	1	cohort	cohort	NOUN
dpc-3032	164	2	1	1	NUM
dpc-3032	164	3	n=37	n=37	PROPN
dpc-3032	164	4	cohort	cohort	NOUN
dpc-3032	164	5	2	2	NUM
dpc-3032	164	6	n=3	n=3	NOUN
dpc-3032	164	7	cohort	cohort	NOUN
dpc-3032	164	8	3	3	NUM
dpc-3032	164	9	n=8	n=8	ADP
dpc-3032	164	10	total	total	NOUN
dpc-3032	164	11	n=48	n=48	ADP
dpc-3032	164	12	total	total	ADJ
dpc-3032	164	13	duration	duration	NOUN
dpc-3032	164	14	of	of	ADP
dpc-3032	164	15	exposure	exposure	NOUN
dpc-3032	164	16	in	in	ADP
dpc-3032	164	17	days	day	NOUN
dpc-3032	164	18	n	n	CCONJ
dpc-3032	164	19	/	/	SYM
dpc-3032	164	20	nmiss	nmiss	ADJ
dpc-3032	164	21	37/0	37/0	NUM
dpc-3032	164	22	3/0	3/0	NUM
dpc-3032	164	23	7/1	7/1	NUM
dpc-3032	164	24	47/1	47/1	ADP
dpc-3032	164	25	mean	mean	ADJ
dpc-3032	164	26	(	(	PUNCT
dpc-3032	164	27	sd	sd	NOUN
dpc-3032	164	28	)	)	PUNCT
dpc-3032	164	29	350.1	350.1	NUM
dpc-3032	164	30	(	(	PUNCT
dpc-3032	164	31	344.0	344.0	NUM
dpc-3032	164	32	)	)	PUNCT
dpc-3032	164	33	376.3	376.3	NUM
dpc-3032	164	34	(	(	PUNCT
dpc-3032	164	35	577.4	577.4	NUM
dpc-3032	164	36	)	)	PUNCT
dpc-3032	164	37	485.0	485.0	NUM
dpc-3032	164	38	(	(	PUNCT
dpc-3032	164	39	399.8	399.8	NUM
dpc-3032	164	40	)	)	PUNCT
dpc-3032	164	41	371.8	371.8	NUM
dpc-3032	164	42	(	(	PUNCT
dpc-3032	164	43	361.0	361.0	NUM
dpc-3032	164	44	)	)	PUNCT
dpc-3032	164	45	median	median	NOUN
dpc-3032	164	46	173.0	173.0	NUM
dpc-3032	164	47	43.0	43.0	NUM
dpc-3032	164	48	456.0	456.0	NUM
dpc-3032	164	49	173.0	173.0	NUM
dpc-3032	164	50	q1	q1	NOUN
dpc-3032	164	51	,	,	PUNCT
dpc-3032	164	52	q3	q3	PROPN
dpc-3032	164	53	85.0	85.0	NUM
dpc-3032	164	54	,	,	PUNCT
dpc-3032	164	55	441,0	441,0	NUM
dpc-3032	164	56	43.0	43.0	NUM
dpc-3032	164	57	,	,	PUNCT
dpc-3032	164	58	1043.0	1043.0	NUM
dpc-3032	164	59	104.0	104.0	NUM
dpc-3032	164	60	,	,	PUNCT
dpc-3032	164	61	840.0	840.0	NUM
dpc-3032	164	62	85.0	85.0	NUM
dpc-3032	164	63	,	,	PUNCT
dpc-3032	164	64	717.0	717.0	NUM
dpc-3032	164	65	min	min	NOUN
dpc-3032	164	66	,	,	PUNCT
dpc-3032	164	67	max	max	PROPN
dpc-3032	164	68	30	30	NUM
dpc-3032	164	69	,	,	PUNCT
dpc-3032	164	70	1076	1076	NUM
dpc-3032	164	71	43	43	NUM
dpc-3032	164	72	,	,	PUNCT
dpc-3032	164	73	1043	1043	NUM
dpc-3032	164	74	85	85	NUM
dpc-3032	164	75	,	,	PUNCT
dpc-3032	164	76	1070	1070	NUM
dpc-3032	164	77	30	30	NUM
dpc-3032	164	78	,	,	PUNCT
dpc-3032	164	79	1076	1076	NUM
dpc-3032	164	80	total	total	ADJ
dpc-3032	164	81	number	number	NOUN
dpc-3032	164	82	of	of	ADP
dpc-3032	164	83	days	day	NOUN
dpc-3032	164	84	on	on	ADP
dpc-3032	164	85	treatment	treatment	NOUN
dpc-3032	164	86	mean	mean	NOUN
dpc-3032	164	87	(	(	PUNCT
dpc-3032	164	88	sd	sd	NOUN
dpc-3032	164	89	)	)	PUNCT
dpc-3032	164	90	241.9	241.9	NUM
dpc-3032	164	91	(	(	PUNCT
dpc-3032	164	92	210.8	210.8	NUM
dpc-3032	164	93	)	)	PUNCT
dpc-3032	164	94	334.3	334.3	NUM
dpc-3032	164	95	(	(	PUNCT
dpc-3032	164	96	504.6	504.6	NUM
dpc-3032	164	97	)	)	PUNCT
dpc-3032	164	98	262.6	262.6	NUM
dpc-3032	164	99	(	(	PUNCT
dpc-3032	164	100	245.8	245.8	NUM
dpc-3032	164	101	)	)	PUNCT
dpc-3032	164	102	250.9	250.9	NUM
dpc-3032	164	103	(	(	PUNCT
dpc-3032	164	104	232.9	232.9	NUM
dpc-3032	164	105	)	)	PUNCT
dpc-3032	164	106	median	median	NOUN
dpc-3032	164	107	167	167	NUM
dpc-3032	164	108	43	43	NUM
dpc-3032	164	109	124	124	NUM
dpc-3032	164	110	156	156	NUM
dpc-3032	164	111	q1	q1	NOUN
dpc-3032	164	112	,	,	PUNCT
dpc-3032	164	113	q3	q3	NOUN
dpc-3032	164	114	85.0	85.0	NUM
dpc-3032	164	115	,	,	PUNCT
dpc-3032	164	116	361.0	361.0	NUM
dpc-3032	164	117	43.0	43.0	NUM
dpc-3032	164	118	,	,	PUNCT
dpc-3032	164	119	917.0	917.0	NUM
dpc-3032	164	120	104.0	104.0	NUM
dpc-3032	164	121	,	,	PUNCT
dpc-3032	164	122	497.0	497.0	NUM
dpc-3032	164	123	85.0	85.0	NUM
dpc-3032	164	124	,	,	PUNCT
dpc-3032	164	125	374.0	374.0	NUM
dpc-3032	164	126	min	min	NOUN
dpc-3032	164	127	,	,	PUNCT
dpc-3032	164	128	max	max	PROPN
dpc-3032	164	129	0	0	NUM
dpc-3032	164	130	,	,	PUNCT
dpc-3032	164	131	716	716	NUM
dpc-3032	164	132	43	43	NUM
dpc-3032	164	133	,	,	PUNCT
dpc-3032	164	134	917	917	NUM
dpc-3032	164	135	85	85	NUM
dpc-3032	164	136	,	,	PUNCT
dpc-3032	164	137	717	717	NUM
dpc-3032	164	138	30	30	NUM
dpc-3032	164	139	,	,	PUNCT
dpc-3032	164	140	1066	1066	NUM
dpc-3032	164	141	total	total	ADJ
dpc-3032	164	142	number	number	NOUN
dpc-3032	164	143	of	of	ADP
dpc-3032	164	144	days	day	NOUN
dpc-3032	164	145	on	on	ADP
dpc-3032	164	146	pause	pause	NOUN
dpc-3032	164	147	from	from	ADP
dpc-3032	164	148	treatment	treatment	NOUN
dpc-3032	164	149	mean	mean	NOUN
dpc-3032	164	150	(	(	PUNCT
dpc-3032	164	151	sd	sd	NOUN
dpc-3032	164	152	)	)	PUNCT
dpc-3032	164	153	108.1	108.1	NUM
dpc-3032	164	154	(	(	PUNCT
dpc-3032	164	155	230.2	230.2	NUM
dpc-3032	164	156	)	)	PUNCT
dpc-3032	164	157	42.0	42.0	NUM
dpc-3032	164	158	(	(	PUNCT
dpc-3032	164	159	72.7	72.7	NUM
dpc-3032	164	160	)	)	PUNCT
dpc-3032	164	161	222.4	222.4	NUM
dpc-3032	164	162	(	(	PUNCT
dpc-3032	164	163	293.6	293.6	NUM
dpc-3032	164	164	)	)	PUNCT
dpc-3032	164	165	120.9	120.9	NUM
dpc-3032	164	166	(	(	PUNCT
dpc-3032	164	167	234.6	234.6	NUM
dpc-3032	164	168	)	)	PUNCT
dpc-3032	164	169	median	median	NOUN
dpc-3032	164	170	0.0	0.0	NUM
dpc-3032	164	171	0.0	0.0	NUM
dpc-3032	164	172	0.0	0.0	NUM
dpc-3032	164	173	0.0	0.0	NUM
dpc-3032	164	174	q1	q1	NOUN
dpc-3032	164	175	,	,	PUNCT
dpc-3032	164	176	q3	q3	NOUN
dpc-3032	164	177	0.0	0.0	NUM
dpc-3032	164	178	,	,	PUNCT
dpc-3032	164	179	0.0	0.0	NUM
dpc-3032	164	180	0.0	0.0	NUM
dpc-3032	164	181	,	,	PUNCT
dpc-3032	164	182	126.0	126.0	NUM
dpc-3032	164	183	0.0	0.0	NUM
dpc-3032	164	184	,	,	PUNCT
dpc-3032	164	185	573.0	573.0	NUM
dpc-3032	164	186	0.0	0.0	NUM
dpc-3032	164	187	,	,	PUNCT
dpc-3032	164	188	0.0	0.0	NUM
dpc-3032	164	189	min	min	NOUN
dpc-3032	164	190	,	,	PUNCT
dpc-3032	164	191	max	max	PROPN
dpc-3032	164	192	0	0	NUM
dpc-3032	164	193	,	,	PUNCT
dpc-3032	164	194	716	716	NUM
dpc-3032	164	195	0	0	NUM
dpc-3032	164	196	,	,	PUNCT
dpc-3032	164	197	126	126	NUM
dpc-3032	164	198	0	0	NUM
dpc-3032	164	199	,	,	PUNCT
dpc-3032	164	200	652	652	NUM
dpc-3032	164	201	0	0	NUM
dpc-3032	164	202	,	,	PUNCT
dpc-3032	164	203	716	716	NUM
dpc-3032	164	204	n	n	CCONJ
dpc-3032	164	205	/	/	SYM
dpc-3032	164	206	nmiss	nmiss	ADJ
dpc-3032	164	207	,	,	PUNCT
dpc-3032	164	208	number	number	NOUN
dpc-3032	164	209	of	of	ADP
dpc-3032	164	210	subjects	subject	NOUN
dpc-3032	164	211	with	with	ADP
dpc-3032	164	212	evaluable	evaluable	ADJ
dpc-3032	164	213	/	/	SYM
dpc-3032	164	214	missing	miss	VERB
dpc-3032	164	215	data	datum	NOUN
dpc-3032	164	216	;	;	PUNCT
dpc-3032	164	217	q1	q1	PROPN
dpc-3032	164	218	,	,	PUNCT
dpc-3032	164	219	first	first	ADV
dpc-3032	164	220	quartile	quartile	NOUN
dpc-3032	164	221	;	;	PUNCT
dpc-3032	164	222	q3	q3	PROPN
dpc-3032	164	223	,	,	PUNCT
dpc-3032	164	224	third	third	ADJ
dpc-3032	164	225	quartile	quartile	NOUN
dpc-3032	164	226	;	;	PUNCT
dpc-3032	164	227	sd	sd	NOUN
dpc-3032	164	228	,	,	PUNCT
dpc-3032	164	229	standard	standard	ADJ
dpc-3032	164	230	deviation	deviation	NOUN
dpc-3032	164	231	.	.	PUNCT
dpc-3032	165	1	the	the	DET
dpc-3032	165	2	same	same	ADJ
dpc-3032	165	3	patient	patient	NOUN
dpc-3032	165	4	could	could	AUX
dpc-3032	165	5	report	report	VERB
dpc-3032	165	6	more	more	ADJ
dpc-3032	165	7	than	than	ADP
dpc-3032	165	8	one	one	NUM
dpc-3032	165	9	treatment	treatment	NOUN
dpc-3032	165	10	discontinuation	discontinuation	NOUN
dpc-3032	165	11	.	.	PUNCT
dpc-3032	166	1	original	original	ADJ
dpc-3032	166	2	article	article	NOUN
dpc-3032	166	3	|	|	ADV
dpc-3032	166	4	dermatol	dermatol	ADJ
dpc-3032	166	5	pract	pract	NOUN
dpc-3032	166	6	concept	concept	NOUN
dpc-3032	166	7	.	.	PUNCT
dpc-3032	167	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	167	2	7	7	NUM
dpc-3032	167	3	1.0	1.0	NUM
dpc-3032	167	4	a	a	DET
dpc-3032	167	5	0.9	0.9	NUM
dpc-3032	167	6	0.8	0.8	NUM
dpc-3032	167	7	0.7	0.7	NUM
dpc-3032	167	8	0.6	0.6	NUM
dpc-3032	167	9	0.5	0.5	NUM
dpc-3032	167	10	pr	pr	NOUN
dpc-3032	167	11	op	op	NOUN
dpc-3032	167	12	or	or	CCONJ
dpc-3032	167	13	ti	ti	NOUN
dpc-3032	167	14	on	on	ADP
dpc-3032	167	15	o	o	PROPN
dpc-3032	167	16	f	f	X
dpc-3032	167	17	s	s	PROPN
dpc-3032	167	18	ub	ub	INTJ
dpc-3032	167	19	je	je	PROPN
dpc-3032	167	20	ct	ct	PROPN
dpc-3032	167	21	s	s	PROPN
dpc-3032	167	22	0.4	0.4	NUM
dpc-3032	167	23	0.3	0.3	NUM
dpc-3032	167	24	0.2	0.2	NUM
dpc-3032	167	25	0.1	0.1	NUM
dpc-3032	167	26	0.0	0.0	NUM
dpc-3032	167	27	0	0	NUM
dpc-3032	167	28	50	50	NUM
dpc-3032	167	29	100	100	NUM
dpc-3032	167	30	150	150	NUM
dpc-3032	167	31	200	200	NUM
dpc-3032	167	32	250	250	NUM
dpc-3032	167	33	time	time	NOUN
dpc-3032	167	34	(	(	PUNCT
dpc-3032	167	35	days	day	NOUN
dpc-3032	167	36	)	)	PUNCT
dpc-3032	167	37	cohort	cohort	NOUN
dpc-3032	167	38	1	1	NUM
dpc-3032	167	39	cohort	cohort	NOUN
dpc-3032	167	40	2	2	NUM
dpc-3032	167	41	cohort	cohort	NOUN
dpc-3032	167	42	3	3	NUM
dpc-3032	167	43	total	total	NOUN
dpc-3032	167	44	300	300	NUM
dpc-3032	167	45	350	350	NUM
dpc-3032	167	46	400	400	NUM
dpc-3032	167	47	450	450	NUM
dpc-3032	167	48	500	500	NUM
dpc-3032	167	49	censored	censored	ADJ
dpc-3032	167	50	time	time	NOUN
dpc-3032	167	51	to	to	ADP
dpc-3032	167	52	clinical	clinical	ADJ
dpc-3032	167	53	response	response	NOUN
dpc-3032	167	54	1.0	1.0	NUM
dpc-3032	167	55	b	b	NOUN
dpc-3032	167	56	0.9	0.9	NUM
dpc-3032	167	57	0.8	0.8	NUM
dpc-3032	167	58	0.7	0.7	NUM
dpc-3032	167	59	0.6	0.6	NUM
dpc-3032	167	60	0.5	0.5	NUM
dpc-3032	167	61	pr	pr	NOUN
dpc-3032	167	62	op	op	NOUN
dpc-3032	167	63	or	or	CCONJ
dpc-3032	167	64	ti	ti	NOUN
dpc-3032	167	65	on	on	ADP
dpc-3032	167	66	o	o	PROPN
dpc-3032	167	67	f	f	X
dpc-3032	167	68	s	s	PROPN
dpc-3032	167	69	ub	ub	INTJ
dpc-3032	167	70	je	je	PROPN
dpc-3032	167	71	ct	ct	PROPN
dpc-3032	167	72	s	s	PROPN
dpc-3032	167	73	0.4	0.4	NUM
dpc-3032	167	74	0.3	0.3	NUM
dpc-3032	167	75	0.2	0.2	NUM
dpc-3032	167	76	0.1	0.1	NUM
dpc-3032	167	77	0.0	0.0	NUM
dpc-3032	167	78	0	0	NUM
dpc-3032	167	79	100	100	NUM
dpc-3032	167	80	200	200	NUM
dpc-3032	167	81	300	300	NUM
dpc-3032	167	82	400	400	NUM
dpc-3032	167	83	500	500	NUM
dpc-3032	167	84	600	600	NUM
dpc-3032	167	85	time	time	NOUN
dpc-3032	167	86	(	(	PUNCT
dpc-3032	167	87	days	day	NOUN
dpc-3032	167	88	)	)	PUNCT
dpc-3032	167	89	cohort	cohort	NOUN
dpc-3032	167	90	1	1	NUM
dpc-3032	167	91	cohort	cohort	NOUN
dpc-3032	167	92	2	2	NUM
dpc-3032	167	93	cohort	cohort	NOUN
dpc-3032	167	94	3	3	NUM
dpc-3032	167	95	total	total	NOUN
dpc-3032	167	96	700	700	NUM
dpc-3032	167	97	800	800	NUM
dpc-3032	167	98	900	900	NUM
dpc-3032	167	99	1000	1000	NUM
dpc-3032	167	100	1100	1100	NUM
dpc-3032	167	101	1200	1200	NUM
dpc-3032	167	102	1300	1300	NUM
dpc-3032	167	103	censored	censor	VERB
dpc-3032	167	104	duration	duration	NOUN
dpc-3032	167	105	of	of	ADP
dpc-3032	167	106	response	response	NOUN
dpc-3032	167	107	figure	figure	NOUN
dpc-3032	167	108	1	1	NUM
dpc-3032	167	109	.	.	PUNCT
dpc-3032	168	1	kaplan	kaplan	PROPN
dpc-3032	168	2	-	-	PUNCT
dpc-3032	168	3	meier	meier	PROPN
dpc-3032	168	4	plots	plot	NOUN
dpc-3032	168	5	of	of	ADP
dpc-3032	168	6	(	(	PUNCT
dpc-3032	168	7	a	a	DET
dpc-3032	168	8	)	)	PUNCT
dpc-3032	168	9	time	time	NOUN
dpc-3032	168	10	to	to	ADP
dpc-3032	168	11	clinical	clinical	ADJ
dpc-3032	168	12	response	response	NOUN
dpc-3032	168	13	,	,	PUNCT
dpc-3032	168	14	(	(	PUNCT
dpc-3032	168	15	b	b	X
dpc-3032	168	16	)	)	PUNCT
dpc-3032	168	17	duration	duration	NOUN
dpc-3032	168	18	of	of	ADP
dpc-3032	168	19	response	response	NOUN
dpc-3032	168	20	and	and	CCONJ
dpc-3032	168	21	(	(	PUNCT
dpc-3032	168	22	c	c	NOUN
dpc-3032	168	23	)	)	PUNCT
dpc-3032	168	24	time	time	NOUN
dpc-3032	168	25	to	to	PART
dpc-3032	168	26	recurrence	recurrence	VERB
dpc-3032	168	27	on	on	ADP
dpc-3032	168	28	cohorts	cohort	NOUN
dpc-3032	168	29	1	1	NUM
dpc-3032	168	30	,	,	PUNCT
dpc-3032	168	31	2	2	NUM
dpc-3032	168	32	,	,	PUNCT
dpc-3032	168	33	3	3	NUM
dpc-3032	168	34	and	and	CCONJ
dpc-3032	168	35	in	in	ADP
dpc-3032	168	36	total	total	NOUN
dpc-3032	168	37	.	.	PUNCT
dpc-3032	169	1	8	8	NUM
dpc-3032	169	2	original	original	ADJ
dpc-3032	169	3	article	article	NOUN
dpc-3032	169	4	|	|	ADV
dpc-3032	169	5	dermatol	dermatol	ADJ
dpc-3032	169	6	pract	pract	NOUN
dpc-3032	169	7	concept	concept	NOUN
dpc-3032	169	8	.	.	PUNCT
dpc-3032	170	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	170	2	table	table	NOUN
dpc-3032	170	3	4	4	NUM
dpc-3032	170	4	.	.	PUNCT
dpc-3032	170	5	adverse	adverse	ADJ
dpc-3032	170	6	events	event	NOUN
dpc-3032	170	7	,	,	PUNCT
dpc-3032	170	8	safety	safety	NOUN
dpc-3032	170	9	population	population	NOUN
dpc-3032	170	10	.	.	PUNCT
dpc-3032	171	1	cohort	cohort	NOUN
dpc-3032	171	2	1	1	NUM
dpc-3032	171	3	(	(	PUNCT
dpc-3032	171	4	n=37	n=37	NOUN
dpc-3032	171	5	)	)	PUNCT
dpc-3032	171	6	cohort	cohort	NOUN
dpc-3032	171	7	2	2	NUM
dpc-3032	171	8	(	(	PUNCT
dpc-3032	171	9	n=3	n=3	NOUN
dpc-3032	171	10	)	)	PUNCT
dpc-3032	171	11	cohort	cohort	NOUN
dpc-3032	171	12	3	3	NUM
dpc-3032	171	13	(	(	PUNCT
dpc-3032	171	14	n=8	n=8	NUM
dpc-3032	171	15	)	)	PUNCT
dpc-3032	171	16	total	total	NOUN
dpc-3032	171	17	(	(	PUNCT
dpc-3032	171	18	n=48	n=48	NOUN
dpc-3032	171	19	)	)	PUNCT
dpc-3032	171	20	any	any	DET
dpc-3032	171	21	adverse	adverse	ADJ
dpc-3032	171	22	event	event	NOUN
dpc-3032	171	23	,	,	PUNCT
dpc-3032	171	24	n	n	PROPN
dpc-3032	171	25	(	(	PUNCT
dpc-3032	171	26	%	%	INTJ
dpc-3032	171	27	)	)	PUNCT
dpc-3032	171	28	35	35	NUM
dpc-3032	171	29	(	(	PUNCT
dpc-3032	171	30	94.6	94.6	NUM
dpc-3032	171	31	)	)	PUNCT
dpc-3032	171	32	3	3	NUM
dpc-3032	171	33	(	(	PUNCT
dpc-3032	171	34	100.0	100.0	NUM
dpc-3032	171	35	)	)	PUNCT
dpc-3032	171	36	7	7	NUM
dpc-3032	171	37	(	(	PUNCT
dpc-3032	171	38	87.5	87.5	NUM
dpc-3032	171	39	)	)	PUNCT
dpc-3032	171	40	45	45	NUM
dpc-3032	171	41	(	(	PUNCT
dpc-3032	171	42	93.8	93.8	NUM
dpc-3032	171	43	)	)	PUNCT
dpc-3032	171	44	any	any	DET
dpc-3032	171	45	adverse	adverse	ADJ
dpc-3032	171	46	event	event	NOUN
dpc-3032	171	47	of	of	ADP
dpc-3032	171	48	special	special	ADJ
dpc-3032	171	49	interest	interest	NOUN
dpc-3032	171	50	,	,	PUNCT
dpc-3032	171	51	n	n	PROPN
dpc-3032	171	52	(	(	PUNCT
dpc-3032	171	53	%	%	INTJ
dpc-3032	171	54	)	)	PUNCT
dpc-3032	171	55	28	28	NUM
dpc-3032	171	56	(	(	PUNCT
dpc-3032	171	57	75.7	75.7	NUM
dpc-3032	171	58	)	)	PUNCT
dpc-3032	171	59	1	1	NUM
dpc-3032	171	60	(	(	PUNCT
dpc-3032	171	61	33.3	33.3	NUM
dpc-3032	171	62	)	)	PUNCT
dpc-3032	171	63	7	7	NUM
dpc-3032	171	64	(	(	PUNCT
dpc-3032	171	65	87.5	87.5	NUM
dpc-3032	171	66	)	)	PUNCT
dpc-3032	171	67	36	36	NUM
dpc-3032	171	68	(	(	PUNCT
dpc-3032	171	69	75.0	75.0	NUM
dpc-3032	171	70	)	)	PUNCT
dpc-3032	171	71	any	any	DET
dpc-3032	171	72	serious	serious	ADJ
dpc-3032	171	73	adverse	adverse	ADJ
dpc-3032	171	74	event	event	NOUN
dpc-3032	171	75	,	,	PUNCT
dpc-3032	171	76	n	n	PROPN
dpc-3032	171	77	(	(	PUNCT
dpc-3032	171	78	%	%	INTJ
dpc-3032	171	79	)	)	PUNCT
dpc-3032	171	80	13	13	NUM
dpc-3032	171	81	(	(	PUNCT
dpc-3032	171	82	35.1	35.1	NUM
dpc-3032	171	83	)	)	SYM
dpc-3032	171	84	1	1	NUM
dpc-3032	171	85	(	(	PUNCT
dpc-3032	171	86	33.3	33.3	NUM
dpc-3032	171	87	)	)	SYM
dpc-3032	171	88	2	2	NUM
dpc-3032	171	89	(	(	PUNCT
dpc-3032	171	90	25.0	25.0	NUM
dpc-3032	171	91	)	)	PUNCT
dpc-3032	171	92	16	16	NUM
dpc-3032	171	93	(	(	PUNCT
dpc-3032	171	94	33.3	33.3	NUM
dpc-3032	171	95	)	)	PUNCT
dpc-3032	171	96	saes	sae	NOUN
dpc-3032	171	97	with	with	ADP
dpc-3032	171	98	fatal	fatal	ADJ
dpc-3032	171	99	outcome	outcome	NOUN
dpc-3032	171	100	,	,	PUNCT
dpc-3032	171	101	n	n	CCONJ
dpc-3032	171	102	(	(	PUNCT
dpc-3032	171	103	%	%	INTJ
dpc-3032	171	104	)	)	PUNCT
dpc-3032	171	105	11	11	NUM
dpc-3032	171	106	(	(	PUNCT
dpc-3032	171	107	29.7	29.7	NUM
dpc-3032	171	108	)	)	PUNCT
dpc-3032	171	109	0	0	NUM
dpc-3032	171	110	0	0	NUM
dpc-3032	171	111	11	11	NUM
dpc-3032	171	112	(	(	PUNCT
dpc-3032	171	113	22.9	22.9	NUM
dpc-3032	171	114	)	)	PUNCT
dpc-3032	171	115	adverse	adverse	ADJ
dpc-3032	171	116	event	event	NOUN
dpc-3032	171	117	leading	lead	VERB
dpc-3032	171	118	to	to	ADP
dpc-3032	171	119	withdrawal	withdrawal	NOUN
dpc-3032	171	120	of	of	ADP
dpc-3032	171	121	study	study	NOUN
dpc-3032	171	122	treatmentb	treatmentb	VERB
dpc-3032	171	123	,	,	PUNCT
dpc-3032	171	124	n	n	PROPN
dpc-3032	171	125	(	(	PUNCT
dpc-3032	171	126	%	%	INTJ
dpc-3032	171	127	)	)	PUNCT
dpc-3032	171	128	8	8	NUM
dpc-3032	171	129	(	(	PUNCT
dpc-3032	171	130	21.6	21.6	NUM
dpc-3032	171	131	)	)	PUNCT
dpc-3032	171	132	0	0	NUM
dpc-3032	171	133	2	2	NUM
dpc-3032	171	134	(	(	PUNCT
dpc-3032	171	135	25.0	25.0	NUM
dpc-3032	171	136	)	)	PUNCT
dpc-3032	171	137	10	10	NUM
dpc-3032	171	138	(	(	PUNCT
dpc-3032	171	139	20.8	20.8	NUM
dpc-3032	171	140	)	)	PUNCT
dpc-3032	171	141	number	number	NOUN
dpc-3032	171	142	of	of	ADP
dpc-3032	171	143	events	event	NOUN
dpc-3032	171	144	14	14	NUM
dpc-3032	171	145	0	0	NUM
dpc-3032	171	146	2	2	NUM
dpc-3032	171	147	16	16	NUM
dpc-3032	171	148	ageusia	ageusia	NOUN
dpc-3032	171	149	/	/	SYM
dpc-3032	171	150	dysgeusia	dysgeusia	PROPN
dpc-3032	171	151	4	4	NUM
dpc-3032	171	152	(	(	PUNCT
dpc-3032	171	153	21.6	21.6	NUM
dpc-3032	171	154	)	)	PUNCT
dpc-3032	171	155	0	0	NUM
dpc-3032	171	156	2	2	NUM
dpc-3032	171	157	(	(	PUNCT
dpc-3032	171	158	25	25	NUM
dpc-3032	171	159	)	)	PUNCT
dpc-3032	171	160	abnormal	abnormal	ADJ
dpc-3032	171	161	weight	weight	NOUN
dpc-3032	171	162	loss	loss	NOUN
dpc-3032	171	163	2	2	NUM
dpc-3032	171	164	(	(	PUNCT
dpc-3032	171	165	5.4	5.4	NUM
dpc-3032	171	166	)	)	PUNCT
dpc-3032	171	167	0	0	NUM
dpc-3032	171	168	0	0	NUM
dpc-3032	172	1	asthenia	asthenia	NOUN
dpc-3032	172	2	1	1	NUM
dpc-3032	172	3	(	(	PUNCT
dpc-3032	172	4	2.7	2.7	NUM
dpc-3032	172	5	)	)	PUNCT
dpc-3032	172	6	0	0	NUM
dpc-3032	172	7	0	0	NUM
dpc-3032	172	8	fatigue	fatigue	NOUN
dpc-3032	172	9	2	2	NUM
dpc-3032	172	10	(	(	PUNCT
dpc-3032	172	11	5.4	5.4	NUM
dpc-3032	172	12	)	)	PUNCT
dpc-3032	172	13	0	0	NUM
dpc-3032	172	14	0	0	NUM
dpc-3032	172	15	muscular	muscular	ADJ
dpc-3032	172	16	weakness	weakness	NOUN
dpc-3032	172	17	1	1	NUM
dpc-3032	172	18	(	(	PUNCT
dpc-3032	172	19	2.7	2.7	NUM
dpc-3032	172	20	)	)	PUNCT
dpc-3032	172	21	0	0	NUM
dpc-3032	172	22	0	0	NUM
dpc-3032	172	23	muscular	muscular	ADJ
dpc-3032	172	24	spasm	spasm	NOUN
dpc-3032	172	25	3	3	NUM
dpc-3032	172	26	(	(	PUNCT
dpc-3032	172	27	8.1	8.1	NUM
dpc-3032	172	28	)	)	PUNCT
dpc-3032	172	29	0	0	NUM
dpc-3032	172	30	0	0	NUM
dpc-3032	172	31	nausea	nausea	NOUN
dpc-3032	172	32	1	1	NUM
dpc-3032	172	33	(	(	PUNCT
dpc-3032	172	34	2.7	2.7	NUM
dpc-3032	172	35	)	)	PUNCT
dpc-3032	172	36	0	0	NUM
dpc-3032	172	37	0	0	NUM
dpc-3032	172	38	pruritus	pruritus	NOUN
dpc-3032	172	39	0	0	NUM
dpc-3032	172	40	0	0	NUM
dpc-3032	172	41	1	1	NUM
dpc-3032	172	42	(	(	PUNCT
dpc-3032	172	43	12.5	12.5	NUM
dpc-3032	172	44	)	)	PUNCT
dpc-3032	172	45	back	back	ADV
dpc-3032	172	46	pain	pain	NOUN
dpc-3032	172	47	0	0	NUM
dpc-3032	172	48	0	0	NUM
dpc-3032	172	49	1	1	NUM
dpc-3032	172	50	(	(	PUNCT
dpc-3032	172	51	12.5	12.5	NUM
dpc-3032	172	52	)	)	PUNCT
dpc-3032	172	53	adverse	adverse	ADJ
dpc-3032	172	54	events	event	NOUN
dpc-3032	172	55	leading	lead	VERB
dpc-3032	172	56	to	to	ADP
dpc-3032	172	57	interruption	interruption	NOUN
dpc-3032	172	58	of	of	ADP
dpc-3032	172	59	study	study	NOUN
dpc-3032	172	60	treatment	treatment	NOUN
dpc-3032	172	61	,	,	PUNCT
dpc-3032	172	62	n	n	PROPN
dpc-3032	172	63	5	5	NUM
dpc-3032	172	64	(	(	PUNCT
dpc-3032	172	65	13.5	13.5	NUM
dpc-3032	172	66	)	)	PUNCT
dpc-3032	172	67	1	1	NUM
dpc-3032	172	68	(	(	PUNCT
dpc-3032	172	69	33.3	33.3	NUM
dpc-3032	172	70	)	)	SYM
dpc-3032	172	71	1	1	NUM
dpc-3032	172	72	(	(	PUNCT
dpc-3032	172	73	12.5	12.5	NUM
dpc-3032	172	74	)	)	PUNCT
dpc-3032	172	75	7	7	NUM
dpc-3032	172	76	(	(	PUNCT
dpc-3032	172	77	14.6	14.6	NUM
dpc-3032	172	78	)	)	PUNCT
dpc-3032	172	79	number	number	NOUN
dpc-3032	172	80	of	of	ADP
dpc-3032	172	81	adverse	adverse	ADJ
dpc-3032	172	82	events	event	NOUN
dpc-3032	172	83	leading	lead	VERB
dpc-3032	172	84	to	to	ADP
dpc-3032	172	85	interruption	interruption	NOUN
dpc-3032	172	86	of	of	ADP
dpc-3032	172	87	study	study	NOUN
dpc-3032	172	88	treatment	treatment	NOUN
dpc-3032	172	89	9	9	NUM
dpc-3032	172	90	2	2	NUM
dpc-3032	172	91	1	1	NUM
dpc-3032	172	92	12	12	NUM
dpc-3032	172	93	nausea	nausea	NOUN
dpc-3032	172	94	1	1	NUM
dpc-3032	172	95	(	(	PUNCT
dpc-3032	172	96	2.7	2.7	NUM
dpc-3032	172	97	)	)	PUNCT
dpc-3032	172	98	1	1	NUM
dpc-3032	172	99	(	(	PUNCT
dpc-3032	172	100	33.3	33.3	NUM
dpc-3032	172	101	)	)	PUNCT
dpc-3032	172	102	0	0	NUM
dpc-3032	172	103	2	2	NUM
dpc-3032	172	104	(	(	PUNCT
dpc-3032	172	105	4.2	4.2	NUM
dpc-3032	172	106	)	)	PUNCT
dpc-3032	172	107	1.0	1.0	NUM
dpc-3032	172	108	c	c	NOUN
dpc-3032	172	109	0.9	0.9	NUM
dpc-3032	172	110	0.8	0.8	NUM
dpc-3032	172	111	0.7	0.7	NUM
dpc-3032	172	112	0.6	0.6	NUM
dpc-3032	172	113	0.5	0.5	NUM
dpc-3032	172	114	pr	pr	NOUN
dpc-3032	172	115	op	op	NOUN
dpc-3032	172	116	or	or	CCONJ
dpc-3032	172	117	ti	ti	NOUN
dpc-3032	172	118	on	on	ADP
dpc-3032	172	119	o	o	PROPN
dpc-3032	172	120	f	f	X
dpc-3032	172	121	s	s	PROPN
dpc-3032	172	122	ub	ub	INTJ
dpc-3032	172	123	je	je	PROPN
dpc-3032	172	124	ct	ct	PROPN
dpc-3032	172	125	s	s	PROPN
dpc-3032	172	126	0.4	0.4	NUM
dpc-3032	173	1	0.3	0.3	NUM
dpc-3032	173	2	0.2	0.2	NUM
dpc-3032	173	3	0.1	0.1	NUM
dpc-3032	173	4	0.0	0.0	NUM
dpc-3032	173	5	0	0	NUM
dpc-3032	173	6	100	100	NUM
dpc-3032	173	7	200	200	NUM
dpc-3032	173	8	300	300	NUM
dpc-3032	173	9	400	400	NUM
dpc-3032	173	10	500	500	NUM
dpc-3032	173	11	600	600	NUM
dpc-3032	173	12	time	time	NOUN
dpc-3032	173	13	(	(	PUNCT
dpc-3032	173	14	days	day	NOUN
dpc-3032	173	15	)	)	PUNCT
dpc-3032	173	16	cohort	cohort	NOUN
dpc-3032	173	17	1	1	NUM
dpc-3032	173	18	cohort	cohort	NOUN
dpc-3032	173	19	2	2	NUM
dpc-3032	173	20	cohort	cohort	NOUN
dpc-3032	173	21	3	3	NUM
dpc-3032	173	22	total	total	NOUN
dpc-3032	173	23	700	700	NUM
dpc-3032	173	24	800	800	NUM
dpc-3032	173	25	900	900	NUM
dpc-3032	173	26	1000	1000	NUM
dpc-3032	173	27	1100	1100	NUM
dpc-3032	173	28	1200	1200	NUM
dpc-3032	173	29	1300	1300	NUM
dpc-3032	173	30	censored	censor	VERB
dpc-3032	173	31	time	time	NOUN
dpc-3032	173	32	to	to	PART
dpc-3032	173	33	recurrence	recurrence	VERB
dpc-3032	173	34	all	all	DET
dpc-3032	173	35	applicable	applicable	ADJ
dpc-3032	173	36	patients	patient	NOUN
dpc-3032	173	37	figure	figure	VERB
dpc-3032	173	38	1	1	NUM
dpc-3032	173	39	.	.	PUNCT
dpc-3032	174	1	kaplan	kaplan	PROPN
dpc-3032	174	2	-	-	PUNCT
dpc-3032	174	3	meier	meier	PROPN
dpc-3032	174	4	plots	plot	NOUN
dpc-3032	174	5	of	of	ADP
dpc-3032	174	6	(	(	PUNCT
dpc-3032	174	7	a	a	DET
dpc-3032	174	8	)	)	PUNCT
dpc-3032	174	9	time	time	NOUN
dpc-3032	174	10	to	to	ADP
dpc-3032	174	11	clinical	clinical	ADJ
dpc-3032	174	12	response	response	NOUN
dpc-3032	174	13	,	,	PUNCT
dpc-3032	174	14	(	(	PUNCT
dpc-3032	174	15	b	b	X
dpc-3032	174	16	)	)	PUNCT
dpc-3032	174	17	duration	duration	NOUN
dpc-3032	174	18	of	of	ADP
dpc-3032	174	19	response	response	NOUN
dpc-3032	174	20	and	and	CCONJ
dpc-3032	174	21	(	(	PUNCT
dpc-3032	174	22	c	c	NOUN
dpc-3032	174	23	)	)	PUNCT
dpc-3032	174	24	time	time	NOUN
dpc-3032	174	25	to	to	PART
dpc-3032	174	26	recurrence	recurrence	VERB
dpc-3032	174	27	on	on	ADP
dpc-3032	174	28	cohorts	cohort	NOUN
dpc-3032	174	29	1	1	NUM
dpc-3032	174	30	,	,	PUNCT
dpc-3032	174	31	2	2	NUM
dpc-3032	174	32	,	,	PUNCT
dpc-3032	174	33	3	3	NUM
dpc-3032	174	34	and	and	CCONJ
dpc-3032	174	35	in	in	ADP
dpc-3032	174	36	total	total	NOUN
dpc-3032	174	37	.	.	PUNCT
dpc-3032	175	1	(	(	PUNCT
dpc-3032	175	2	continued	continue	VERB
dpc-3032	175	3	)	)	PUNCT
dpc-3032	175	4	original	original	ADJ
dpc-3032	175	5	article	article	NOUN
dpc-3032	175	6	|	|	ADV
dpc-3032	175	7	dermatol	dermatol	ADJ
dpc-3032	175	8	pract	pract	NOUN
dpc-3032	175	9	concept	concept	NOUN
dpc-3032	175	10	.	.	PUNCT
dpc-3032	176	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	176	2	9	9	NUM
dpc-3032	176	3	the	the	DET
dpc-3032	176	4	journal	journal	NOUN
dpc-3032	176	5	of	of	ADP
dpc-3032	176	6	investigative	investigative	ADJ
dpc-3032	176	7	dermatology	dermatology	NOUN
dpc-3032	176	8	symposium	symposium	NOUN
dpc-3032	176	9	proceedings	proceeding	NOUN
dpc-3032	176	10	,	,	PUNCT
dpc-3032	176	11	1999	1999	NUM
dpc-3032	176	12	;	;	PUNCT
dpc-3032	176	13	4	4	NUM
dpc-3032	176	14	:	:	SYM
dpc-3032	176	15	41	41	NUM
dpc-3032	176	16	-	-	SYM
dpc-3032	176	17	45	45	NUM
dpc-3032	176	18	.	.	PUNCT
dpc-3032	177	1	doi:10.1038	doi:10.1038	NOUN
dpc-3032	177	2	/	/	SYM
dpc-3032	177	3	sj.jidsp.5640179	sj.jidsp.5640179	PROPN
dpc-3032	177	4	3	3	X
dpc-3032	177	5	.	.	X
dpc-3032	177	6	epstein	epstein	PROPN
dpc-3032	177	7	eh	eh	PROPN
dpc-3032	177	8	.	.	PROPN
dpc-3032	177	9	basal	basal	PROPN
dpc-3032	177	10	cell	cell	NOUN
dpc-3032	177	11	carcinomas	carcinoma	NOUN
dpc-3032	177	12	:	:	PUNCT
dpc-3032	177	13	attack	attack	NOUN
dpc-3032	177	14	of	of	ADP
dpc-3032	177	15	the	the	DET
dpc-3032	177	16	hedgehog	hedgehog	PROPN
dpc-3032	177	17	.	.	PUNCT
dpc-3032	177	18	nature	nature	NOUN
dpc-3032	177	19	reviews	review	VERB
dpc-3032	177	20	cancer	cancer	NOUN
dpc-3032	177	21	,	,	PUNCT
dpc-3032	177	22	2008	2008	NUM
dpc-3032	177	23	;	;	PUNCT
dpc-3032	177	24	8	8	NUM
dpc-3032	177	25	:	:	SYM
dpc-3032	177	26	743	743	NUM
dpc-3032	177	27	-	-	SYM
dpc-3032	177	28	754	754	NUM
dpc-3032	177	29	.	.	PUNCT
dpc-3032	178	1	doi:10.1038	doi:10.1038	NOUN
dpc-3032	178	2	/	/	SYM
dpc-3032	178	3	nrc2503	nrc2503	ADJ
dpc-3032	178	4	4	4	NUM
dpc-3032	178	5	.	.	PUNCT
dpc-3032	178	6	von	von	PROPN
dpc-3032	178	7	hoff	hoff	PROPN
dpc-3032	178	8	dd	dd	PROPN
dpc-3032	178	9	,	,	PUNCT
dpc-3032	178	10	lorusso	lorusso	ADJ
dpc-3032	178	11	pm	pm	NOUN
dpc-3032	178	12	,	,	PUNCT
dpc-3032	178	13	rudin	rudin	PROPN
dpc-3032	178	14	cm	cm	PROPN
dpc-3032	178	15	,	,	PUNCT
dpc-3032	178	16	et	et	PROPN
dpc-3032	178	17	al	al	PROPN
dpc-3032	178	18	.	.	PROPN
dpc-3032	178	19	inhibition	inhibition	NOUN
dpc-3032	178	20	of	of	ADP
dpc-3032	178	21	the	the	DET
dpc-3032	178	22	hedgehog	hedgehog	ADJ
dpc-3032	178	23	pathway	pathway	NOUN
dpc-3032	178	24	in	in	ADP
dpc-3032	178	25	advanced	advanced	ADJ
dpc-3032	178	26	basal	basal	NOUN
dpc-3032	178	27	-	-	PUNCT
dpc-3032	178	28	cell	cell	NOUN
dpc-3032	178	29	carcinoma	carcinoma	NOUN
dpc-3032	178	30	.	.	PUNCT
dpc-3032	179	1	the	the	DET
dpc-3032	179	2	new	new	PROPN
dpc-3032	179	3	england	england	PROPN
dpc-3032	179	4	journal	journal	PROPN
dpc-3032	179	5	of	of	ADP
dpc-3032	179	6	medicine	medicine	NOUN
dpc-3032	179	7	,	,	PUNCT
dpc-3032	179	8	2009	2009	NUM
dpc-3032	179	9	;	;	PUNCT
dpc-3032	179	10	361	361	NUM
dpc-3032	179	11	:	:	PUNCT
dpc-3032	179	12	1164	1164	NUM
dpc-3032	179	13	-	-	SYM
dpc-3032	179	14	1172	1172	NUM
dpc-3032	179	15	.	.	PUNCT
dpc-3032	180	1	doi:10.1056	doi:10.1056	PROPN
dpc-3032	180	2	/nejmoa0905360	/nejmoa0905360	PUNCT
dpc-3032	181	1	5	5	X
dpc-3032	181	2	.	.	X
dpc-3032	181	3	caro	caro	PROPN
dpc-3032	181	4	i	i	PROPN
dpc-3032	181	5	,	,	PUNCT
dpc-3032	181	6	low	low	PROPN
dpc-3032	181	7	ja	ja	PROPN
dpc-3032	181	8	.	.	PUNCT
dpc-3032	182	1	the	the	DET
dpc-3032	182	2	role	role	NOUN
dpc-3032	182	3	of	of	ADP
dpc-3032	182	4	the	the	DET
dpc-3032	182	5	hedgehog	hedgehog	NOUN
dpc-3032	182	6	signaling	signal	VERB
dpc-3032	182	7	pathway	pathway	NOUN
dpc-3032	182	8	in	in	ADP
dpc-3032	182	9	the	the	DET
dpc-3032	182	10	development	development	NOUN
dpc-3032	182	11	of	of	ADP
dpc-3032	182	12	basal	basal	ADJ
dpc-3032	182	13	cell	cell	NOUN
dpc-3032	182	14	carcinoma	carcinoma	NOUN
dpc-3032	182	15	and	and	CCONJ
dpc-3032	182	16	opportunities	opportunity	NOUN
dpc-3032	182	17	for	for	ADP
dpc-3032	182	18	treatment	treatment	NOUN
dpc-3032	182	19	.	.	PUNCT
dpc-3032	183	1	clinical	clinical	ADJ
dpc-3032	183	2	cancer	cancer	NOUN
dpc-3032	183	3	research	research	NOUN
dpc-3032	183	4	:	:	PUNCT
dpc-3032	183	5	an	an	DET
dpc-3032	183	6	official	official	ADJ
dpc-3032	183	7	journal	journal	NOUN
dpc-3032	183	8	of	of	ADP
dpc-3032	183	9	the	the	DET
dpc-3032	183	10	american	american	PROPN
dpc-3032	183	11	association	association	PROPN
dpc-3032	183	12	for	for	ADP
dpc-3032	183	13	cancer	cancer	NOUN
dpc-3032	183	14	research	research	NOUN
dpc-3032	183	15	,	,	PUNCT
dpc-3032	183	16	2010	2010	NUM
dpc-3032	183	17	;	;	PUNCT
dpc-3032	183	18	16	16	NUM
dpc-3032	183	19	:	:	SYM
dpc-3032	183	20	3335	3335	NUM
dpc-3032	183	21	-	-	SYM
dpc-3032	183	22	3339	3339	NUM
dpc-3032	183	23	.	.	PUNCT
dpc-3032	184	1	doi:10.1158/1078	doi:10.1158/1078	PROPN
dpc-3032	184	2	-	-	PUNCT
dpc-3032	184	3	0432.ccr-09	0432.ccr-09	NUM
dpc-3032	184	4	-	-	PUNCT
dpc-3032	184	5	2570	2570	NUM
dpc-3032	184	6	6	6	NUM
dpc-3032	184	7	.	.	PUNCT
dpc-3032	185	1	lindelöf	lindelöf	PROPN
dpc-3032	185	2	b	b	PROPN
dpc-3032	185	3	,	,	PUNCT
dpc-3032	185	4	lapins	lapins	PROPN
dpc-3032	185	5	j	j	PROPN
dpc-3032	185	6	,	,	PUNCT
dpc-3032	185	7	dal	dal	PROPN
dpc-3032	185	8	h.	h.	PROPN
dpc-3032	185	9	shift	shift	NOUN
dpc-3032	185	10	in	in	ADP
dpc-3032	185	11	occupational	occupational	ADJ
dpc-3032	185	12	risk	risk	NOUN
dpc-3032	185	13	for	for	ADP
dpc-3032	185	14	basal	basal	ADJ
dpc-3032	185	15	cell	cell	NOUN
dpc-3032	185	16	carcinoma	carcinoma	NOUN
dpc-3032	185	17	from	from	ADP
dpc-3032	185	18	outdoor	outdoor	NOUN
dpc-3032	185	19	to	to	ADP
dpc-3032	185	20	indoor	indoor	ADJ
dpc-3032	185	21	workers	worker	NOUN
dpc-3032	185	22	:	:	PUNCT
dpc-3032	185	23	a	a	DET
dpc-3032	185	24	large	large	ADJ
dpc-3032	185	25	population	population	NOUN
dpc-3032	185	26	-	-	PUNCT
dpc-3032	185	27	based	base	VERB
dpc-3032	185	28	case	case	NOUN
dpc-3032	185	29	-	-	PUNCT
dpc-3032	185	30	control	control	NOUN
dpc-3032	185	31	register	register	NOUN
dpc-3032	185	32	study	study	NOUN
dpc-3032	185	33	from	from	ADP
dpc-3032	185	34	sweden	sweden	PROPN
dpc-3032	185	35	.	.	PUNCT
dpc-3032	186	1	acta	acta	PROPN
dpc-3032	186	2	dermato	dermato	PROPN
dpc-3032	186	3	-	-	PUNCT
dpc-3032	186	4	venereologica	venereologica	PROPN
dpc-3032	186	5	,	,	PUNCT
dpc-3032	186	6	2017	2017	NUM
dpc-3032	186	7	;	;	PUNCT
dpc-3032	186	8	97	97	NUM
dpc-3032	186	9	:	:	SYM
dpc-3032	186	10	830	830	NUM
dpc-3032	186	11	-	-	SYM
dpc-3032	186	12	833	833	NUM
dpc-3032	186	13	.	.	PUNCT
dpc-3032	186	14	doi:10.2340	doi:10.2340	NOUN
dpc-3032	186	15	/00015555	/00015555	PUNCT
dpc-3032	186	16	-	-	PUNCT
dpc-3032	186	17	2660	2660	NUM
dpc-3032	186	18	7	7	NUM
dpc-3032	186	19	.	.	PUNCT
dpc-3032	187	1	gorlin	gorlin	PROPN
dpc-3032	187	2	rj	rj	PROPN
dpc-3032	187	3	.	.	PUNCT
dpc-3032	188	1	nevoid	nevoid	PROPN
dpc-3032	188	2	basal	basal	PROPN
dpc-3032	188	3	-	-	PUNCT
dpc-3032	188	4	cell	cell	NOUN
dpc-3032	188	5	carcinoma	carcinoma	NOUN
dpc-3032	188	6	syndrome	syndrome	NOUN
dpc-3032	188	7	.	.	PUNCT
dpc-3032	189	1	medicine	medicine	NOUN
dpc-3032	189	2	,	,	PUNCT
dpc-3032	189	3	1987	1987	NUM
dpc-3032	189	4	;	;	PUNCT
dpc-3032	189	5	66	66	NUM
dpc-3032	189	6	:	:	SYM
dpc-3032	189	7	98	98	NUM
dpc-3032	189	8	-	-	SYM
dpc-3032	189	9	113	113	NUM
dpc-3032	189	10	.	.	PUNCT
dpc-3032	190	1	doi:10.1097/00005792	doi:10.1097/00005792	NOUN
dpc-3032	190	2	-	-	PUNCT
dpc-3032	190	3	198703000	198703000	NUM
dpc-3032	190	4	-	-	PUNCT
dpc-3032	190	5	00002	00002	NUM
dpc-3032	190	6	8	8	NUM
dpc-3032	190	7	.	.	X
dpc-3032	190	8	tang	tang	PROPN
dpc-3032	190	9	jy	jy	PROPN
dpc-3032	190	10	,	,	PUNCT
dpc-3032	190	11	mackay	mackay	PROPN
dpc-3032	190	12	-	-	PUNCT
dpc-3032	190	13	wiggan	wiggan	VERB
dpc-3032	190	14	jm	jm	PROPN
dpc-3032	190	15	,	,	PUNCT
dpc-3032	190	16	aszterbaum	aszterbaum	PROPN
dpc-3032	190	17	m	m	PROPN
dpc-3032	190	18	,	,	PUNCT
dpc-3032	190	19	et	et	PROPN
dpc-3032	190	20	al	al	PROPN
dpc-3032	190	21	.	.	PUNCT
dpc-3032	191	1	inhibiting	inhibit	VERB
dpc-3032	191	2	the	the	DET
dpc-3032	191	3	hedgehog	hedgehog	NOUN
dpc-3032	191	4	pathway	pathway	NOUN
dpc-3032	191	5	in	in	ADP
dpc-3032	191	6	patients	patient	NOUN
dpc-3032	191	7	with	with	ADP
dpc-3032	191	8	the	the	DET
dpc-3032	191	9	basal	basal	NOUN
dpc-3032	191	10	-	-	PUNCT
dpc-3032	191	11	cell	cell	NOUN
dpc-3032	191	12	nevus	nevus	ADJ
dpc-3032	191	13	syndrome	syndrome	NOUN
dpc-3032	191	14	.	.	PUNCT
dpc-3032	192	1	the	the	DET
dpc-3032	192	2	new	new	PROPN
dpc-3032	192	3	england	england	PROPN
dpc-3032	192	4	journal	journal	PROPN
dpc-3032	192	5	of	of	ADP
dpc-3032	192	6	medicine	medicine	NOUN
dpc-3032	192	7	,	,	PUNCT
dpc-3032	192	8	2012	2012	NUM
dpc-3032	192	9	;	;	PUNCT
dpc-3032	192	10	366	366	NUM
dpc-3032	192	11	:	:	PUNCT
dpc-3032	192	12	2180	2180	NUM
dpc-3032	192	13	-	-	SYM
dpc-3032	192	14	2188	2188	NUM
dpc-3032	192	15	.	.	PUNCT
dpc-3032	193	1	doi:10.1056	doi:10.1056	PROPN
dpc-3032	193	2	/	/	SYM
dpc-3032	193	3	nejmoa1113538	nejmoa1113538	PROPN
dpc-3032	193	4	9	9	NUM
dpc-3032	193	5	.	.	PUNCT
dpc-3032	193	6	spiker	spiker	PROPN
dpc-3032	193	7	am	am	PROPN
dpc-3032	193	8	,	,	PUNCT
dpc-3032	193	9	troxell	troxell	PROPN
dpc-3032	193	10	t	t	PROPN
dpc-3032	193	11	,	,	PUNCT
dpc-3032	193	12	ramsey	ramsey	PROPN
dpc-3032	193	13	ml	ml	PROPN
dpc-3032	193	14	.	.	PUNCT
dpc-3032	194	1	gorlin	gorlin	PROPN
dpc-3032	194	2	syndrome	syndrome	PROPN
dpc-3032	194	3	.	.	PUNCT
dpc-3032	195	1	statpearls	statpearls	PROPN
dpc-3032	195	2	.	.	PUNCT
dpc-3032	196	1	treasure	treasure	NOUN
dpc-3032	196	2	island	island	NOUN
dpc-3032	196	3	(	(	PUNCT
dpc-3032	196	4	fl	fl	PROPN
dpc-3032	196	5	):	):	PUNCT
dpc-3032	196	6	statpearls	statpearl	NOUN
dpc-3032	196	7	publishing	publish	VERB
dpc-3032	196	8	copyright	copyright	NOUN
dpc-3032	196	9	©	©	PROPN
dpc-3032	196	10	2021	2021	NUM
dpc-3032	196	11	,	,	PUNCT
dpc-3032	196	12	statpearls	statpearls	PROPN
dpc-3032	196	13	publishing	publishing	PROPN
dpc-3032	196	14	llc	llc	PROPN
dpc-3032	196	15	.	.	PROPN
dpc-3032	196	16	,	,	PUNCT
dpc-3032	196	17	2021	2021	NUM
dpc-3032	196	18	.	.	PUNCT
dpc-3032	197	1	10	10	NUM
dpc-3032	197	2	.	.	PUNCT
dpc-3032	198	1	sekulic	sekulic	PROPN
dpc-3032	198	2	a	a	DET
dpc-3032	198	3	,	,	PUNCT
dpc-3032	198	4	migden	migden	PROPN
dpc-3032	198	5	mr	mr	PROPN
dpc-3032	198	6	,	,	PUNCT
dpc-3032	198	7	oro	oro	PROPN
dpc-3032	198	8	ae	ae	PROPN
dpc-3032	198	9	,	,	PUNCT
dpc-3032	198	10	et	et	PROPN
dpc-3032	198	11	al	al	PROPN
dpc-3032	198	12	.	.	PROPN
dpc-3032	198	13	efficacy	efficacy	NOUN
dpc-3032	198	14	and	and	CCONJ
dpc-3032	198	15	safety	safety	NOUN
dpc-3032	198	16	of	of	ADP
dpc-3032	198	17	vismodegib	vismodegib	NOUN
dpc-3032	198	18	in	in	ADP
dpc-3032	198	19	advanced	advanced	ADJ
dpc-3032	198	20	basal	basal	NOUN
dpc-3032	198	21	-	-	PUNCT
dpc-3032	198	22	cell	cell	NOUN
dpc-3032	198	23	carcinoma	carcinoma	NOUN
dpc-3032	198	24	.	.	PUNCT
dpc-3032	199	1	the	the	DET
dpc-3032	199	2	new	new	PROPN
dpc-3032	199	3	england	england	PROPN
dpc-3032	199	4	journal	journal	PROPN
dpc-3032	199	5	of	of	ADP
dpc-3032	199	6	medicine	medicine	NOUN
dpc-3032	199	7	,	,	PUNCT
dpc-3032	199	8	2012	2012	NUM
dpc-3032	199	9	;	;	PUNCT
dpc-3032	199	10	366	366	NUM
dpc-3032	199	11	:	:	PUNCT
dpc-3032	199	12	2171	2171	NUM
dpc-3032	199	13	-	-	SYM
dpc-3032	199	14	2179	2179	NUM
dpc-3032	199	15	.	.	PUNCT
dpc-3032	200	1	doi:10.1056	doi:10.1056	PROPN
dpc-3032	201	1	/nejmoa1113713	/nejmoa1113713	PUNCT
dpc-3032	202	1	11	11	X
dpc-3032	202	2	.	.	PUNCT
dpc-3032	202	3	sekulic	sekulic	PROPN
dpc-3032	202	4	a	a	DET
dpc-3032	202	5	,	,	PUNCT
dpc-3032	202	6	migden	migden	ADJ
dpc-3032	202	7	mr	mr	PROPN
dpc-3032	202	8	,	,	PUNCT
dpc-3032	202	9	basset	basset	NOUN
dpc-3032	202	10	-	-	PUNCT
dpc-3032	202	11	seguin	seguin	NOUN
dpc-3032	202	12	n	n	CCONJ
dpc-3032	202	13	,	,	PUNCT
dpc-3032	202	14	et	et	PROPN
dpc-3032	202	15	al	al	PROPN
dpc-3032	202	16	.	.	PUNCT
dpc-3032	203	1	long	long	ADJ
dpc-3032	203	2	-	-	PUNCT
dpc-3032	203	3	term	term	NOUN
dpc-3032	203	4	safety	safety	NOUN
dpc-3032	203	5	and	and	CCONJ
dpc-3032	203	6	efficacy	efficacy	NOUN
dpc-3032	203	7	of	of	ADP
dpc-3032	203	8	vismodegib	vismodegib	NOUN
dpc-3032	203	9	in	in	ADP
dpc-3032	203	10	patients	patient	NOUN
dpc-3032	203	11	with	with	ADP
dpc-3032	203	12	advanced	advanced	ADJ
dpc-3032	203	13	basal	basal	NOUN
dpc-3032	203	14	cell	cell	NOUN
dpc-3032	203	15	carcinoma	carcinoma	NOUN
dpc-3032	203	16	:	:	PUNCT
dpc-3032	203	17	final	final	ADJ
dpc-3032	203	18	update	update	NOUN
dpc-3032	203	19	of	of	ADP
dpc-3032	203	20	the	the	DET
dpc-3032	203	21	pivotal	pivotal	ADJ
dpc-3032	203	22	erivance	erivance	NOUN
dpc-3032	203	23	bcc	bcc	PROPN
dpc-3032	203	24	study	study	NOUN
dpc-3032	203	25	.	.	PUNCT
dpc-3032	204	1	bmc	bmc	NOUN
dpc-3032	204	2	cancer	cancer	NOUN
dpc-3032	204	3	,	,	PUNCT
dpc-3032	204	4	2017	2017	NUM
dpc-3032	204	5	;	;	PUNCT
dpc-3032	204	6	17	17	NUM
dpc-3032	204	7	:	:	SYM
dpc-3032	204	8	332	332	NUM
dpc-3032	204	9	.	.	PUNCT
dpc-3032	205	1	doi:10.1186	doi:10.1186	PROPN
dpc-3032	205	2	/	/	SYM
dpc-3032	205	3	s12885	s12885	PROPN
dpc-3032	205	4	-	-	PUNCT
dpc-3032	205	5	017	017	NUM
dpc-3032	205	6	-3286	-3286	NOUN
dpc-3032	205	7	-	-	PUNCT
dpc-3032	205	8	5	5	NUM
dpc-3032	205	9	12	12	NUM
dpc-3032	205	10	.	.	PUNCT
dpc-3032	206	1	basset	basset	NOUN
dpc-3032	206	2	-	-	PUNCT
dpc-3032	206	3	séguin	séguin	NOUN
dpc-3032	206	4	n	n	CCONJ
dpc-3032	206	5	,	,	PUNCT
dpc-3032	206	6	hauschild	hauschild	VERB
dpc-3032	206	7	a	a	X
dpc-3032	206	8	,	,	PUNCT
dpc-3032	206	9	kunstfeld	kunstfeld	PROPN
dpc-3032	206	10	r	r	NOUN
dpc-3032	206	11	,	,	PUNCT
dpc-3032	207	1	et	et	PROPN
dpc-3032	207	2	al	al	PROPN
dpc-3032	207	3	.	.	PROPN
dpc-3032	207	4	vismodegib	vismodegib	PROPN
dpc-3032	207	5	in	in	ADP
dpc-3032	207	6	patients	patient	NOUN
dpc-3032	207	7	with	with	ADP
dpc-3032	207	8	advanced	advanced	ADJ
dpc-3032	207	9	basal	basal	NOUN
dpc-3032	207	10	cell	cell	NOUN
dpc-3032	207	11	carcinoma	carcinoma	NOUN
dpc-3032	207	12	:	:	PUNCT
dpc-3032	207	13	primary	primary	ADJ
dpc-3032	207	14	analysis	analysis	NOUN
dpc-3032	207	15	of	of	ADP
dpc-3032	207	16	stevie	stevie	NOUN
dpc-3032	207	17	,	,	PUNCT
dpc-3032	207	18	an	an	DET
dpc-3032	207	19	international	international	ADJ
dpc-3032	207	20	,	,	PUNCT
dpc-3032	207	21	open	open	ADJ
dpc-3032	207	22	-	-	PUNCT
dpc-3032	207	23	label	label	NOUN
dpc-3032	207	24	trial	trial	NOUN
dpc-3032	207	25	.	.	PUNCT
dpc-3032	208	1	european	european	ADJ
dpc-3032	208	2	life	life	NOUN
dpc-3032	208	3	-	-	PUNCT
dpc-3032	208	4	threatening	threatening	ADJ
dpc-3032	208	5	or	or	CCONJ
dpc-3032	208	6	fatal	fatal	ADJ
dpc-3032	208	7	events	event	NOUN
dpc-3032	208	8	,	,	PUNCT
dpc-3032	208	9	none	none	NOUN
dpc-3032	208	10	were	be	AUX
dpc-3032	208	11	judged	judge	VERB
dpc-3032	208	12	to	to	PART
dpc-3032	208	13	be	be	AUX
dpc-3032	208	14	related	relate	VERB
dpc-3032	208	15	to	to	ADP
dpc-3032	208	16	vismodegib	vismodegib	NOUN
dpc-3032	208	17	treatment	treatment	NOUN
dpc-3032	208	18	.	.	PUNCT
dpc-3032	209	1	in	in	ADP
dpc-3032	209	2	all	all	PRON
dpc-3032	209	3	,	,	PUNCT
dpc-3032	209	4	a	a	DET
dpc-3032	209	5	non	non	ADJ
dpc-3032	209	6	-	-	ADJ
dpc-3032	209	7	interventional	interventional	ADJ
dpc-3032	209	8	study	study	NOUN
dpc-3032	209	9	design	design	NOUN
dpc-3032	209	10	can	can	AUX
dpc-3032	209	11	not	not	PART
dpc-3032	209	12	be	be	AUX
dpc-3032	209	13	compared	compare	VERB
dpc-3032	209	14	to	to	ADP
dpc-3032	209	15	the	the	DET
dpc-3032	209	16	strength	strength	NOUN
dpc-3032	209	17	of	of	ADP
dpc-3032	209	18	a	a	DET
dpc-3032	209	19	controlled	control	VERB
dpc-3032	209	20	clinical	clinical	ADJ
dpc-3032	209	21	trial	trial	NOUN
dpc-3032	209	22	.	.	PUNCT
dpc-3032	210	1	the	the	DET
dpc-3032	210	2	data	data	NOUN
dpc-3032	210	3	collection	collection	NOUN
dpc-3032	210	4	follows	follow	VERB
dpc-3032	210	5	the	the	DET
dpc-3032	210	6	standard	standard	ADJ
dpc-3032	210	7	care	care	NOUN
dpc-3032	210	8	at	at	ADP
dpc-3032	210	9	each	each	DET
dpc-3032	210	10	study	study	NOUN
dpc-3032	210	11	site	site	NOUN
dpc-3032	210	12	and	and	CCONJ
dpc-3032	210	13	obviously	obviously	ADV
dpc-3032	210	14	varies	vary	VERB
dpc-3032	210	15	between	between	ADP
dpc-3032	210	16	clinics	clinic	NOUN
dpc-3032	210	17	.	.	PUNCT
dpc-3032	211	1	treatment	treatment	NOUN
dpc-3032	211	2	durations	duration	NOUN
dpc-3032	211	3	were	be	AUX
dpc-3032	211	4	not	not	PART
dpc-3032	211	5	standardized	standardize	VERB
dpc-3032	211	6	but	but	CCONJ
dpc-3032	211	7	adjusted	adjust	VERB
dpc-3032	211	8	to	to	ADP
dpc-3032	211	9	each	each	DET
dpc-3032	211	10	patient	patient	ADJ
dpc-3032	211	11	and	and	CCONJ
dpc-3032	211	12	frequent	frequent	ADJ
dpc-3032	211	13	treatment	treatment	NOUN
dpc-3032	211	14	pauses	pause	NOUN
dpc-3032	211	15	were	be	AUX
dpc-3032	211	16	allowed	allow	VERB
dpc-3032	211	17	;	;	PUNCT
dpc-3032	211	18	all	all	PRON
dpc-3032	211	19	which	which	PRON
dpc-3032	211	20	might	might	AUX
dpc-3032	211	21	influence	influence	VERB
dpc-3032	211	22	the	the	DET
dpc-3032	211	23	response	response	NOUN
dpc-3032	211	24	outcome	outcome	NOUN
dpc-3032	211	25	.	.	PUNCT
dpc-3032	212	1	the	the	DET
dpc-3032	212	2	patient	patient	ADJ
dpc-3032	212	3	demographics	demographic	NOUN
dpc-3032	212	4	show	show	VERB
dpc-3032	212	5	some	some	DET
dpc-3032	212	6	imbalances	imbalance	NOUN
dpc-3032	212	7	between	between	ADP
dpc-3032	212	8	the	the	DET
dpc-3032	212	9	cohorts	cohort	NOUN
dpc-3032	212	10	,	,	PUNCT
dpc-3032	212	11	but	but	CCONJ
dpc-3032	212	12	with	with	ADP
dpc-3032	212	13	exception	exception	NOUN
dpc-3032	212	14	of	of	ADP
dpc-3032	212	15	the	the	DET
dpc-3032	212	16	younger	young	ADJ
dpc-3032	212	17	age	age	NOUN
dpc-3032	212	18	in	in	ADP
dpc-3032	212	19	cohort	cohort	NOUN
dpc-3032	212	20	3	3	NUM
dpc-3032	212	21	,	,	PUNCT
dpc-3032	212	22	these	these	DET
dpc-3032	212	23	differences	difference	NOUN
dpc-3032	212	24	do	do	AUX
dpc-3032	212	25	not	not	PART
dpc-3032	212	26	appear	appear	VERB
dpc-3032	212	27	relevant	relevant	ADJ
dpc-3032	212	28	.	.	PUNCT
dpc-3032	213	1	comparison	comparison	NOUN
dpc-3032	213	2	of	of	ADP
dpc-3032	213	3	the	the	DET
dpc-3032	213	4	cohorts	cohort	NOUN
dpc-3032	213	5	must	must	AUX
dpc-3032	213	6	be	be	AUX
dpc-3032	213	7	done	do	VERB
dpc-3032	213	8	with	with	ADP
dpc-3032	213	9	great	great	ADJ
dpc-3032	213	10	caution	caution	NOUN
dpc-3032	213	11	,	,	PUNCT
dpc-3032	213	12	due	due	ADP
dpc-3032	213	13	to	to	ADP
dpc-3032	213	14	the	the	DET
dpc-3032	213	15	big	big	ADJ
dpc-3032	213	16	differences	difference	NOUN
dpc-3032	213	17	in	in	ADP
dpc-3032	213	18	number	number	NOUN
dpc-3032	213	19	of	of	ADP
dpc-3032	213	20	patients	patient	NOUN
dpc-3032	213	21	between	between	ADP
dpc-3032	213	22	them	they	PRON
dpc-3032	213	23	.	.	PUNCT
dpc-3032	214	1	however	however	ADV
dpc-3032	214	2	,	,	PUNCT
dpc-3032	214	3	in	in	ADP
dpc-3032	214	4	general	general	ADJ
dpc-3032	214	5	the	the	DET
dpc-3032	214	6	collected	collect	VERB
dpc-3032	214	7	data	datum	NOUN
dpc-3032	214	8	mirror	mirror	VERB
dpc-3032	214	9	the	the	DET
dpc-3032	214	10	standard	standard	NOUN
dpc-3032	214	11	of	of	ADP
dpc-3032	214	12	care	care	NOUN
dpc-3032	214	13	of	of	ADP
dpc-3032	214	14	the	the	DET
dpc-3032	214	15	patient	patient	ADJ
dpc-3032	214	16	population	population	NOUN
dpc-3032	214	17	at	at	ADP
dpc-3032	214	18	each	each	DET
dpc-3032	214	19	clinic	clinic	NOUN
dpc-3032	214	20	and	and	CCONJ
dpc-3032	214	21	reflect	reflect	VERB
dpc-3032	214	22	the	the	DET
dpc-3032	214	23	real	real	ADJ
dpc-3032	214	24	-	-	PUNCT
dpc-3032	214	25	life	life	NOUN
dpc-3032	214	26	treatment	treatment	NOUN
dpc-3032	214	27	of	of	ADP
dpc-3032	214	28	patients	patient	NOUN
dpc-3032	214	29	with	with	ADP
dpc-3032	214	30	abcc	abcc	NOUN
dpc-3032	214	31	,	,	PUNCT
dpc-3032	214	32	which	which	PRON
dpc-3032	214	33	was	be	AUX
dpc-3032	214	34	the	the	DET
dpc-3032	214	35	purpose	purpose	NOUN
dpc-3032	214	36	of	of	ADP
dpc-3032	214	37	the	the	DET
dpc-3032	214	38	study	study	NOUN
dpc-3032	214	39	.	.	PUNCT
dpc-3032	215	1	to	to	PART
dpc-3032	215	2	conclude	conclude	VERB
dpc-3032	215	3	,	,	PUNCT
dpc-3032	215	4	this	this	DET
dpc-3032	215	5	study	study	NOUN
dpc-3032	215	6	is	be	AUX
dpc-3032	215	7	the	the	DET
dpc-3032	215	8	largest	large	ADJ
dpc-3032	215	9	study	study	NOUN
dpc-3032	215	10	performed	perform	VERB
dpc-3032	215	11	in	in	ADP
dpc-3032	215	12	sweden	sweden	PROPN
dpc-3032	215	13	with	with	ADP
dpc-3032	215	14	abcc	abcc	PROPN
dpc-3032	215	15	patients	patient	NOUN
dpc-3032	215	16	treated	treat	VERB
dpc-3032	215	17	with	with	ADP
dpc-3032	215	18	vismodegib	vismodegib	NOUN
dpc-3032	215	19	and	and	CCONJ
dpc-3032	215	20	mirrors	mirror	NOUN
dpc-3032	215	21	the	the	DET
dpc-3032	215	22	routine	routine	ADJ
dpc-3032	215	23	clinical	clinical	ADJ
dpc-3032	215	24	care	care	NOUN
dpc-3032	215	25	of	of	ADP
dpc-3032	215	26	abcc	abcc	NOUN
dpc-3032	215	27	.	.	PUNCT
dpc-3032	216	1	vismodegib	vismodegib	PROPN
dpc-3032	216	2	treatment	treatment	NOUN
dpc-3032	216	3	resulted	result	VERB
dpc-3032	216	4	in	in	ADP
dpc-3032	216	5	a	a	DET
dpc-3032	216	6	high	high	ADJ
dpc-3032	216	7	number	number	NOUN
dpc-3032	216	8	of	of	ADP
dpc-3032	216	9	patients	patient	NOUN
dpc-3032	216	10	with	with	ADP
dpc-3032	216	11	a	a	DET
dpc-3032	216	12	clinical	clinical	ADJ
dpc-3032	216	13	response	response	NOUN
dpc-3032	216	14	and	and	CCONJ
dpc-3032	216	15	pfs	pfs	PROPN
dpc-3032	216	16	and	and	CCONJ
dpc-3032	216	17	os	os	NOUN
dpc-3032	216	18	in	in	ADP
dpc-3032	216	19	the	the	DET
dpc-3032	216	20	same	same	ADJ
dpc-3032	216	21	range	range	NOUN
dpc-3032	216	22	as	as	ADP
dpc-3032	216	23	in	in	ADP
dpc-3032	216	24	other	other	ADJ
dpc-3032	216	25	trials	trial	NOUN
dpc-3032	216	26	despite	despite	SCONJ
dpc-3032	216	27	a	a	DET
dpc-3032	216	28	shorter	short	ADJ
dpc-3032	216	29	and	and	CCONJ
dpc-3032	216	30	more	more	ADV
dpc-3032	216	31	intermittent	intermittent	ADJ
dpc-3032	216	32	treatment	treatment	NOUN
dpc-3032	216	33	duration	duration	NOUN
dpc-3032	216	34	.	.	PUNCT
dpc-3032	217	1	the	the	DET
dpc-3032	217	2	close	close	ADJ
dpc-3032	217	3	monitoring	monitoring	NOUN
dpc-3032	217	4	of	of	ADP
dpc-3032	217	5	patient	patient	ADJ
dpc-3032	217	6	safety	safety	NOUN
dpc-3032	217	7	,	,	PUNCT
dpc-3032	217	8	tolerability	tolerability	NOUN
dpc-3032	217	9	and	and	CCONJ
dpc-3032	217	10	adaptation	adaptation	NOUN
dpc-3032	217	11	of	of	ADP
dpc-3032	217	12	treatment	treatment	NOUN
dpc-3032	217	13	,	,	PUNCT
dpc-3032	217	14	including	include	VERB
dpc-3032	217	15	re	re	NOUN
dpc-3032	217	16	-	-	NOUN
dpc-3032	217	17	challenge	challenge	NOUN
dpc-3032	217	18	of	of	ADP
dpc-3032	217	19	treatment	treatment	NOUN
dpc-3032	217	20	in	in	ADP
dpc-3032	217	21	some	some	DET
dpc-3032	217	22	cases	case	NOUN
dpc-3032	217	23	,	,	PUNCT
dpc-3032	217	24	may	may	AUX
dpc-3032	217	25	be	be	AUX
dpc-3032	217	26	a	a	DET
dpc-3032	217	27	step	step	NOUN
dpc-3032	217	28	towards	towards	ADP
dpc-3032	217	29	optimizing	optimize	VERB
dpc-3032	217	30	the	the	DET
dpc-3032	217	31	treatment	treatment	NOUN
dpc-3032	217	32	schedule	schedule	NOUN
dpc-3032	217	33	of	of	ADP
dpc-3032	217	34	abcc	abcc	PROPN
dpc-3032	217	35	patients	patient	NOUN
dpc-3032	217	36	.	.	PUNCT
dpc-3032	218	1	references	reference	NOUN
dpc-3032	218	2	1	1	NUM
dpc-3032	218	3	.	.	PUNCT
dpc-3032	218	4	stegmayer	stegmayer	PROPN
dpc-3032	218	5	b.	b.	PROPN
dpc-3032	218	6	basal	basal	PROPN
dpc-3032	218	7	cell	cell	NOUN
dpc-3032	218	8	carcinoma	carcinoma	NOUN
dpc-3032	218	9	in	in	ADP
dpc-3032	218	10	sweden	sweden	PROPN
dpc-3032	218	11	2004	2004	NUM
dpc-3032	218	12	-	-	SYM
dpc-3032	218	13	2008	2008	NUM
dpc-3032	218	14	.	.	PUNCT
dpc-3032	219	1	socialstyrelsen	socialstyrelsen	PROPN
dpc-3032	219	2	;	;	PUNCT
dpc-3032	219	3	2009	2009	NUM
dpc-3032	219	4	2009	2009	NUM
dpc-3032	219	5	-	-	SYM
dpc-3032	219	6	12	12	NUM
dpc-3032	219	7	-	-	SYM
dpc-3032	219	8	12	12	NUM
dpc-3032	219	9	.	.	PUNCT
dpc-3032	220	1	2	2	X
dpc-3032	220	2	.	.	X
dpc-3032	220	3	aszterbaum	aszterbaum	PROPN
dpc-3032	220	4	m	m	PROPN
dpc-3032	220	5	,	,	PUNCT
dpc-3032	220	6	beech	beech	PROPN
dpc-3032	220	7	j	j	PROPN
dpc-3032	220	8	,	,	PUNCT
dpc-3032	220	9	epstein	epstein	PROPN
dpc-3032	220	10	eh	eh	PROPN
dpc-3032	220	11	,	,	PUNCT
dpc-3032	220	12	jr	jr	PROPN
dpc-3032	220	13	.	.	PROPN
dpc-3032	220	14	ultraviolet	ultraviolet	ADJ
dpc-3032	220	15	radiation	radiation	NOUN
dpc-3032	220	16	mutagenesis	mutagenesis	NOUN
dpc-3032	220	17	of	of	ADP
dpc-3032	220	18	hedgehog	hedgehog	NOUN
dpc-3032	220	19	pathway	pathway	NOUN
dpc-3032	220	20	genes	gene	NOUN
dpc-3032	220	21	in	in	ADP
dpc-3032	220	22	basal	basal	ADJ
dpc-3032	220	23	cell	cell	NOUN
dpc-3032	220	24	carcinomas	carcinoma	NOUN
dpc-3032	220	25	.	.	PUNCT
dpc-3032	221	1	cohort	cohort	NOUN
dpc-3032	221	2	1	1	NUM
dpc-3032	221	3	(	(	PUNCT
dpc-3032	221	4	n=37	n=37	NOUN
dpc-3032	221	5	)	)	PUNCT
dpc-3032	221	6	cohort	cohort	NOUN
dpc-3032	221	7	2	2	NUM
dpc-3032	221	8	(	(	PUNCT
dpc-3032	221	9	n=3	n=3	NOUN
dpc-3032	221	10	)	)	PUNCT
dpc-3032	221	11	cohort	cohort	NOUN
dpc-3032	221	12	3	3	NUM
dpc-3032	221	13	(	(	PUNCT
dpc-3032	221	14	n=8	n=8	NUM
dpc-3032	221	15	)	)	PUNCT
dpc-3032	221	16	total	total	NOUN
dpc-3032	221	17	(	(	PUNCT
dpc-3032	221	18	n=48	n=48	NOUN
dpc-3032	221	19	)	)	PUNCT
dpc-3032	221	20	diarrhoea	diarrhoea	NOUN
dpc-3032	221	21	1	1	NUM
dpc-3032	221	22	(	(	PUNCT
dpc-3032	221	23	2.7	2.7	NUM
dpc-3032	221	24	)	)	PUNCT
dpc-3032	221	25	0	0	NUM
dpc-3032	222	1	0	0	NUM
dpc-3032	222	2	1	1	NUM
dpc-3032	222	3	(	(	PUNCT
dpc-3032	222	4	2.1	2.1	NUM
dpc-3032	222	5	)	)	PUNCT
dpc-3032	222	6	gastrointestinal	gastrointestinal	ADJ
dpc-3032	222	7	disorder	disorder	NOUN
dpc-3032	222	8	1	1	NUM
dpc-3032	222	9	(	(	PUNCT
dpc-3032	222	10	2.7	2.7	NUM
dpc-3032	222	11	)	)	PUNCT
dpc-3032	222	12	0	0	NUM
dpc-3032	222	13	0	0	NUM
dpc-3032	222	14	1	1	NUM
dpc-3032	222	15	(	(	PUNCT
dpc-3032	222	16	2.1	2.1	NUM
dpc-3032	222	17	)	)	PUNCT
dpc-3032	222	18	vomiting	vomit	VERB
dpc-3032	222	19	1	1	NUM
dpc-3032	222	20	(	(	PUNCT
dpc-3032	222	21	2.7	2.7	NUM
dpc-3032	222	22	)	)	PUNCT
dpc-3032	222	23	0	0	NUM
dpc-3032	222	24	0	0	NUM
dpc-3032	222	25	1	1	NUM
dpc-3032	222	26	(	(	PUNCT
dpc-3032	222	27	2.1	2.1	NUM
dpc-3032	222	28	)	)	PUNCT
dpc-3032	222	29	drug	drug	NOUN
dpc-3032	222	30	ineffective	ineffective	ADJ
dpc-3032	222	31	2	2	NUM
dpc-3032	222	32	(	(	PUNCT
dpc-3032	222	33	5.4	5.4	NUM
dpc-3032	222	34	)	)	PUNCT
dpc-3032	222	35	0	0	NUM
dpc-3032	222	36	0	0	NUM
dpc-3032	222	37	2	2	NUM
dpc-3032	222	38	(	(	PUNCT
dpc-3032	222	39	4.2	4.2	NUM
dpc-3032	222	40	)	)	PUNCT
dpc-3032	222	41	fatigue	fatigue	NOUN
dpc-3032	222	42	0	0	NUM
dpc-3032	222	43	1	1	NUM
dpc-3032	222	44	(	(	PUNCT
dpc-3032	222	45	33.3	33.3	NUM
dpc-3032	222	46	)	)	PUNCT
dpc-3032	222	47	0	0	NUM
dpc-3032	222	48	1	1	NUM
dpc-3032	222	49	(	(	PUNCT
dpc-3032	222	50	2.1	2.1	NUM
dpc-3032	222	51	)	)	PUNCT
dpc-3032	222	52	dysgeusia	dysgeusia	NOUN
dpc-3032	222	53	2	2	NUM
dpc-3032	222	54	(	(	PUNCT
dpc-3032	222	55	5.4	5.4	NUM
dpc-3032	222	56	)	)	PUNCT
dpc-3032	222	57	0	0	NUM
dpc-3032	222	58	0	0	NUM
dpc-3032	222	59	2	2	NUM
dpc-3032	222	60	(	(	PUNCT
dpc-3032	222	61	4.2	4.2	NUM
dpc-3032	222	62	)	)	PUNCT
dpc-3032	222	63	upper	upper	ADJ
dpc-3032	222	64	limb	limb	NOUN
dpc-3032	222	65	fracture	fracture	NOUN
dpc-3032	222	66	0	0	NUM
dpc-3032	222	67	0	0	NUM
dpc-3032	222	68	1	1	NUM
dpc-3032	222	69	(	(	PUNCT
dpc-3032	222	70	12.5	12.5	NUM
dpc-3032	222	71	)	)	SYM
dpc-3032	222	72	1	1	NUM
dpc-3032	222	73	(	(	PUNCT
dpc-3032	222	74	2.1	2.1	NUM
dpc-3032	222	75	)	)	PUNCT
dpc-3032	222	76	abnormal	abnormal	ADJ
dpc-3032	222	77	loss	loss	NOUN
dpc-3032	222	78	of	of	ADP
dpc-3032	222	79	weight	weight	NOUN
dpc-3032	222	80	1	1	NUM
dpc-3032	222	81	(	(	PUNCT
dpc-3032	222	82	2.7	2.7	NUM
dpc-3032	222	83	)	)	PUNCT
dpc-3032	222	84	0	0	NUM
dpc-3032	222	85	0	0	NUM
dpc-3032	222	86	1	1	NUM
dpc-3032	222	87	(	(	PUNCT
dpc-3032	222	88	2.1	2.1	NUM
dpc-3032	222	89	)	)	PUNCT
dpc-3032	222	90	table	table	NOUN
dpc-3032	222	91	4	4	NUM
dpc-3032	222	92	.	.	PUNCT
dpc-3032	222	93	adverse	adverse	ADJ
dpc-3032	222	94	events	event	NOUN
dpc-3032	222	95	,	,	PUNCT
dpc-3032	222	96	safety	safety	NOUN
dpc-3032	222	97	population	population	NOUN
dpc-3032	222	98	.	.	PUNCT
dpc-3032	223	1	(	(	PUNCT
dpc-3032	223	2	continued	continue	VERB
dpc-3032	223	3	)	)	PUNCT
dpc-3032	224	1	n	n	NOUN
dpc-3032	224	2	=	=	NOUN
dpc-3032	224	3	number	number	NOUN
dpc-3032	224	4	of	of	ADP
dpc-3032	224	5	subjects	subject	NOUN
dpc-3032	224	6	a	a	DET
dpc-3032	224	7	10	10	NUM
dpc-3032	224	8	of	of	ADP
dpc-3032	224	9	the	the	DET
dpc-3032	224	10	fatal	fatal	ADJ
dpc-3032	224	11	saes	saes	PROPN
dpc-3032	224	12	occurred	occur	VERB
dpc-3032	224	13	during	during	ADP
dpc-3032	224	14	the	the	DET
dpc-3032	224	15	follow	follow	NOUN
dpc-3032	224	16	-	-	PUNCT
dpc-3032	224	17	up	up	NOUN
dpc-3032	224	18	period	period	NOUN
dpc-3032	224	19	and	and	CCONJ
dpc-3032	224	20	1	1	NUM
dpc-3032	224	21	during	during	ADP
dpc-3032	224	22	the	the	DET
dpc-3032	224	23	treatment	treatment	NOUN
dpc-3032	224	24	phase	phase	NOUN
dpc-3032	224	25	.	.	PUNCT
dpc-3032	225	1	3	3	NUM
dpc-3032	225	2	fatal	fatal	ADJ
dpc-3032	225	3	saes	sae	NOUN
dpc-3032	225	4	occurred	occur	VERB
dpc-3032	225	5	during	during	ADP
dpc-3032	225	6	the	the	DET
dpc-3032	225	7	follow	follow	VERB
dpc-3032	225	8	-	-	PUNCT
dpc-3032	225	9	up	up	ADP
dpc-3032	225	10	study	study	NOUN
dpc-3032	225	11	phase	phase	NOUN
dpc-3032	225	12	but	but	CCONJ
dpc-3032	225	13	were	be	AUX
dpc-3032	225	14	found	find	VERB
dpc-3032	225	15	after	after	ADP
dpc-3032	225	16	database	database	NOUN
dpc-3032	225	17	lock	lock	NOUN
dpc-3032	225	18	and	and	CCONJ
dpc-3032	225	19	are	be	AUX
dpc-3032	225	20	included	include	VERB
dpc-3032	225	21	here	here	ADV
dpc-3032	225	22	.	.	PUNCT
dpc-3032	226	1	b	b	NOUN
dpc-3032	226	2	the	the	DET
dpc-3032	226	3	same	same	ADJ
dpc-3032	226	4	patient	patient	NOUN
dpc-3032	226	5	can	can	AUX
dpc-3032	226	6	report	report	VERB
dpc-3032	226	7	more	more	ADJ
dpc-3032	226	8	than	than	ADP
dpc-3032	226	9	one	one	NUM
dpc-3032	226	10	event	event	NOUN
dpc-3032	226	11	.	.	PUNCT
dpc-3032	227	1	10	10	NUM
dpc-3032	227	2	original	original	ADJ
dpc-3032	227	3	article	article	NOUN
dpc-3032	227	4	|	|	ADV
dpc-3032	227	5	dermatol	dermatol	ADJ
dpc-3032	227	6	pract	pract	NOUN
dpc-3032	227	7	concept	concept	NOUN
dpc-3032	227	8	.	.	PUNCT
dpc-3032	228	1	2023;13(2):e2023211	2023;13(2):e2023211	NUM
dpc-3032	228	2	18	18	NUM
dpc-3032	228	3	.	.	PUNCT
dpc-3032	229	1	gutzmer	gutzmer	NOUN
dpc-3032	229	2	r	r	PROPN
dpc-3032	229	3	,	,	PUNCT
dpc-3032	229	4	schulze	schulze	NOUN
dpc-3032	229	5	hj	hj	PROPN
dpc-3032	229	6	,	,	PUNCT
dpc-3032	229	7	hauschild	hauschild	PROPN
dpc-3032	229	8	a	a	X
dpc-3032	229	9	,	,	PUNCT
dpc-3032	229	10	et	et	PROPN
dpc-3032	229	11	al	al	PROPN
dpc-3032	229	12	.	.	PROPN
dpc-3032	229	13	effectiveness	effectiveness	PROPN
dpc-3032	229	14	,	,	PUNCT
dpc-3032	229	15	safety	safety	NOUN
dpc-3032	229	16	and	and	CCONJ
dpc-3032	229	17	utilization	utilization	NOUN
dpc-3032	229	18	of	of	ADP
dpc-3032	229	19	vismodegib	vismodegib	NOUN
dpc-3032	229	20	in	in	ADP
dpc-3032	229	21	locally	locally	ADV
dpc-3032	229	22	advanced	advance	VERB
dpc-3032	229	23	basal	basal	NOUN
dpc-3032	229	24	cell	cell	NOUN
dpc-3032	229	25	carcinoma	carcinoma	NOUN
dpc-3032	229	26	under	under	ADP
dpc-3032	229	27	real	real	ADJ
dpc-3032	229	28	-	-	PUNCT
dpc-3032	229	29	world	world	NOUN
dpc-3032	229	30	conditions	condition	NOUN
dpc-3032	229	31	in	in	ADP
dpc-3032	229	32	germany	germany	PROPN
dpc-3032	229	33	the	the	DET
dpc-3032	229	34	non	non	ADJ
dpc-3032	229	35	interventional	interventional	PROPN
dpc-3032	229	36	study	study	PROPN
dpc-3032	229	37	niels	niels	PROPN
dpc-3032	229	38	.	.	PUNCT
dpc-3032	230	1	journal	journal	PROPN
dpc-3032	230	2	of	of	ADP
dpc-3032	230	3	the	the	DET
dpc-3032	230	4	european	european	PROPN
dpc-3032	230	5	academy	academy	PROPN
dpc-3032	230	6	of	of	ADP
dpc-3032	230	7	dermatology	dermatology	NOUN
dpc-3032	230	8	and	and	CCONJ
dpc-3032	230	9	venereology	venereology	NOUN
dpc-3032	230	10	:	:	PUNCT
dpc-3032	230	11	jeadv	jeadv	NOUN
dpc-3032	230	12	,	,	PUNCT
dpc-3032	230	13	2021	2021	NUM
dpc-3032	230	14	;	;	PUNCT
dpc-3032	230	15	35	35	NUM
dpc-3032	230	16	:	:	SYM
dpc-3032	230	17	1678	1678	NUM
dpc-3032	230	18	-	-	SYM
dpc-3032	230	19	1685	1685	NUM
dpc-3032	230	20	.	.	PUNCT
dpc-3032	231	1	doi:10.1111	doi:10.1111	NOUN
dpc-3032	231	2	/	/	SYM
dpc-3032	231	3	jdv.17332	jdv.17332	NUM
dpc-3032	231	4	19	19	NUM
dpc-3032	231	5	.	.	PUNCT
dpc-3032	232	1	kaatz	kaatz	PROPN
dpc-3032	232	2	m	m	PROPN
dpc-3032	232	3	,	,	PUNCT
dpc-3032	232	4	mohr	mohr	PROPN
dpc-3032	232	5	p	p	PROPN
dpc-3032	232	6	,	,	PUNCT
dpc-3032	232	7	livingstone	livingstone	PROPN
dpc-3032	232	8	e	e	PROPN
dpc-3032	232	9	,	,	PUNCT
dpc-3032	232	10	et	et	PROPN
dpc-3032	232	11	al	al	PROPN
dpc-3032	232	12	.	.	PROPN
dpc-3032	232	13	effectiveness	effectiveness	PROPN
dpc-3032	232	14	,	,	PUNCT
dpc-3032	232	15	safety	safety	NOUN
dpc-3032	232	16	and	and	CCONJ
dpc-3032	232	17	utilization	utilization	NOUN
dpc-3032	232	18	of	of	ADP
dpc-3032	232	19	vismodegib	vismodegib	NOUN
dpc-3032	232	20	for	for	ADP
dpc-3032	232	21	locally	locally	ADV
dpc-3032	232	22	advanced	advance	VERB
dpc-3032	232	23	basal	basal	NOUN
dpc-3032	232	24	cell	cell	NOUN
dpc-3032	232	25	carcinoma	carcinoma	NOUN
dpc-3032	232	26	under	under	ADP
dpc-3032	232	27	real	real	ADJ
dpc-3032	232	28	-	-	PUNCT
dpc-3032	232	29	world	world	NOUN
dpc-3032	232	30	conditions	condition	NOUN
dpc-3032	232	31	:	:	PUNCT
dpc-3032	232	32	non	non	ADJ
dpc-3032	232	33	-	-	ADJ
dpc-3032	232	34	interventional	interventional	ADJ
dpc-3032	232	35	cohort	cohort	NOUN
dpc-3032	232	36	study	study	NOUN
dpc-3032	232	37	jonas	jonas	PROPN
dpc-3032	232	38	.	.	PUNCT
dpc-3032	233	1	acta	acta	PROPN
dpc-3032	233	2	dermato	dermato	PROPN
dpc-3032	233	3	-	-	PUNCT
dpc-3032	233	4	venereologica	venereologica	NOUN
dpc-3032	233	5	,	,	PUNCT
dpc-3032	233	6	2022	2022	NUM
dpc-3032	233	7	;	;	PUNCT
dpc-3032	233	8	102	102	NUM
dpc-3032	233	9	:	:	PUNCT
dpc-3032	233	10	adv00695	adv00695	NOUN
dpc-3032	233	11	.	.	PUNCT
dpc-3032	234	1	doi:10.2340	doi:10.2340	PROPN
dpc-3032	234	2	/	/	SYM
dpc-3032	234	3	actadv.v102.293	actadv.v102.293	PRON
dpc-3032	234	4	20	20	NUM
dpc-3032	234	5	.	.	PUNCT
dpc-3032	235	1	dummer	dummer	PROPN
dpc-3032	235	2	r	r	PROPN
dpc-3032	235	3	,	,	PUNCT
dpc-3032	235	4	basset	basset	NOUN
dpc-3032	235	5	-	-	PUNCT
dpc-3032	235	6	seguin	seguin	NOUN
dpc-3032	235	7	n	n	CCONJ
dpc-3032	235	8	,	,	PUNCT
dpc-3032	235	9	hansson	hansson	PROPN
dpc-3032	235	10	j	j	PROPN
dpc-3032	235	11	,	,	PUNCT
dpc-3032	235	12	et	et	PROPN
dpc-3032	235	13	al	al	PROPN
dpc-3032	235	14	.	.	PROPN
dpc-3032	235	15	impact	impact	NOUN
dpc-3032	235	16	of	of	ADP
dpc-3032	235	17	treatment	treatment	NOUN
dpc-3032	235	18	breaks	break	NOUN
dpc-3032	235	19	on	on	ADP
dpc-3032	235	20	vismodegib	vismodegib	NOUN
dpc-3032	235	21	patient	patient	ADJ
dpc-3032	235	22	outcomes	outcome	NOUN
dpc-3032	235	23	:	:	PUNCT
dpc-3032	235	24	exploratory	exploratory	ADJ
dpc-3032	235	25	analysis	analysis	NOUN
dpc-3032	235	26	of	of	ADP
dpc-3032	235	27	the	the	DET
dpc-3032	235	28	stevie	stevie	PROPN
dpc-3032	235	29	study	study	PROPN
dpc-3032	235	30	.	.	PUNCT
dpc-3032	236	1	journal	journal	NOUN
dpc-3032	236	2	of	of	ADP
dpc-3032	236	3	clinical	clinical	ADJ
dpc-3032	236	4	oncology	oncology	NOUN
dpc-3032	236	5	,	,	PUNCT
dpc-3032	236	6	2015	2015	NUM
dpc-3032	236	7	;	;	PUNCT
dpc-3032	236	8	33	33	NUM
dpc-3032	236	9	:	:	SYM
dpc-3032	236	10	9024	9024	NUM
dpc-3032	236	11	-	-	SYM
dpc-3032	236	12	9024	9024	NUM
dpc-3032	236	13	.	.	PUNCT
dpc-3032	237	1	doi:10.1200	doi:10.1200	PROPN
dpc-3032	237	2	/	/	SYM
dpc-3032	237	3	jco.2015.33.15_suppl.9024	jco.2015.33.15_suppl.9024	PROPN
dpc-3032	237	4	21	21	NUM
dpc-3032	237	5	.	.	PUNCT
dpc-3032	238	1	frampton	frampton	PROPN
dpc-3032	238	2	je	je	PROPN
dpc-3032	238	3	,	,	PUNCT
dpc-3032	238	4	basset	basset	NOUN
dpc-3032	238	5	-	-	PUNCT
dpc-3032	238	6	séguin	séguin	PROPN
dpc-3032	238	7	n.	n.	PROPN
dpc-3032	238	8	vismodegib	vismodegib	PROPN
dpc-3032	238	9	:	:	PUNCT
dpc-3032	238	10	a	a	DET
dpc-3032	238	11	review	review	NOUN
dpc-3032	238	12	in	in	ADP
dpc-3032	238	13	advanced	advanced	ADJ
dpc-3032	238	14	basal	basal	NOUN
dpc-3032	238	15	cell	cell	NOUN
dpc-3032	238	16	carcinoma	carcinoma	NOUN
dpc-3032	238	17	.	.	PUNCT
dpc-3032	239	1	drugs	drug	NOUN
dpc-3032	239	2	,	,	PUNCT
dpc-3032	239	3	2018	2018	NUM
dpc-3032	239	4	;	;	PUNCT
dpc-3032	239	5	78	78	NUM
dpc-3032	239	6	:	:	PUNCT
dpc-3032	239	7	1145	1145	NUM
dpc-3032	239	8	-	-	SYM
dpc-3032	239	9	1156	1156	NUM
dpc-3032	239	10	.	.	PUNCT
dpc-3032	240	1	doi:10.1007	doi:10.1007	VERB
dpc-3032	240	2	/s40265	/s40265	NOUN
dpc-3032	240	3	-	-	PUNCT
dpc-3032	240	4	018	018	NUM
dpc-3032	240	5	-	-	PUNCT
dpc-3032	240	6	0948	0948	NUM
dpc-3032	240	7	-	-	SYM
dpc-3032	240	8	9	9	NUM
dpc-3032	240	9	22	22	NUM
dpc-3032	240	10	.	.	PUNCT
dpc-3032	241	1	lacouture	lacouture	NOUN
dpc-3032	241	2	me	i	PRON
dpc-3032	241	3	,	,	PUNCT
dpc-3032	241	4	dréno	dréno	VERB
dpc-3032	241	5	b	b	NUM
dpc-3032	241	6	,	,	PUNCT
dpc-3032	241	7	ascierto	ascierto	PROPN
dpc-3032	241	8	pa	pa	PROPN
dpc-3032	241	9	,	,	PUNCT
dpc-3032	241	10	et	et	PROPN
dpc-3032	241	11	al	al	PROPN
dpc-3032	241	12	.	.	PUNCT
dpc-3032	241	13	characterization	characterization	NOUN
dpc-3032	241	14	and	and	CCONJ
dpc-3032	241	15	management	management	NOUN
dpc-3032	241	16	of	of	ADP
dpc-3032	241	17	hedgehog	hedgehog	PROPN
dpc-3032	241	18	pathway	pathway	NOUN
dpc-3032	241	19	inhibitor	inhibitor	NOUN
dpc-3032	241	20	-	-	PUNCT
dpc-3032	241	21	related	relate	VERB
dpc-3032	241	22	adverse	adverse	ADJ
dpc-3032	241	23	events	event	NOUN
dpc-3032	241	24	in	in	ADP
dpc-3032	241	25	patients	patient	NOUN
dpc-3032	241	26	with	with	ADP
dpc-3032	241	27	advanced	advanced	ADJ
dpc-3032	241	28	basal	basal	NOUN
dpc-3032	241	29	cell	cell	NOUN
dpc-3032	241	30	carcinoma	carcinoma	NOUN
dpc-3032	241	31	.	.	PUNCT
dpc-3032	242	1	the	the	DET
dpc-3032	242	2	oncologist	oncologist	NOUN
dpc-3032	242	3	,	,	PUNCT
dpc-3032	242	4	2016	2016	NUM
dpc-3032	242	5	;	;	PUNCT
dpc-3032	242	6	21	21	NUM
dpc-3032	242	7	:	:	PUNCT
dpc-3032	242	8	1218	1218	NUM
dpc-3032	242	9	-	-	SYM
dpc-3032	242	10	1229	1229	NUM
dpc-3032	242	11	.	.	PUNCT
dpc-3032	242	12	doi:10.1634	doi:10.1634	NOUN
dpc-3032	242	13	/	/	SYM
dpc-3032	242	14	theoncologist	theoncologist	NOUN
dpc-3032	242	15	.2016	.2016	PROPN
dpc-3032	242	16	-	-	NOUN
dpc-3032	242	17	0186	0186	NUM
dpc-3032	242	18	23	23	NUM
dpc-3032	242	19	.	.	PUNCT
dpc-3032	243	1	peris	peris	PROPN
dpc-3032	243	2	k	k	PROPN
dpc-3032	243	3	,	,	PUNCT
dpc-3032	243	4	fargnoli	fargnoli	PROPN
dpc-3032	243	5	mc	mc	PROPN
dpc-3032	243	6	,	,	PUNCT
dpc-3032	243	7	garbe	garbe	NOUN
dpc-3032	243	8	c	c	PROPN
dpc-3032	243	9	,	,	PUNCT
dpc-3032	243	10	et	et	PROPN
dpc-3032	243	11	al	al	PROPN
dpc-3032	243	12	.	.	PUNCT
dpc-3032	243	13	diagnosis	diagnosis	NOUN
dpc-3032	243	14	and	and	CCONJ
dpc-3032	243	15	treatment	treatment	NOUN
dpc-3032	243	16	of	of	ADP
dpc-3032	243	17	basal	basal	ADJ
dpc-3032	243	18	cell	cell	NOUN
dpc-3032	243	19	carcinoma	carcinoma	NOUN
dpc-3032	243	20	:	:	PUNCT
dpc-3032	243	21	european	european	ADJ
dpc-3032	243	22	consensus	consensus	NOUN
dpc-3032	243	23	-	-	PUNCT
dpc-3032	243	24	based	base	VERB
dpc-3032	243	25	interdisciplinary	interdisciplinary	ADJ
dpc-3032	243	26	guidelines	guideline	NOUN
dpc-3032	243	27	.	.	PUNCT
dpc-3032	244	1	european	european	ADJ
dpc-3032	244	2	journal	journal	PROPN
dpc-3032	244	3	of	of	ADP
dpc-3032	244	4	cancer	cancer	NOUN
dpc-3032	244	5	(	(	PUNCT
dpc-3032	244	6	oxford	oxford	PROPN
dpc-3032	244	7	,	,	PUNCT
dpc-3032	244	8	england	england	PROPN
dpc-3032	244	9	:	:	PUNCT
dpc-3032	244	10	1990	1990	NUM
dpc-3032	244	11	)	)	PUNCT
dpc-3032	244	12	,	,	PUNCT
dpc-3032	244	13	2019	2019	NUM
dpc-3032	244	14	;	;	PUNCT
dpc-3032	244	15	118	118	NUM
dpc-3032	244	16	:	:	SYM
dpc-3032	244	17	10	10	NUM
dpc-3032	244	18	-	-	SYM
dpc-3032	244	19	34	34	NUM
dpc-3032	244	20	.	.	PUNCT
dpc-3032	245	1	doi:10.1016	doi:10.1016	PROPN
dpc-3032	245	2	/	/	SYM
dpc-3032	245	3	j.ejca.2019	j.ejca.2019	PROPN
dpc-3032	245	4	.06.003	.06.003	PROPN
dpc-3032	245	5	journal	journal	PROPN
dpc-3032	245	6	of	of	ADP
dpc-3032	245	7	cancer	cancer	NOUN
dpc-3032	245	8	(	(	PUNCT
dpc-3032	245	9	oxford	oxford	PROPN
dpc-3032	245	10	,	,	PUNCT
dpc-3032	245	11	england	england	PROPN
dpc-3032	245	12	:	:	PUNCT
dpc-3032	245	13	1990	1990	NUM
dpc-3032	245	14	)	)	PUNCT
dpc-3032	245	15	,	,	PUNCT
dpc-3032	245	16	2017	2017	NUM
dpc-3032	245	17	;	;	PUNCT
dpc-3032	245	18	86	86	NUM
dpc-3032	245	19	:	:	SYM
dpc-3032	245	20	334	334	NUM
dpc-3032	245	21	-	-	SYM
dpc-3032	245	22	348	348	NUM
dpc-3032	245	23	.	.	PUNCT
dpc-3032	246	1	doi:10.1016	doi:10.1016	PROPN
dpc-3032	246	2	/	/	SYM
dpc-3032	246	3	j.ejca.2017.08.022	j.ejca.2017.08.022	PROPN
dpc-3032	246	4	13	13	NUM
dpc-3032	246	5	.	.	PUNCT
dpc-3032	247	1	dréno	dréno	PROPN
dpc-3032	247	2	b	b	NUM
dpc-3032	247	3	,	,	PUNCT
dpc-3032	247	4	kunstfeld	kunstfeld	PROPN
dpc-3032	247	5	r	r	NOUN
dpc-3032	247	6	,	,	PUNCT
dpc-3032	247	7	hauschild	hauschild	NOUN
dpc-3032	247	8	a	a	X
dpc-3032	247	9	,	,	PUNCT
dpc-3032	247	10	et	et	PROPN
dpc-3032	247	11	al	al	PROPN
dpc-3032	247	12	.	.	PROPN
dpc-3032	248	1	two	two	NUM
dpc-3032	248	2	intermittent	intermittent	ADJ
dpc-3032	248	3	vismodegib	vismodegib	NOUN
dpc-3032	248	4	dosing	dose	VERB
dpc-3032	248	5	regimens	regimen	NOUN
dpc-3032	248	6	in	in	ADP
dpc-3032	248	7	patients	patient	NOUN
dpc-3032	248	8	with	with	ADP
dpc-3032	248	9	multiple	multiple	ADJ
dpc-3032	248	10	basal	basal	NOUN
dpc-3032	248	11	-	-	PUNCT
dpc-3032	248	12	cell	cell	NOUN
dpc-3032	248	13	carcinomas	carcinoma	NOUN
dpc-3032	248	14	(	(	PUNCT
dpc-3032	248	15	mikie	mikie	NOUN
dpc-3032	248	16	):	):	PUNCT
dpc-3032	248	17	a	a	DET
dpc-3032	248	18	randomised	randomise	VERB
dpc-3032	248	19	,	,	PUNCT
dpc-3032	248	20	regimen	regimen	NOUN
dpc-3032	248	21	-	-	PUNCT
dpc-3032	248	22	controlled	control	VERB
dpc-3032	248	23	,	,	PUNCT
dpc-3032	248	24	double	double	ADJ
dpc-3032	248	25	-	-	PUNCT
dpc-3032	248	26	blind	blind	ADJ
dpc-3032	248	27	,	,	PUNCT
dpc-3032	248	28	phase	phase	NOUN
dpc-3032	248	29	2	2	NUM
dpc-3032	248	30	trial	trial	NOUN
dpc-3032	248	31	.	.	PUNCT
dpc-3032	249	1	the	the	DET
dpc-3032	249	2	lancet	lancet	PROPN
dpc-3032	249	3	oncology	oncology	NOUN
dpc-3032	249	4	,	,	PUNCT
dpc-3032	249	5	2017	2017	NUM
dpc-3032	249	6	;	;	PUNCT
dpc-3032	249	7	18	18	NUM
dpc-3032	249	8	:	:	SYM
dpc-3032	249	9	404	404	NUM
dpc-3032	249	10	-	-	SYM
dpc-3032	249	11	412	412	NUM
dpc-3032	249	12	.	.	PUNCT
dpc-3032	249	13	doi:10.1016	doi:10.1016	PROPN
dpc-3032	249	14	/	/	SYM
dpc-3032	249	15	s1470	s1470	PROPN
dpc-3032	249	16	-	-	PUNCT
dpc-3032	249	17	2045(17)30072	2045(17)30072	NUM
dpc-3032	249	18	-	-	SYM
dpc-3032	249	19	4	4	NUM
dpc-3032	249	20	14	14	NUM
dpc-3032	249	21	.	.	PUNCT
dpc-3032	249	22	woltsche	woltsche	NOUN
dpc-3032	249	23	n	n	CCONJ
dpc-3032	249	24	,	,	PUNCT
dpc-3032	249	25	pichler	pichler	NOUN
dpc-3032	249	26	n	n	CCONJ
dpc-3032	249	27	,	,	PUNCT
dpc-3032	249	28	wolf	wolf	PROPN
dpc-3032	249	29	i	i	PRON
dpc-3032	249	30	,	,	PUNCT
dpc-3032	249	31	di	di	PROPN
dpc-3032	249	32	meo	meo	PROPN
dpc-3032	249	33	n	n	CCONJ
dpc-3032	249	34	,	,	PUNCT
dpc-3032	249	35	zalaudek	zalaudek	PROPN
dpc-3032	249	36	i.	i.	PROPN
dpc-3032	249	37	managing	manage	VERB
dpc-3032	249	38	adverse	adverse	ADJ
dpc-3032	249	39	effects	effect	NOUN
dpc-3032	249	40	by	by	ADP
dpc-3032	249	41	dose	dose	NOUN
dpc-3032	249	42	reduction	reduction	NOUN
dpc-3032	249	43	during	during	ADP
dpc-3032	249	44	routine	routine	ADJ
dpc-3032	249	45	treatment	treatment	NOUN
dpc-3032	249	46	of	of	ADP
dpc-3032	249	47	locally	locally	ADV
dpc-3032	249	48	advanced	advance	VERB
dpc-3032	249	49	basal	basal	NOUN
dpc-3032	249	50	cell	cell	NOUN
dpc-3032	249	51	carcinoma	carcinoma	NOUN
dpc-3032	249	52	with	with	ADP
dpc-3032	249	53	the	the	DET
dpc-3032	249	54	hedgehog	hedgehog	PROPN
dpc-3032	249	55	inhibitor	inhibitor	NOUN
dpc-3032	249	56	vismodegib	vismodegib	NOUN
dpc-3032	249	57	:	:	PUNCT
dpc-3032	249	58	a	a	DET
dpc-3032	249	59	single	single	ADJ
dpc-3032	249	60	centre	centre	NOUN
dpc-3032	249	61	experience	experience	NOUN
dpc-3032	249	62	.	.	PUNCT
dpc-3032	250	1	journal	journal	NOUN
dpc-3032	250	2	of	of	ADP
dpc-3032	250	3	the	the	DET
dpc-3032	250	4	european	european	PROPN
dpc-3032	250	5	academy	academy	PROPN
dpc-3032	250	6	of	of	ADP
dpc-3032	250	7	dermatology	dermatology	NOUN
dpc-3032	250	8	and	and	CCONJ
dpc-3032	250	9	venereology	venereology	NOUN
dpc-3032	250	10	:	:	PUNCT
dpc-3032	250	11	jeadv	jeadv	NOUN
dpc-3032	250	12	,	,	PUNCT
dpc-3032	250	13	2019	2019	NUM
dpc-3032	250	14	;	;	PUNCT
dpc-3032	250	15	33	33	NUM
dpc-3032	250	16	:	:	PUNCT
dpc-3032	250	17	e144	e144	PROPN
dpc-3032	250	18	-	-	PUNCT
dpc-3032	250	19	e145	e145	PROPN
dpc-3032	250	20	.	.	PUNCT
dpc-3032	251	1	doi:10.1111	doi:10.1111	NOUN
dpc-3032	251	2	/	/	SYM
dpc-3032	251	3	jdv.15367	jdv.15367	ADP
dpc-3032	251	4	15	15	NUM
dpc-3032	251	5	.	.	PUNCT
dpc-3032	252	1	routt	routt	PROPN
dpc-3032	252	2	e	e	PROPN
dpc-3032	252	3	,	,	PUNCT
dpc-3032	252	4	ratner	ratner	PROPN
dpc-3032	252	5	d.	d.	PROPN
dpc-3032	252	6	outcomes	outcome	NOUN
dpc-3032	252	7	for	for	ADP
dpc-3032	252	8	basal	basal	ADJ
dpc-3032	252	9	cell	cell	NOUN
dpc-3032	252	10	carcinoma	carcinoma	NOUN
dpc-3032	252	11	treated	treat	VERB
dpc-3032	252	12	with	with	ADP
dpc-3032	252	13	vismodegib	vismodegib	NOUN
dpc-3032	252	14	extended	extend	VERB
dpc-3032	252	15	alternate	alternate	ADJ
dpc-3032	252	16	day	day	NOUN
dpc-3032	252	17	dosing	dose	VERB
dpc-3032	252	18	.	.	PUNCT
dpc-3032	253	1	dermatologic	dermatologic	ADJ
dpc-3032	253	2	surgery	surgery	NOUN
dpc-3032	253	3	:	:	PUNCT
dpc-3032	253	4	official	official	ADJ
dpc-3032	253	5	publication	publication	NOUN
dpc-3032	253	6	for	for	ADP
dpc-3032	253	7	american	american	ADJ
dpc-3032	253	8	society	society	NOUN
dpc-3032	253	9	for	for	ADP
dpc-3032	253	10	dermatologic	dermatologic	ADJ
dpc-3032	253	11	surgery	surgery	NOUN
dpc-3032	254	1	[	[	X
dpc-3032	254	2	et	et	NOUN
dpc-3032	254	3	al	al	PROPN
dpc-3032	254	4	]	]	X
dpc-3032	254	5	,	,	PUNCT
dpc-3032	254	6	2020	2020	NUM
dpc-3032	254	7	;	;	PUNCT
dpc-3032	254	8	46	46	NUM
dpc-3032	254	9	:	:	SYM
dpc-3032	254	10	1109	1109	NUM
dpc-3032	254	11	-	-	SYM
dpc-3032	254	12	1112	1112	NUM
dpc-3032	254	13	.	.	PUNCT
dpc-3032	255	1	doi:10.1097	doi:10.1097	PROPN
dpc-3032	255	2	/	/	SYM
dpc-3032	255	3	dss	dss	NOUN
dpc-3032	255	4	.0000000000001985	.0000000000001985	NOUN
dpc-3032	256	1	16	16	NUM
dpc-3032	256	2	.	.	PUNCT
dpc-3032	257	1	wong	wong	PROPN
dpc-3032	257	2	c	c	PROPN
dpc-3032	257	3	,	,	PUNCT
dpc-3032	257	4	poblete	poblete	NOUN
dpc-3032	257	5	-	-	PUNCT
dpc-3032	257	6	lopez	lopez	NOUN
dpc-3032	257	7	c	c	PROPN
dpc-3032	257	8	,	,	PUNCT
dpc-3032	257	9	vidimos	vidimos	PROPN
dpc-3032	257	10	a.	a.	NOUN
dpc-3032	257	11	comparison	comparison	NOUN
dpc-3032	257	12	of	of	ADP
dpc-3032	257	13	daily	daily	ADJ
dpc-3032	257	14	dosing	dose	VERB
dpc-3032	257	15	versus	versus	ADP
dpc-3032	257	16	monday	monday	PROPN
dpc-3032	257	17	through	through	ADP
dpc-3032	257	18	friday	friday	PROPN
dpc-3032	257	19	dosing	dosing	NOUN
dpc-3032	257	20	of	of	ADP
dpc-3032	257	21	vismodegib	vismodegib	NOUN
dpc-3032	257	22	for	for	ADP
dpc-3032	257	23	locally	locally	ADV
dpc-3032	257	24	advanced	advance	VERB
dpc-3032	257	25	basal	basal	NOUN
dpc-3032	257	26	cell	cell	NOUN
dpc-3032	257	27	carcinoma	carcinoma	NOUN
dpc-3032	257	28	and	and	CCONJ
dpc-3032	257	29	basal	basal	NOUN
dpc-3032	257	30	cell	cell	NOUN
dpc-3032	257	31	nevus	nevus	ADJ
dpc-3032	257	32	syndrome	syndrome	NOUN
dpc-3032	257	33	:	:	PUNCT
dpc-3032	257	34	a	a	DET
dpc-3032	257	35	retrospective	retrospective	ADJ
dpc-3032	257	36	case	case	NOUN
dpc-3032	257	37	series	series	NOUN
dpc-3032	257	38	.	.	PUNCT
dpc-3032	258	1	journal	journal	PROPN
dpc-3032	258	2	of	of	ADP
dpc-3032	258	3	the	the	DET
dpc-3032	258	4	american	american	PROPN
dpc-3032	258	5	academy	academy	PROPN
dpc-3032	258	6	of	of	ADP
dpc-3032	258	7	dermatology	dermatology	NOUN
dpc-3032	258	8	,	,	PUNCT
dpc-3032	258	9	2020	2020	NUM
dpc-3032	258	10	;	;	PUNCT
dpc-3032	258	11	82	82	NUM
dpc-3032	258	12	:	:	SYM
dpc-3032	258	13	1539	1539	NUM
dpc-3032	258	14	-	-	SYM
dpc-3032	258	15	1542	1542	NUM
dpc-3032	258	16	.	.	PUNCT
dpc-3032	259	1	doi:10.1016	doi:10.1016	PROPN
dpc-3032	259	2	/	/	SYM
dpc-3032	259	3	j.jaad.2020.02.050	j.jaad.2020.02.050	PROPN
dpc-3032	259	4	17	17	NUM
dpc-3032	259	5	.	.	PUNCT
dpc-3032	260	1	apalla	apalla	PROPN
dpc-3032	260	2	z	z	PROPN
dpc-3032	260	3	,	,	PUNCT
dpc-3032	260	4	spyridis	spyridis	NOUN
dpc-3032	260	5	i	i	PRON
dpc-3032	260	6	,	,	PUNCT
dpc-3032	260	7	kyrgidis	kyrgidi	VERB
dpc-3032	260	8	a	a	PRON
dpc-3032	260	9	,	,	PUNCT
dpc-3032	260	10	et	et	PROPN
dpc-3032	260	11	al	al	PROPN
dpc-3032	260	12	.	.	PROPN
dpc-3032	260	13	vismodegib	vismodegib	PROPN
dpc-3032	260	14	in	in	ADP
dpc-3032	260	15	real	real	ADJ
dpc-3032	260	16	-	-	PUNCT
dpc-3032	260	17	life	life	NOUN
dpc-3032	260	18	clinical	clinical	ADJ
dpc-3032	260	19	settings	setting	NOUN
dpc-3032	260	20	:	:	PUNCT
dpc-3032	260	21	a	a	DET
dpc-3032	260	22	multicenter	multicenter	NOUN
dpc-3032	260	23	,	,	PUNCT
dpc-3032	260	24	longitudinal	longitudinal	ADJ
dpc-3032	260	25	cohort	cohort	NOUN
dpc-3032	260	26	providing	provide	VERB
dpc-3032	260	27	long	long	ADJ
dpc-3032	260	28	-	-	PUNCT
dpc-3032	260	29	term	term	NOUN
dpc-3032	260	30	data	datum	NOUN
dpc-3032	260	31	on	on	ADP
dpc-3032	260	32	efficacy	efficacy	NOUN
dpc-3032	260	33	and	and	CCONJ
dpc-3032	260	34	safety	safety	NOUN
dpc-3032	260	35	.	.	PUNCT
dpc-3032	261	1	journal	journal	NOUN
dpc-3032	261	2	of	of	ADP
dpc-3032	261	3	the	the	DET
dpc-3032	261	4	american	american	PROPN
dpc-3032	261	5	academy	academy	PROPN
dpc-3032	261	6	of	of	ADP
dpc-3032	261	7	dermatology	dermatology	NOUN
dpc-3032	261	8	,	,	PUNCT
dpc-3032	261	9	2021	2021	NUM
dpc-3032	261	10	;	;	PUNCT
dpc-3032	261	11	85	85	NUM
dpc-3032	261	12	:	:	SYM
dpc-3032	261	13	1589	1589	NUM
dpc-3032	261	14	-	-	SYM
dpc-3032	261	15	1592	1592	NUM
dpc-3032	261	16	.	.	PUNCT
dpc-3032	262	1	doi:10.1016	doi:10.1016	PROPN
dpc-3032	262	2	/j.jaad.2020.11.036	/j.jaad.2020.11.036	PUNCT